Timothy Price
Adelaide Medical School
Faculty of Health and Medical Sciences
Eligible to supervise Masters and PhD - email supervisor to discuss availability.
Professor Tim Price MBBS FRACP DHlthSc (Med)
Professor Tim Price trained in Medical oncology at the RAH and completed a Gastrointestinal Fellowship at The Royal Marsden Hospital and Institute of Cancer Research, London. He is currently Head of Clinical Oncology Research at The Queen Elizabeth Hospital, Woodville. He is also the Clinical Director of the BRAGG Comprehensive Cancer Centre of SA/NT. He has also positions as Visiting Medical Oncologist at Calvary Hospital North Adelaide, Western Hospital Henley Beach and Lyell McEwin Health Service. He is a Clinical Professor within the Faculty of Medicine, at the University of Adelaide.
"I am a fulltime Clinician / Translational Researcher and have been an active contributor in the field of Clinical, Epidemiological and Translational Science at National and International levels. My research focus has primarily related to Clinical Trial activity, but has subsequently evolved to assessing both the impact of Clinical Trial data and its translation into standard practice as reflected by changes in practice and evidence for improved outcomes, together with more basic translational research by improving the understanding of the molecular pathways currently relevant in colorectal cancer (in particular the vascular endothelial growth factor pathway and the epithelial growth factor path way)". My main Clinical Research focus is in the area of Gastrointestinal Cancers, Neuroendocrine Tumours and Phase 1 trials.
- My Research
- Career
- Publications
- Grants and Funding
- Teaching
- Supervision
- Professional Activities
- Contact
My research focus over the last five years has been primarily investigating the relevance of the EGFR and VEGF pathways in advanced colorectal cancer. Via a collaboration with investigators of the MAX trail, a large International Randomised Phase 3 study of anti-VEGF therapy and chemotherapy, and the Basil Hetzel Institute my team investigated the proposed cross talk between the EGFR and VEGF pathways and the potential of KRAS/RAS, BRAF, PTEN and PIC3CA as predictors of anti-VEGF therapy. Furthermore our laboratory also assessed novel predictors of resistance to anti-EGFR therapy. As part of the AGITG collaboration I was a member of the Clinical Trial Management Team that produced and presented the evidence to support KRAS mutation as a predictor of non-response to anit-EGFR therapy and the subsequent NEJM paper. This data has led to changes in clinical practice internationally. It is now well recognised that KRAS and RAS mutation testing should be an integral part of standard clinical practice in advanced colorectal care and this is now mandated prior to prescribing anti-EGFR therapy. These findings have led to significant improvements in patient care preventing access to these agents in patients who will be resistant to them and therefore reducing the impact on quality of life of an ineffective therapy. This also has obviously implications for the Health Care System in terms of cost savings. Ongoing investigation of alternate pathways and markers continue to be a focus of our laboratory and this will lead to further honour’s projects.
Basic/Translational Science
Beyond the ongoing work around the EGFR pathway, the recent focus of our laboratory has been also to look at novel therapies and currently we are investigating the role of aquaporin in the development of metastatic disease in advanced colorectal cancer. As part of this research focus I will supervise a PhD student (Dr Yoko Tomita) to further assess the potential for this novel targeted agent in preventing metastatic potential using a number of preclinical models with a view to early phase Clinical Trials in man to follow. The link with my Clinical Research unit at TQEH and experience in Phase I trials will allow this to progress in a timely fashion.
Clinical Research/Science
As is supported by the recent publications on anti-EGFR therapy my clinical trial program has led to significant roles in this area of practice. As a member of the international steering committee for the Panitumumab 181 study, we have confirmed the activity of a combination regimen of chemotherapy and panitumumab (anti-EGFR agent) in second line colorectal cancer. Furthermore we have also provided additional literature on extended RAS mutation status, the first such evidence in the second line setting, which has reinforced the international trend away from purely KRAS exon 2 mutation testing to an all RAS mutation testing platform for advanced colorectal cancer. As the co-chair of the International Randomised Study (ASPECTT trial) comparing the two available anti-EGFR agents (Cetuximab and Panitumumab), our work has led to the first evidence of non-inferiority of both agents and therefore because of differing toxicity and delivery scheduling, this has allowed clinicians and funders to assess the optimal agent to be used in their own clinical settings based on logistics rather than efficacy.
Translational and Epidemiological/Population Health Colorectal Research.
As part of my membership of the Adelaide Colorectal Tumour Group and the Scientific Advisory committee that oversees the South Australian metastatic colorectal registry, there have been a number of areas of population research undertaken (see CV). Firstly there has been the epidemiological or population health based analysis relating to changes in clinical practice and outcomes for metastatic colorectal cancer resulting from the new agents available, and the evolution of surgical care and radiological technology over time. Our group has led reviews of the impact of late recurrence, primary site of colorectal cancer and outcome for advanced disease, improved survival with new systemic therapies in standard care and care and outcome patterns in the geriatric colorectal cancer space, to name a few. The breadth of this research can be evidenced by my attached publication list, which highlights a number of areas of research that I have both led and designed or collaborated in. Over site of the Registry for metastatic colorectal cancer and the subsequent projects is an important component of my role as a member of the Scientific Advisory Committee of the registry.
In keeping with my international profile I have been a member of the ESMO Colorectal Guidelines Group, initially publishing in 2012. The guidelines are currently being reviewed and are due to be published in an updated form later in 2016. Furthermore, as part of the Adelaide Colorectal Tumour Group and together with international collaborators we have published three Australian consensus documents on clinical care for advanced colorectal cancer which I have lead, together with a gastric cancer consensus document. This ongoing collaboration will lead to a further consensus meeting and updated guidelines in Vienna this year. In addition because of my National profile I have been recently asked to chair the NHMRC/Cancer Council Colorectal Guidelines and this will be a two year project overseeing the review of data and updating of guidelines for all aspects of colorectal cancer including prevention, screening and management of localised and advanced colorectal cancer.
-
Appointments
Date Position Institution name 2016 - ongoing Professor University of Adelaide 2008 - 2015 Associate Professor University of Adelaide -
Education
Date Institution name Country Title 2012 - 2014 University of Adelaide Australia Doctor of Health Science (Medicine) 1982 - 1988 University of Adelaide Australia MBBS -
Postgraduate Training
Date Title Institution Country 1999 - 2000 Research Fellow Institute of Cancer Research United Kingdom 1998 - 2000 Clinical Research Fellow The Royal Marsden NHS Foundation Trust United Kingdom RACP University of Sydney Australia -
Research Interests
-
Journals
Year Citation 2024 Man Ying Li, C., Li, R., Drew, P., Price, T., Smith, E., Maddern, G. J., . . . Fenix, K. (2024). Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: current strategies and future challenges. Cancer Treatment Reviews, 122, 102665-1-102665-11.
Scopus2 Europe PMC12024 Bedrikovetski, S., Traeger, L., Fitzsimmons, T., Price, T. J., Ruszkiewicz, A. R., Vather, R., & Sammour, T. (2024). ASO Visual Abstract: Association Between RAS/BRAF Mutations and Complete Response After Total Neoadjuvant Therapy of Patients with Rectal Cancer: A Prospective Multicentered Study. Annals of surgical oncology, 31(3), 1698-1699.
Scopus2 WoS1 Europe PMC12024 Vasconcelos, J. P. S., Chen, N., Titmuss, E., Tu, D., Brule, S. Y., Goodwin, R., . . . Loree, J. M. (2024). Transverse Colon Primary Tumor Location as a Biomarker in Metastatic Colorectal Cancer: A Pooled Analysis of CCTG/AGITG CO.17 and CO.20 Randomized Clinical Trials. Clinical Cancer Research, 30(6), 1121-1130.
Scopus1 Europe PMC12024 Li, C. M. Y., Tomita, Y., Dhakal, B., Tin, T., Li, R., Wright, J. A., . . . Fenix, K. (2024). Generation and assessment of cytokine-induced killer cells for the treatment of colorectal cancer liver metastases. Cancer Immunology Immunotherapy, 73(1), 6-1-6-16.
2024 Foo, T., Roy, A., Karapetis, C., Townsend, A., & Price, T. (2024). Metastatic colorectal cancer- third line therapy and beyond. Expert Review of Anticancer Therapy, 24(5), 219-227.
2024 Li, R., Liu, S., Yeo, K., Edwards, S., Li, M. Y., Santos, R., . . . Smith, E. (2024). Diagnostic and prognostic significance of circulating secreted frizzled-related protein 5 in colorectal cancer. Cancer Medicine, 13(11), 11 pages.
Europe PMC12024 Kawazoe, A., Xu, R. H., García-Alfonso, P., Passhak, M., Teng, H. W., Shergill, A., . . . Smyth, E. (2024). Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study. Journal of Clinical Oncology, 42(24), 2918-2927.
Scopus6 Europe PMC82024 Chen, C., Luo, X., Tang, W., Geng, H., Martínez-Pérez, J., Price, T., . . . Zhang, Y. (2024). Regorafenib combined with immune checkpoint inhibitors versus regorafenib monotherapy as a late-line treatment for metastatic colorectal cancer: a single-center, retrospective cohort study. Journal of Gastrointestinal Oncology, 15(4), 1497-1507.
2023 Wyrwicz, L., Taieb, J., Price, T., Bachet, J. -B., Karthaus, M., Vidot, L., . . . Heinemann, V. (2023). Clinical and quality of life outcomes with trifluridine/tipiracil: PRECONNECT and TALLISUR studies. COLORECTAL CANCER, 12(3), 11 pages.
2023 Jiang, D. M., Parshad, S., Zhan, L., Sim, H. W., Siu, L. L., Liu, G., . . . Chen, E. X. (2023). Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer. Clinical Colorectal Cancer, 22(4), 457-463.
2023 Guccione, L., Gough, K., Drosdowsky, A., Price, T., Pavlakis, N., Wyld, D., . . . Schofield, P. (2023). The unmet information needs, quality of life, and care experiences of patients with neuroendocrine tumours (NETs) at follow-up: 6 months from diagnosis.. Support Care Cancer, 31(10), 1-11.
2023 Geerinckx, B., Teuwen, L. A., Foo, T., Vandamme, T., Smith, A., Peeters, M., & Price, T. (2023). Novel therapeutic strategies in pancreatic cancer: moving beyond cytotoxic chemotherapy. Expert Review of Anticancer Therapy, 23(12), 1237-1249.
Scopus4 Europe PMC22023 Wardill, H. R., Wooley, L. T., Bellas, O. M., Cao, K., Cross, C. B., van Dyk, M., . . . Price, T. J. (2023). Supporting gut health with medicinal cannabis in people with advanced cancer: potential benefits and challenges. British Journal of Cancer, 130(1), 19-30.
Scopus2 Europe PMC22023 Kumarasinghe, M. P., Houghton, D., Allanson, B. M., & Price, T. J. (2023). What Therapeutic Biomarkers in Gastro-Esophageal Junction and Gastric Cancer Should a Pathologist Know About?. Surgical Pathology Clinics, 16(4), 659-672.
Scopus12023 Mikaeel, R. R., Edwards, S., Winter, J. M., Young, J. P., Young, G. P., Price, T. J., & Symonds, E. L. (2023). Age-Specific Differences in the Risk of Colorectal Precursor Lesions Among Patients with Type 2 Diabetes Undergoing Surveillance Colonoscopy. Asian Pacific Journal of Cancer Prevention, 24(5), 1769-1779.
2023 M. Naeini, M., Newell, F., Aoude, L. G., Bonazzi, V. F., Patel, K., Lampe, G., . . . Waddell, N. (2023). Multi-omic features of oesophageal adenocarcinoma in patients treated with preoperative neoadjuvant therapy. Nature Communications, 14(1), 17 pages.
Scopus10 WoS5 Europe PMC52023 Taieb, J., Price, T., Vidot, L., Chevallier, B., Wyrwicz, L., & Bachet, J. B. (2023). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy. BMC Cancer, 23(1), 11 pages.
Scopus7 WoS3 Europe PMC52023 Li, M., Chan, D. L., Tapia Rico, G., Cehic, G., Lawrence, B., Wyld, D., . . . Pavlakis, N. (2023). Australasian Consensus Statement on the Identification, Prevention, and Management of Hormonal Crises in Patients with Neuroendocrine Neoplasms Undergoing Peptide Receptor Radionuclide Therapy. Neuroendocrinology, 113(3), 281-288.
Scopus4 WoS1 Europe PMC12023 Bedrikovetski, S., Traeger, L., Price, T. J., Carruthers, S., Selva-Nayagam, S., Moore, J. W., & Sammour, T. (2023). Can sarcopenia predict complete response after total neoadjuvant therapy in advanced rectal cancer? A multicentre observational cohort study. Journal of Surgical Oncology, 128(1), 75-84.
Scopus9 WoS2 Europe PMC42023 Lam, L. L., Pavlakis, N., Shitara, K., Sjoquist, K. M., Martin, A. J., Yip, S., . . . Goldstein, D. (2023). INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer, 23(1), 12 pages.
Scopus6 Europe PMC122023 Shepherdson, M., Kilburn, D., Ullah, S., Price, T., Karapetis, C. S., Nguyen, P., . . . Roy, A. C. (2023). Survival outcomes for patients with colorectal cancer with synchronous liver only metastasis. ANZ Journal of Surgery, 93(7-8), 1847-1853.
Scopus3 WoS2 Europe PMC12023 Dhakal, B., Tomita, Y., Drew, P., Price, T., Maddern, G., Smith, E., & Fenix, K. (2023). Perhexiline: Old Drug, New Tricks? A Summary of Its Anti-Cancer Effects. Molecules, 28(8), 3624.
Scopus6 WoS1 Europe PMC22023 Li, C. M. Y., Tomita, Y., Dhakal, B., Li, R., Li, J., Drew, P., . . . Fenix, K. A. (2023). Use of cytokine-induced killer cell therapy in patients with colorectal cancer: a systematic review and meta-analysis. Journal for ImmunoTherapy of Cancer, 11(4), e006764-1-e006764-17.
Scopus6 WoS4 Europe PMC62023 Krishnan, T., Wang, F., Karapetis, C., Roy, A., & Price, T. (2023). Primary site and treatment impact in unresectable metastatic colorectal cancer. Expert Review of Anticancer Therapy, 23(6), 617-623.
Scopus1 Europe PMC12022 Shepherdson, M., Leemaqz, S., Singh, G., Ryder, C., Ullah, S., Canuto, K., . . . Barreto, S. G. (2022). Young-Onset Gastrointestinal Adenocarcinoma Incidence and Survival Trends in the Northern Territory, Australia, with Emphasis on Indigenous Peoples. Cancers, 14(12), 14 pages.
Scopus6 WoS1 Europe PMC52022 Dean, A., Gill, S., McGregor, M., Broadbridge, V., Järveläinen, H. A., & Price, T. (2022). Dual αV-integrin and neuropilin-1 targeting peptide CEND-1 plus nab-paclitaxel and gemcitabine for the treatment of metastatic pancreatic ductal adenocarcinoma: a first-in-human, open-label, multicentre, phase 1 study. The Lancet Gastroenterology and Hepatology, 7(10), 943-951.
Scopus36 WoS14 Europe PMC212022 Pavlakis, N., Tincknell, G., Lim, L. E., Muro, K., Obermannova, R., Lorenzen, S., . . . Lordick, F. (2022). European-Australasian consensus on the management of advanced gastric and gastro-oesophageal junction cancer: current practice and new directions. Therapeutic Advances in Medical Oncology, 14, 17 pages.
Scopus4 WoS12022 Liu, Z., Martin, J. H., Liauw, W., McLachlan, S. A., Link, E., Matera, A., . . . Michael, M. (2022). Evaluation of pharmacogenomics and hepatic nuclear imaging–related covariates by population pharmacokinetic models of irinotecan and its metabolites. European Journal of Clinical Pharmacology, 78(1), 53-64.
Scopus1 WoS1 Europe PMC12022 Nguyen, M., Segelov, E., Goldstein, D., Pavlakis, N., Shapiro, J., Price, T. J., . . . Roy, A. C. (2022). Update on optimal management for pancreatic cancer: expert perspectives from members of the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 22(1), 39-51.
2022 Mikaeel, R. R., Young, J. P., Li, Y., Smith, E., Horsnell, M., Uylaki, W., . . . Price, T. J. (2022). Survey of germline variants in cancer-associated genes in young adults with colorectal cancer. Genes Chromosomes and Cancer, 61(2), 105-113.
Scopus8 WoS4 Europe PMC72022 Alawawdeh, A., Price, T., Karapetis, C., Piantadosi, C., Padbury, R., Roy, A., . . . Townsend, A. R. (2022). Regorafenib outcomes from the population based South Australian Metastatic Colorectal Cancer Registry.. Asia Pac J Clin Oncol, 18(4), 428-433.
Scopus1 WoS12022 Mikaeel, R. R., Young, J. P., Li, Y., Poplawski, N. K., Smith, E., Horsnell, M., . . . Price, T. J. (2022). RNF43 pathogenic Germline variant in a family with colorectal cancer. Clinical Genetics, 101(1), 122-126.
Scopus5 WoS2 Europe PMC52022 Krishnan, T., Roberts-Thomson, R., Broadbridge, V., & Price, T. (2022). Targeting Mutated KRAS Genes to Treat Solid Tumours. Molecular Diagnosis and Therapy, 26(1), 39-49.
Scopus14 WoS7 Europe PMC72022 Fakih, M. G., Kopetz, S., Kuboki, Y., Kim, T. W., Munster, P. N., Krauss, J. C., . . . Price, T. J. (2022). Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trial. The Lancet Oncology, 23(1), 115-124.
Scopus180 WoS92 Europe PMC1162022 Chionh, F., Gebski, V., Al-Obaidi, S. J., Mooi, J. K., Bruhn, M. A., Lee, C. K., . . . Tebbutt, N. C. (2022). VEGF-A, VEGFR1 and VEGFR2 single nucleotide polymorphisms and outcomes from the AGITG MAX trial of capecitabine, bevacizumab and mitomycin C in metastatic colorectal cancer. Scientific Reports, 12(1), 14 pages.
Scopus8 WoS4 Europe PMC52022 Smith, A., Roy, A., Karapetis, C. S., Broadbridge, V., & Price, T. (2022). Immunotherapy use in oesophagogastric cancers—a review of the literature. British Journal of Cancer, 127(1), 21-29.
Scopus3 WoS2 Europe PMC22022 Foo, T., Goldstein, D., Segelov, E., Shapiro, J., Pavlakis, N., Desai, J., . . . Roy, A. C. (2022). The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours. Targeted Oncology, 17(2), 95-110.
Scopus5 WoS4 Europe PMC32022 Smith, A., Geerinckx, B., & Price, T. J. (2022). Insights from the IDEA Collaboration: Are They Enough?. Journal of Clinical Oncology, 40(16), 1843-1844.
Scopus1 WoS12022 Guccione, L., Gough, K., Drosdowsky, A., Price, T., Pavlakis, N., Wyld, D., . . . Schofield, P. (2022). The unmet supportive care needs, quality of life, and care experiences of patients with functioning and non-functioning Neuroendocrine tumours (NETs) at early diagnosis. Patient Education and Counseling, 105(1), 212-220.
Scopus1 WoS1 Europe PMC12022 Chan, D. L., Pavlakis, N., Crumbaker, M., Lawrence, B., Barber, C., Price, T. J., . . . Oberg, K. (2022). Vigilance for carcinoid heart disease is still required in the era of somatostatin analogues: Lessons from a case series. Asia-Pacific Journal of Clinical Oncology, 18(3), 209-216.
Scopus1 WoS12021 Michael, M., Chantrill, L., Price, T., Chan, D. L., Wakelin, K., & Cummins, M. (2021). Real-world management and patient perspectives on QOL with neuroendocrine tumors: An ANZ perspective. Asia-Pacific Journal of Clinical Oncology, 17(S2), 3-10.
Scopus1 WoS1 Europe PMC12021 Tomita, Y., Smith, E., Palethorpe, H. M., Nakhjavani, M., Yeo, K. K. L., Townsend, A. R., . . . Hardingham, J. E. (2021). In vitro synergistic inhibition of HT-29 proliferation and 2H-11 and HUVEC tubulogenesis by bacopaside I and II Is associated with Ca²⁺ flux and loss of plasma membrane integrity. Pharmaceuticals, 14(5), 1-18.
Scopus3 WoS22021 Nakhjavani, M., Smith, E., Yeo, K., Palethorpe, H. M., Tomita, Y., Price, T. J., . . . Hardingham, J. E. (2021). Anti-angiogenic properties of ginsenoside rg3 epimers: In vitro assessment of single and combination treatments. Cancers, 13(9), 20 pages.
Scopus19 WoS14 Europe PMC132021 Bernhardt, S. M., Dasari, P., Glynn, D. J., Townsend, A. R., Price, T. J., & Ingman, W. V. (2021). Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells. Breast cancer research and treatment, 187(3), 681-693.
Scopus2 Europe PMC12021 Nakhjavani, M., Smith, E., Yeo, K., Tomita, Y., Price, T. J., Yool, A., . . . Hardingham, J. E. (2021). Differential antiangiogenic and anticancer activities of the active metabolites of ginsenoside Rg3. Journal of Ginseng Research, 48(2), 10 pages.
Scopus2 Europe PMC22021 Skoulidis, F., Li, B. T., Dy, G. K., Price, T. J., Falchook, G. S., Wolf, J., . . . Govindan, R. (2021). Sotorasib for lung cancers with KRAS P.G12C mutation. New England Journal of Medicine, 384(25), 2371-2381.
Scopus953 WoS606 Europe PMC6222021 Mikaeel, R. R., Young, J. P., Tapia Rico, G., Hewett, P. J., Hardingham, J. E., Uylaki, W., . . . Price, T. J. (2021). Immunohistochemistry features and molecular pathology of appendiceal neoplasms. Critical Reviews in Clinical Laboratory Sciences, 58(6), 369-384.
Scopus7 WoS5 Europe PMC32021 Loree, J. M., Dowers, A., Tu, D., Jonker, D. J., Edelstein, D. L., Quinn, H., . . . Kopetz, S. (2021). Expanded low allele frequency RAS and BRAF V600E testing in metastatic colorectal cancer as predictive biomarkers for cetuximab in the randomized CO.17 trial. Clinical Cancer Research, 27(1), 52-59.
Scopus17 WoS10 Europe PMC122021 Mooi, J., Chionh, F., Savas, P., Da Gama Duarte, J., Chong, G., Brown, S., . . . Tebbutt, N. C. (2021). Dual antiangiogenesis agents bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer: results of a phase II study. Clinical Cancer Research, 27(8), 2159-2167.
Scopus13 WoS6 Europe PMC62021 Li, M., Roder, D., D'Onise, K., Walters, D., Farshid, G., Buckley, E., . . . Olver, I. (2021). Female breast cancer treatment and survival in South Australia: Results from linked health data.. Eur J Cancer Care (Engl), 30(5), 1-12.
Scopus2 WoS2 Europe PMC22021 Michael, M., Liauw, W., McLachlan, S. A., Link, E., Matera, A., Thompson, M., . . . Burge, M. E. (2021). Pharmacogenomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynamics: the predict IR study. Cancer Chemotherapy and Pharmacology, 88(1), 39-52.
2021 Alawawdeh, A., Krishnan, T., Roy, A., Karapetis, C., Joshi, R., Singhal, N., & Price, T. (2021). Curative therapy for rectal cancer. Expert Review of Anticancer Therapy, 21(2), 193-203.
Scopus7 WoS5 Europe PMC42021 Mikaeel, R. R., Symonds, E. L., Kimber, J., Smith, E., Horsnell, M., Uylaki, W., . . . Young, J. P. (2021). Young-onset colorectal cancer is associated with a personal history of type 2 diabetes. Asia Pacific Journal of Clinical Oncology, 17(1), 131-138.
Scopus22 WoS17 Europe PMC102021 Mikaeel, R., Young, J. P., Tapia Rico, G., Hardingham, J. E., Hewett, P. J., Symonds, E. L., . . . Price, T. J. (2021). Appendiceal Neoplasm Incidence and Mortality Rates are on the Rise in Australia. Expert Review of Gastroenterology and Hepatology, 15(2), 203-210.
Scopus4 WoS2 Europe PMC22021 Bernhardt, S. M., Dasari, P., Glynn, D. J., Woolford, L., Moldenhauer, L. M., Walsh, D., . . . Ingman, W. V. (2021). Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pymt mouse mammary tumours.. BMC Cancer, 21(1), 1-12.
Scopus3 WoS2 Europe PMC22021 Sartore-Bianchi, A., García-Alfonso, P., Geissler, M., Köhne, C. H., Peeters, M., Price, T., . . . Modest, D. P. (2021). Relationships Between Köhne Category/Baseline Tumor Load and Early Tumor Shrinkage, Depth of Response, and Outcomes in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 20(4), 305-313.
Scopus3 WoS12021 Nakhjavani, M., Smith, E., Palethorpe, H. M., Tomita, Y., Yeo, K., Price, T. J., . . . Hardingham, J. E. (2021). Anti-Cancer Effects of an Optimised Combination of Ginsenoside Rg3 Epimers on Triple Negative Breast Cancer Models. Pharmaceuticals, 14(7), 20 pages.
Scopus8 WoS7 Europe PMC42021 Dunn, C., Hong, W., Gibbs, P., Ackland, S., Sjoquist, K., Tebbutt, N. C., . . . Burge, M. (2021). Personalizing First-Line Systemic Therapy in Metastatic Colorectal Cancer: Is There a Role for Initial Low-Intensity Therapy in 2021 and Beyond? A Perspective From Members of the Australasian Gastrointestinal Trials Group: First-Line Therapy in Metastatic Colorectal Cancer. Clinical Colorectal Cancer, 20(3), 245-255.
Scopus2 WoS2 Europe PMC12021 Siu, H. W. D., Tebbutt, N., Chantrill, L., Karapetis, C., Steer, C., Wilson, K., . . . Burge, M. (2021). MONARCC: a randomised phase II study of panitumumab monotherapy and panitumumab plus 5-fluorouracil as first-line therapy for RAS and BRAF wildtype metastatic colorectal cancer: a study by the Australasian Gastrointestinal Trials Group (AGITG). BMC Cancer, 21(1), 9 pages.
Scopus3 Europe PMC12021 Schmoll, H. J., Stein, A., van Cutsem, E., Price, T., Hofheinz, R. D., Nordlinger, B., . . . Haustermans, K. (2021). Pre- And postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD. Journal of Clinical Oncology, 39(1), 17-29.
Scopus64 WoS37 Europe PMC372021 Reid, J. L., Kanhere, H. A., Hewett, P. J., Price, T. J., Maddern, G. J., & Trochsler, M. I. (2021). Can pressurised intraperitoneal aerosol chemotherapy with oxaliplatin (PIPAC-O+) be added to standard treatment for resectable high-risk gastric cancer patients? A study protocol. Pleura and Peritoneum, 6(4), 151-154.
Scopus4 WoS2 Europe PMC22021 Vanlint, A. S., Adams, J., & Price, T. (2021). COVID-19 prompts rapid and safe transition of chemotherapy into homes. Australian Health Review, 45(6), 782-783.
Scopus2 Europe PMC22021 Abbas, M. N., Bright, T., Price, T., Karapetis, C., Thompson, S., Connell, C., . . . Roy, A. (2021). Patterns of care and outcomes for gastric and gastro-oesophageal junction cancer in an Australian population. ANZ Journal of Surgery, 91(12), 2675-2682.
Scopus2 WoS2 Europe PMC22021 Alawawdeh, A., Piantadosi, C., Townsend, A. R., Karapetis, C. S., Padbury, R., Roy, A. C., . . . Price, T. J. (2021). Prognostic differences of RAS mutations: Results from South Australian (SA) Metastatic Colorectal Registry.. Targeted Oncology, 17(1), 35-41.
Scopus3 WoS2 Europe PMC22021 Sassi, C., Capozzo, R., Hammer, M., Zecca, C., Federoff, M., Blauwendraat, C., . . . Logroscino, G. (2021). Exploring dementia and neuronal ceroid lipofuscinosis genes in 100 FTD-like patients from 6 towns and rural villages on the Adriatic Sea cost of Apulia. SCIENTIFIC REPORTS, 11(1), 11 pages.
2021 McNeill, D., Karapetis, C., Price, T., Meagher, P., Piantadosi, C., Quinn, S., . . . Roy, A. (2021). Treatment and outcomes of metastatic colorectal cancer patients in public and private hospitals: results from the South Australian Metastatic Colorectal Cancer Registry. Internal Medicine Journal, 51(1), 69-77.
Scopus1 Europe PMC12020 Fontana, E., Nyamundanda, G., Cunningham, D., Tu, D., Cheang, M. C. U., Jonker, D. J., . . . Sadanandam, A. (2020). Intratumoral transcriptome heterogeneity is associated with patient prognosis and sidedness in patients with colorectal cancer treated with Anti-EGFR therapy from the CO.20 trial. JCO Precision Oncology, 4(4), 1152-1162.
Scopus5 WoS6 Europe PMC62020 Tie, J., Cohen, J. D., Lo, S. N., Wang, Y., Li, L., Christie, M., . . . Gibbs, P. (2020). Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies. International Journal of Cancer, 148(4), 1014-1026.
Scopus75 WoS59 Europe PMC532020 Price, T., Ang, A., Boedigheimer, M., Kim, T. W., Li, J., Cascinu, S., . . . Peeters, M. (2020). Frequency of S492R mutations in the epidermal growth factor receptor: analysis of plasma DNA from patients with metastatic colorectal cancer treated with panitumumab or cetuximab monotherapy. Cancer Biology and Therapy, 21(10), 891-898.
Scopus17 WoS8 Europe PMC182020 Chong, L. C., Hardingham, J. E., Townsend, A. R., Piantadosi, C., Rico, G. T., Karapetis, C., . . . Price, T. J. (2020). Rechallenge with Anti-EGFR Therapy in Metastatic Colorectal Cancer (mCRC): Results from South Australia mCRC Registry.. Target Oncol, 15(6), 751-757.
Scopus9 WoS7 Europe PMC72020 Nakhjavani, M., Smith, E., Townsend, A. R., Price, T. J., & Hardingham, J. E. (2020). Anti-Angiogenic Properties of Ginsenoside Rg3. Molecules (Basel, Switzerland), 25(21), 18 pages.
Scopus62 WoS38 Europe PMC302020 Hong, D. S., Fakih, M. G., Strickler, J. H., Desai, J., Durm, G. A., Shapiro, G. I., . . . Li, B. T. (2020). KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. The New England journal of medicine, 383(13), 1207-1217.
Scopus1084 WoS769 Europe PMC7052020 Prasanna, T., Wong, R., Price, T., Shapiro, J., Tie, J., Wong, H. L., . . . Yip, D. (2020). Metastasectomy and BRAF mutation; an analysis of survival outcome in metastatic colorectal cancer. Current Problems in Cancer, 45(1), 9 pages.
Scopus14 WoS10 Europe PMC102020 Bernhardt, S. M., Dasari, P., Walsh, D., Townsend, A. R., Price, T. J., & Ingman, W. V. (2020). Timing of breast cancer surgery during the menstrual cycle-is there an optimal time of the month?. Oncology letters, 20(3), 2045-2057.
Scopus6 WoS1 Europe PMC22020 Bernhardt, S. M., Dasari, P., Wrin, J., Raymond, W., Edwards, S., Walsh, D., . . . Ingman, W. V. (2020). Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age. Breast Cancer Res, 22(1), 1-10.
Scopus12 WoS8 Europe PMC102020 Bernhardt, S. M., Dasari, P., Walsh, D., Raymond, W., Hull, M. L., Townsend, A. R., . . . Ingman, W. V. (2020). The menstrual cycle is an under-appreciated factor in premenopausal breast cancer diagnosis and treatment. Current Opinion in Endocrine and Metabolic Research, 15, 37-42.
Scopus22020 Tomita, Y., Moldovan, M., Chang Lee, R., Hsieh, A. H., Townsend, A., & Price, T. (2020). Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. The Cochrane database of systematic reviews, 2020(11), 121 pages.
Scopus3 Europe PMC122020 Rico, G. T., Townsend, A., Price, T., & Patterson, K. (2020). Metastatic myxopapillary ependymoma treated with immunotherapy achieving durable response. BMJ Case Reports, 13(12), 6 pages.
Scopus5 WoS5 Europe PMC62020 Clarke, S. J., Burge, M., Feeney, K., Gibbs, P., Jones, K., Marx, G., . . . Tebbutt, N. C. (2020). The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. PLoS ONE, 15(3), e0229900.
Scopus15 WoS11 Europe PMC92020 Lau, D. K., Burge, M., Roy, A., Chau, I., Haller, D. G., Shapiro, J. D., . . . Price, T. J. (2020). Update on optimal treatment for metastatic colorectal cancer from the AGITG expert meeting: ESMO congress 2019. Expert Review of Anticancer Therapy, 20(4), 251-270.
Scopus5 WoS3 Europe PMC22020 Roy, A. C., Shapiro, J., Burge, M., Karapetis, C. S., Pavlakis, N., Segelov, E., . . . Price, T. (2020). Management of early-stage gastro-esophageal cancers: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 20(4), 305-324.
WoS12020 Narasimhan, V., Wright, J. A., Churchill, M., Wang, T., Rosati, R., Lannagan, T. R., . . . Woods, S. L. (2020). Medium-throughput drug screening of patient-derived organoids from colorectal peritoneal metastases to direct personalized therapy. Clinical Cancer Research, 26(14), 1-26.
Scopus122 WoS79 Europe PMC912020 Price, T., Burge, M., Chantrill, L., Gibbs, P., Pavlakis, N., Shapiro, J., & Sjoquist, K. (2020). Trifluridine/tipiracil: A practical guide to its use in the management of refractory metastatic colorectal cancer in Australia. Asia-Pacific Journal of Clinical Oncology, 16(S1), 3-12.
Scopus2 WoS1 Europe PMC12020 Bachet, J. B., Wyrwicz, L., Price, T., Cremolini, C., Phelip, J. M., Portales, F., . . . Falcone, A. (2020). Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study. ESMO Open, 5(3), 1-10.
Scopus33 WoS30 Europe PMC172020 Taniguchi, H., Yamanaka, T., Sakai, D., Muro, K., Yamazaki, K., Nakata, S., . . . Price, T. (2020). Efficacy of panitumumab and cetuximab in patients with colorectal cancer previously treated with bevacizumab; a combined analysis of individual patient data from aspecct and wjog6510g. Cancers, 12(7), 1-11.
Scopus9 WoS7 Europe PMC62020 Li, M., Roder, D., D'Onise, K., Walters, D., Farshid, G., Buckley, E., . . . Olver, I. (2020). Monitoring TNM stage of female breast cancer and survival across the South Australian population, with national and international TNM benchmarking: A population-based cohort study. BMJ Open, 10(6), e037069.
Scopus4 WoS3 Europe PMC32019 Nguyen, T. H., Stansborough, J., Ong, G. J., Surikow, S., Price, T. J., & Horowitz, J. D. (2019). Antecedent cancer in takotsubo syndrome predicts both cardiovascular and long-term mortality. Cardio-Oncology, 5(1), 9 pages.
Scopus11 WoS7 Europe PMC42019 Holden, C. A., Poprawski, D., Singhal, N., Buckley, E., Caruso, J., Wichmann, M. W., & Price, T. (2019). A systematic scoping review of determinants of multidisciplinary cancer team access and decision-making in the management of older patients diagnosed with colorectal cancer. Journal of Geriatric Oncology, 11(6), 909-916.
Scopus3 WoS3 Europe PMC12019 McGregor, M., & Price, T. J. (2019). IMblaze 370: lessons learned and future strategies in colorectal cancer treatment. ANNALS OF TRANSLATIONAL MEDICINE, 7(21), 5 pages.
WoS6 Europe PMC32019 Guccione, L., Gough, K., Drosdowsky, A., Fisher, K., Price, T., Pavlakis, N., . . . Schofield, P. (2019). Defining the supportive care needs and psychological morbidity of patients with functioning versus nonfunctioning neuroendocrine tumors: Protocol for a phase 1 trial of a nurse-led online and phone-based intervention. JMIR Research Protocols, 8(12), 12 pages.
Scopus3 WoS3 Europe PMC22019 Jameson, M. B., Gormly, K., Espinoza, D., Hague, W., Asghari, G., Jeffery, G. M., . . . Ackland, S. P. (2019). SPAR - A randomised, placebo-controlled phase II trial of simvastatin in addition to standard chemotherapy and radiation in preoperative treatment for rectal cancer: An AGITG clinical trial. BMC Cancer, 19(1), 12 pages.
Scopus14 WoS12 Europe PMC82019 Burzykowski, T., Coart, E., Saad, E. D., Shi, Q., Sommeijer, D. W., Bokemeyer, C., . . . Wolmark, N. (2019). Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer. JAMA Network Open, 2(9), E1911750.
Scopus8 WoS5 Europe PMC52019 Li, M., Olver, I., Keefe, D., Holden, C., Worthley, D., Price, T., . . . Roder, D. (2019). Pre-diagnostic colonoscopies reduce cancer mortality - Results from linked population-based data in South Australia. BMC Cancer, 19(1), 856.
Scopus10 WoS4 Europe PMC12019 Nakhjavani, M., Hardingham, J. E., Palethorpe, H. M., Price, T. J., & Townsend, A. R. (2019). Druggable molecular targets for the treatment of triple negative breast cancer. Journal of Breast Cancer, 22(3), 341-361.
Scopus42 WoS36 Europe PMC282019 Canon, J., Rex, K., Saiki, A. Y., Mohr, C., Cooke, K., Bagal, D., . . . Lipford, J. R. (2019). The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature, 575(7781), 217-223.
Scopus1374 WoS821 Europe PMC9282019 Woodhouse, B., Pattison, S., Segelov, E., Singh, S., Parker, K., Kong, G., . . . Lawrence, B. (2019). Consensus-derived quality performance indicators for neuroendocrine tumour care. Journal of Clinical Medicine, 8(9), 12 pages.
Scopus7 WoS6 Europe PMC32019 Nakhjavani, M., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., Yool, A. J., . . . Hardingham, J. E. (2019). Stereoselective anti-cancer activities of ginsenoside Rg3 on triple negative breast cancer cell models. Pharmaceuticals, 12(3), 117-1-117-14.
Scopus40 WoS29 Europe PMC232019 Chong, L. C., Karapetis, C., Roy, A., Padbury, R., & Price, T. J. (2019). Authors’ Reply to Yu: “Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry”. Targeted Oncology, 14(3), 367-368.
2019 Tomita, Y., Palethorpe, H. M., Smith, E., Nakhjavani, M., Townsend, A. R., Price, T. J., . . . Hardingham, J. E. (2019). Bumetanide-derived aquaporin 1 inhibitors, AqB013 and AqB050 inhibit tube formation of endothelial cells through induction of apoptosis and impaired migration in vitro. International Journal of Molecular Sciences, 20(8), 1818-1-1818-11.
Scopus16 WoS16 Europe PMC152019 McGregor, M., & Price, T. J. (2019). Moving miRNAs to therapeutic targets in colorectal cancer. EBioMedicine, 43, 13-14.
Europe PMC12019 Taieb, J., Geissler, M., Rivera, F., Karthaus, M., Wilson, R., Loupakis, F., . . . Peeters, M. (2019). Relationship Between Tumor Response and Tumor-Related Symptoms in RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses From 3 Panitumumab Trials. Clinical Colorectal Cancer, 18(4), 245-256.e5.
Scopus2 WoS2 Europe PMC12019 Palethorpe, H. M., Smith, E., Tomita, Y., Nakhjavani, M., Yool, A. J., Price, T. J., . . . Hardingham, J. E. (2019). Bacopasides I and II act in synergy to inhibit the growth, migration and invasion of breast cancer cell lines. Molecules, 24(19), 3539-1-3539-16.
Scopus29 WoS22 Europe PMC142019 Roder, D., Karapetis, C. S., Olver, I., Keefe, D., Padbury, R., Moore, J., . . . Price, T. (2019). Time from diagnosis to treatment of colorectal cancer in a South Australian clinical registry cohort: how it varies and relates to survival.. BMJ open, 9(9), 1-11.
Scopus25 WoS16 Europe PMC142019 Price, T., Shen, L., Ma, B., Esser, R., Chen, W., Gibbs, P., . . . Cheng, A. L. (2019). Phase II APEC trial: The impact of primary tumor side on outcomes of first-line cetuximab plus FOLFOX or FOLFIRI in patients with RAS wild-type metastatic colorectal cancer. Asia-Pacific Journal of Clinical Oncology, 15(4), 225-230.
Scopus4 WoS4 Europe PMC22019 Burge, M., Price, T., & Karapetis, C. S. (2019). First-line therapy for metastatic colorectal cancer: Current perspectives and future directions. Asia-Pacific Journal of Clinical Oncology, 15(S1), 3-14.
Scopus9 WoS5 Europe PMC32019 Young, J., Price, T. J., Hardingham, J., Symonds, E., Smith, E., Ruszkiewicz, A., . . . Poplawski, N. (2019). Type 2 diabetes as a potential risk marker for early onset colorectal cancer.. JOURNAL OF CLINICAL ONCOLOGY, 37(15), 2 pages.
WoS12019 Tang, M., Joensuu, H., Simes, R. J., Price, T. J., Yip, S., Hague, W., . . . Zalcberg, J. (2019). Challenges of international oncology trial collaboration-a call to action. British Journal of Cancer, 121(7), 515-521.
Scopus18 WoS13 Europe PMC122019 Nakhjavani, M., Hardingham, J. E., Palethorpe, H. M., Tomita, Y., Smith, E., Price, T. J., & Townsend, A. R. (2019). Ginsenoside Rg3: Potential molecular targets and therapeutic indication in metastatic breast cancer. Medicines, 6(1), 17-1-17-20.
Europe PMC272019 Chong, L. C., Townsend, A. R., Young, J., Roy, A., Piantadosi, C., Hardingham, J. E., . . . Price, T. J. (2019). Outcomes for Metastatic Colorectal Cancer Based on Microsatellite Instability: Results from the South Australian Metastatic Colorectal Cancer Registry. Targeted Oncology, 14(1), 85-91.
Scopus11 WoS10 Europe PMC82019 Smith, E., Tomita, Y., Palethorpe, H. M., Howell, S., Nakhjavani, M., Townsend, A. R., . . . Hardingham, J. E. (2019). Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation. Epigenetics, 14(2), 158-170.
Scopus9 WoS6 Europe PMC72019 Tapia Rico, G., Price, T., Tebbutt, N., Hardingham, J., Lee, C., Buizen, L., . . . Townsend, A. (2019). Right or left primary site of colorectal cancer: outcomes from the molecular analysis of the AGITG MAX Trial. Clinical Colorectal Cancer, 18(2), 141-148.
Scopus21 WoS18 Europe PMC132019 Peeters, M., Price, T., Boedigheimer, M., Kim, T. W., Ruff, P., Gibbs, P., . . . Ang, A. (2019). Evaluation of emergent mutations in circulating cell-free DNA and clinical outcomes in patients with metastatic colorectal cancer treated with panitumumab in the ASPECCT study. Clinical Cancer Research, 25(4), 1216-1225.
Scopus37 WoS25 Europe PMC232019 Wells, J. C., Tu, D., Siu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C., . . . O'Callaghan, C. J. (2019). Outcomes of Older Patients (≥ 70 Years) Treated With Targeted Therapy in Metastatic Chemorefractory Colorectal Cancer: Retrospective Analysis of NCIC CTG CO.17 and CO.20. Clinical Colorectal Cancer, 18(1), e140-e149.
Scopus5 WoS12019 Tie, J., Cohen, J. D., Wang, Y., Li, L., Christie, M., Simons, K., . . . Gibbs, P. (2019). Serial circulating tumour DNA analysis during multimodality treatment of locally advanced rectal cancer: A prospective biomarker study. Gut, 68(4), 663-671.
Scopus250 WoS204 Europe PMC1652018 Palethorpe, H., Tomita, Y., Smith, E., Pei, J., Townsend, A., Price, T., . . . Hardingham, J. (2018). The aquaporin 1 inhibitor bacopaside II reduces endothelial cell migration and tubulogenesis and induces apoptosis. International Journal of Molecular Sciences, 19(3), 653-1-653-10.
Scopus28 WoS24 Europe PMC172018 Tang, M., Price, T. J., Shapiro, J., Gibbs, P., Haller, D. G., Arnold, D., . . . Burge, M. (2018). Adjuvant therapy for resected colon cancer 2017, including the IDEA analysis. Expert Review of Anticancer Therapy, 18(4), 339-349.
Scopus6 WoS7 Europe PMC32018 Tapia Rico, G., & Price, T. J. (2018). Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential. Expert Opinion on Biological Therapy, 18(4), 449-457.
Scopus27 WoS22 Europe PMC172018 Price, T. (2018). Modified XELIRI (capecitabine plus irinotecan) for metastatic colorectal cancer. The Lancet Oncology, 19(5), 587-589.
Scopus4 WoS4 Europe PMC12018 Lau, D. K., Tay, A. Y., yeung, Y., Chionh, F., Mooi, J., Murone, C., . . . Tebbutt, N. C. (2018). Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol study. British Journal of Cancer, 118(7), 966-971.
Scopus44 WoS33 Europe PMC292018 Townsend, A., Tebbutt, N., Karapetis, C., Cooper, P., Singhal, N., Yeend, S., . . . Price, T. (2018). Phase IB/II study of second-line therapy with Panitumumab, Irinotecan, and Everolimus (PIE) in KRAS wild-type metastatic colorectal cancer. Clinical Cancer Research, 24(16), 3838-3844.
Scopus7 WoS5 Europe PMC52018 McGregor, M., & Price, T. J. (2018). Panitumumab in the treatment of metastatic colorectal cancer, including wild-type RAS, KRAS and NRAS mCRC. Future Oncology, 14(24), 2437-2459.
Scopus7 WoS7 Europe PMC52018 Tapia Rico, G., Karapetis, C., Townsend, A. R., Piantadosi, C., Padbury, R., Roy, A., . . . Price, T. J. (2018). Do we know what to do with our nonagenarian and centenarian patients with metastatic colorectal cancer (mCRC)? Results from the South Australian mCRC registry. Acta Oncologica, 57(11), 1455-1457.
Scopus3 WoS32018 Wong, G. Y. M., Kumar, R., Beeke, C., Ullah, S., Chen, J., Karapetis, C. S., . . . Padbury, R. (2018). Response to: "consideration of KRAS Mutation Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET, in Patients with Colorectal Liver Metastases". Annals of Surgery, 268(1), e9-e10.
2018 Adelson, P., Fusco, K., Karapetis, C., Wattchow, D., Joshi, R., Price, T., . . . Roder, D. (2018). Use of guideline-recommended adjuvant therapies and survival outcomes for people with colorectal cancer at tertiary referral hospitals in South Australia. Journal of Evaluation in Clinical Practice, 24(1), 135-144.
Scopus13 WoS12 Europe PMC92018 Goey, K. K. H., Sørbye, H., Glimelius, B., Adams, R. A., André, T., Arnold, D., . . . Koopman, M. (2018). Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. European Journal of Cancer, 100, 35-45.
Scopus30 WoS25 Europe PMC202018 Jonker, D. J., Nott, L., Yoshino, T., Gill, S., Shapiro, J., Ohtsu, A., . . . O'Callaghan, C. J. (2018). Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial. The Lancet Gastroenterology and Hepatology, 3(4), 263-270.
Scopus133 WoS111 Europe PMC932018 Sultana, A., Meng, R., Piantadosi, C., Brooke-Smith, M., Chen, J., Dolan, P., . . . Padbury, R. (2018). Liver resection for colorectal cancer metastases: a comparison of outcomes over time in South Australia. HPB, 20(4), 340-346.
Scopus10 WoS11 Europe PMC52018 Lee, R., Kanhere, H., Trochsler, M., Broadbridge, V., Maddern, G., & Price, T. (2018). Pancreatic, periampullary and biliary cancer with liver metastases: Should we consider resection in selected cases?. World Journal of Gastrointestinal Oncology, 10(8), 211-220.
Scopus7 WoS7 Europe PMC32018 Shapiro, J. D., Thavaneswaran, S., Underhill, C. R., Robledo, K. P., Karapetis, C. S., Day, F. L., . . . Segelov, E. (2018). Cetuximab Alone or With Irinotecan for Resistant KRAS-, NRAS-, BRAF- and PIK3CA-wild-type Metastatic Colorectal Cancer: The AGITG Randomized Phase II ICECREAM Study. Clinical Colorectal Cancer, 17(4), 313-319.
Scopus10 WoS7 Europe PMC42018 Tapia Rico, G., Li, M., Pavlakis, N., Cehic, G., & Price, T. J. (2018). Prevention and management of carcinoid crises in patients with high-risk neuroendocrine tumours undergoing peptide receptor radionuclide therapy (PRRT): Literature review and case series from two Australian tertiary medical institutions. Cancer Treatment Reviews, 66, 1-6.
Scopus29 WoS18 Europe PMC142018 Mooi, J. K., Wirapati, P., Asher, R., Lee, C. K., Savas, P., Price, T. J., . . . Tebbutt, N. C. (2018). The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial. Annals of Oncology, 29(11), 2240-2246.
Scopus110 WoS99 Europe PMC762018 Shepshelovich, D., Townsend, A. R., Espin-Garcia, O., Latifovic, L., O Callaghan, C. J., Jonker, D. J., . . . Liu, G. (2018). Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer. Cancer Medicine, 7(11), 5478-5487.
Scopus19 WoS17 Europe PMC132018 Kim, T. W., Peeters, M., Thomas, A., Gibbs, P., Hool, K., Zhang, J., . . . Price, T. (2018). Impact of emergent circulating tumor DNA Ras mutation in panitumumab-treated chemoresistant metastatic colorectal cancer. Clinical Cancer Research, 24(22), 5602-5609.
Scopus47 WoS37 Europe PMC312018 Price, T. J., Tang, M., Gibbs, P., Haller, D. G., Peeters, M., Arnold, D., . . . Shapiro, J. (2018). Targeted therapy for metastatic colorectal cancer. Expert Review of Anticancer Therapy, 18(10), 991-1006.
Scopus39 WoS35 Europe PMC252018 Prasanna, T., Karapetis, C. S., Roder, D., Tie, J., Padbury, R., Price, T., . . . Yip, D. (2018). The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Acta Oncologica, 57(11), 1438-1444.
Scopus77 WoS65 Europe PMC522018 Smith, E., Palethorpe, H. M., Tomita, Y., Pei, J., Townsend, A. R., Price, T. J., . . . Hardingham, J. E. (2018). The purified extract from the medicinal plant Bacopa monnieri, bacopaside II, inhibits growth of colon cancer cells in vitro by inducing cell cycle arrest and apoptosis. Cells, 7(7), 81-1-81-11.
Scopus47 WoS36 Europe PMC242018 Peeters, M., Price, T., Taieb, J., Geissler, M., Rivera, F., Canon, J. L., . . . Siena, S. (2018). Relationships between tumour response and primary tumour location, and predictors of long-term survival, in patients with RAS wild-type metastatic colorectal cancer receiving first-line panitumumab therapy: retrospective analyses of the PRIME and PEAK clinical trials. British Journal of Cancer, 119(3), 303-312.
Scopus34 WoS32 Europe PMC172018 Sud, S., O’callaghan, C., Jonker, C., Karapetis, C., Price, T., Tebbutt, N., . . . Goodwin, R. (2018). Hypertension as a predictor of advanced colorectal cancer outcome and cetuximab treatment response. Current Oncology, 25(6), e516-e526.
Scopus8 Europe PMC62018 Gibbs, P., Heinemann, V., Sharma, N. K., Taieb, J., Ricke, J., Peeters, M., . . . Gordon, M. (2018). Effect of Primary Tumor Side on Survival Outcomes in Untreated Patients With Metastatic Colorectal Cancer When Selective Internal Radiation Therapy Is Added to Chemotherapy: Combined Analysis of Two Randomized Controlled Studies. Clinical Colorectal Cancer, 17(4), e617-e629.
Scopus55 WoS42 Europe PMC262018 Leyden, J., Pavlakis, N., Chan, D., Michael, M., Clarke, S., Khasraw, M., & Price, T. (2018). Patient-reported experience of the impact and burden of neuroendocrine tumors: Oceania patient results from a large global survey. Asia-Pacific Journal of Clinical Oncology, 14(3), 256-263.
Scopus10 WoS8 Europe PMC42018 Taieb, J., Falcone, A., Lonardi, S., Price, T. J., Bachet, J. B., Wyrwicz, L., . . . Van Cutsem, E. (2018). Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase IIIb PRECONNECT study. Annals of oncology : official journal of the European Society for Medical Oncology, 29, viii155.
Scopus12018 Falcone, A., André, T., Edeline, J., François, E., Taieb, J., Phelip, J., . . . Seitz, J. (2018). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer (mCRC): Preliminary results from the phase IIIb, international, open-label, early-access PRECONNECT study. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v104-v105.
Scopus2 WoS132018 Schmoll, H., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R., Daisne, J., . . . Van Cutsem, E. (2018). PETACC-6: Preop chemoradiation and postop chemotherapy (capecitabine +/- oxaliplatin) in locally advanced rectal cancer: Overall survival after long term follow-up. Annals of oncology : official journal of the European Society for Medical Oncology, 29, v107.
Scopus1 WoS12018 Price, T. (2018). Convenor's Welcome. Asia-Pacific Journal of Clinical Oncology, 14(S3), 6.
2018 Wong, G., Kumar, R., Beeke, C., Ullah, S., Chen, J., Karapetis, C., . . . Padbury, R. (2018). Survival Outcomes for Patients with Indeterminate 18 FDG-PET Scan for Extrahepatic Disease before Liver Resection for Metastatic Colorectal Cancer: A Retrospective Cohort Study Using a Prospectively Maintained Database to Analyze Survival Outcomes for Patients with Indeterminate Extrahepatic Disease on 18FDG-PET Scan before Liver Resection for Metastatic Colorectal Cancer. Annals of Surgery, 267(5), 929-935.
Scopus6 WoS6 Europe PMC12017 Tapia Rico, G., Townsend, A. R., Broadbridge, V., & Price, T. J. (2017). Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs and Aging, 34(3), 173-189.
Scopus5 WoS4 Europe PMC22017 Parry, S., Burt, R. W., Win, A. K., Aung, Y. K., Woodall, S., Arnold, J., . . . Young, J. P. (2017). Reducing the polyp burden in serrated polyposis by serial colonoscopy: the impact of nationally coordinated community surveillance. The New Zealand Medical Journal, 130(1451), 57-67.
Scopus15 WoS12 Europe PMC52017 Chan, D. L., Sjoquist, K. M., Goldstein, D., Price, T. J., Martin, A. J., Bang, Y. J., . . . Pavlakis, N. (2017). The effect of anti-angiogenic agents on overall survival in metastatic oesophago-gastric cancer: A systematic review and meta-analysis. PLoS ONE, 12(2), 16 pages.
Scopus14 WoS11 Europe PMC102017 Chong, L., Healey, T., Michele, T., & Price, T. (2017). Capecitabine in locally advanced anal cancer, do we need randomised evidence?. Expert Review of Anticancer Therapy, 17(5), 411-416.
Scopus4 WoS4 Europe PMC22017 Price, T. J. (2017). Advanced colorectal cancer treatment options beyond standard systemic therapy. The Lancet Oncology, 18(2), 157-159.
Scopus10 WoS10 Europe PMC62017 Kumar, S., Tomita, Y., Wrin, J., Bruhn, M., Swalling, A., Mohammed, M., . . . Hardingham, J. (2017). High early growth response 1 (EGR1) expression correlates with resistance to anti-EGFR treatment in vitro and with poorer outcome in metastatic colorectal cancer patients treated with cetuximab. Clinical and Translational Oncology, 19(6), 718-726.
Scopus11 WoS12 Europe PMC92017 Tomita, Y., Dorward, H., Yool, A. J., Smith, E., Townsend, A. R., Price, T. J., & Hardingham, J. E. (2017). Role of aquaporin 1 signalling in cancer development and progression. International Journal of Molecular Sciences, 18(2), 299-1-299-17.
Scopus85 WoS73 Europe PMC562017 Marshall-Webb, M., Bright, T., Price, T., Thompson, S., & Watson, D. (2017). Venous thromboembolism in patients with esophageal or gastric cancer undergoing neoadjuvant chemotherapy. Diseases of the Esophagus, 30(2), 1-7.
Scopus20 WoS16 Europe PMC152017 Canavese, M., Ngo, D., Maddern, G., Hardingham, J., Price, T., & Hauben, E. (2017). Biology and therapeutic implications of VEGF-A splice isoforms and single-nucleotide polymorphisms in colorectal cancer. International Journal of Cancer, 140(10), 2183-2191.
Scopus37 WoS30 Europe PMC252017 Linke, K., Tapia Rico, G., & Price, T. J. (2017). Trends in the Treatment of Metastatic Colon and Rectal Cancer in Elderly Patients. Medical Care, 55(1), 86.
2017 Finlay, B., Price, T., & Hewett, P. (2017). Neutropenia and thrombocytopenia after cytoreductive surgery and heated intraperitoneal chemotherapy. Pleura and Peritoneum, 2(3), 137-141.
Scopus3 WoS32017 Peeters, M., Price, T., Taieb, J., Geissler, M., Rivera, F., Canon, J. L., . . . Siena, S. (2017). Impact of primary tumour location on response and resection outcomes in patients with metastatic colorectal cancer (mCRC) undergoing first-line treatment. Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii113-iii114.
Scopus12017 Falcone, A., Seitz, J. F., Price, T., Wyrwicz, L., Dorbon, A., Lopez Busto, N., . . . Van Cutsem, E. (2017). The international open-label early-access study of trifluridine/tipiracil (TAS-102) in patients with pretreated metastatic colorectal cancer (phase IIIb). Annals of oncology : official journal of the European Society for Medical Oncology, 28, iii124.
2017 Moore, J., Price, T., Carruthers, S., Selva-Nayagam, S., Luck, A., Thomas, M., & Hewett, P. (2017). Prospective randomized trial of neoadjuvant chemotherapy during the ‘wait period’ following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial. Colorectal Disease, 19(11), 973-979.
Scopus45 WoS30 Europe PMC222017 Thavaneswaran, S., Kok, P. S., & Price, T. (2017). Evaluating the addition of oxaliplatin to single agent fluoropyrimidine in the treatment of locally advanced rectal cancer: a systematic review and meta-analysis. Expert Review of Anticancer Therapy, 17(10), 965-979.
Scopus6 WoS5 Europe PMC22017 Segelov, E., Lordick, F., Goldstein, D., Chantrill, L. A., Croagh, D., Lawrence, B., . . . Price, T. J. (2017). Current challenges in optimizing systemic therapy for patients with pancreatic cancer: expert perspectives from the Australasian Gastrointestinal Trials Group (AGITG) with invited international faculty. Expert Review of Anticancer Therapy, 17(10), 951-964.
Scopus2 WoS2 Europe PMC22017 Tapia Rico, G., Klevansky, M., Townsend, A., & Price, T. (2017). Synovial metastasis of the knee in a KRAS mutant rectal adenocarcinoma patient. BMJ Case Reports, 2017, bcr-2017-220008.
Scopus3 Europe PMC32017 Chionh, F., Lau, D., Yeung, Y., Price, T., & Tebbutt, N. (2017). Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database of Systematic Reviews, 2017(7), CD008398.
Scopus49 WoS33 Europe PMC232017 Chan, D. L. H., Segelov, E., Wong, R. S. H., Smith, A., Herbertson, R. A., Li, B. T., . . . Pavlakis, N. (2017). Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, 2017(6), 174 pages.
Scopus12 WoS70 Europe PMC492017 Cheng, A. L., Cornelio, G., Shen, L., Price, T., Yang, T. S., Chung, I. J., . . . Lim, R. (2017). Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study. Clinical Colorectal Cancer, 16(2), e73-e88.
Scopus24 WoS18 Europe PMC102017 Rico, G., Price, T., Karapetis, C., Piantadosi, C., Padbury, R., Roy, A., . . . Townsend, A. (2017). Brain metastasis in advanced colorectal cancer: results from the South Australian metastatic colorectal cancer (SAmCRC) registry. Cancer Biology and Medicine, 14(4), 371-376.
Scopus17 WoS13 Europe PMC112017 Young, J. P., Price, T. J., & Parry, S. (2017). Serrated polyposis: The problem of definition and its relationship to the population at risk for syndrome-related colorectal cancer. Translational Cancer Research, 6(Suppl 9), S1480-S1483.
Scopus1 WoS1 Europe PMC12017 Chew, T., Bright, T., Price, T. J., Watson, D. I., & Devitt, P. G. (2017). Follow-Up Practices of Surgeons and Medical Oncologists in Australia and New Zealand Following Resection of Esophagogastric Cancers. Annals of thoracic and cardiovascular surgery : official journal of the Association of Thoracic and Cardiovascular Surgeons of Asia, 23(5), 217-222.
Scopus8 WoS5 Europe PMC42017 Roder, D., Farshid, G., Kollias, J., Koczwara, B., Karapetis, C., Adams, J., . . . Price, T. (2017). Female breast cancer management and survival: the experience of major public hospitals in South Australia over 3 decades-trends by age and in the elderly. Journal of Evaluation in Clinical Practice, 23(6), 1433-1443.
Scopus6 WoS5 Europe PMC32017 Wong, S., Lidums, I., Rosty, C., Ruszkiewicz, A., Parry, S., Win, A., . . . Young, J. (2017). Findings in young adults at colonoscopy from a hospital service database audit. BMC Gastroenterology, 17(1), 56-1-56-9.
Scopus14 WoS15 Europe PMC52017 Chandrasegaram, M. D., Gill, A. J., Samra, J., Price, T., Chen, J., Fawcett, J., & Merrett, N. D. (2017). Ampullary cancer of intestinal origin and duodenal cancer - A logical clinical and therapeutic subgroup in periampullary cancer. World Journal of Gastrointestinal Oncology, 9(10), 407-415.
Scopus35 WoS29 Europe PMC192017 Wasan, H. S., Gibbs, P., Sharma, N. K., Taieb, J., Heinemann, V., Ricke, J., . . . Limentani, S. (2017). First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trials. The Lancet Oncology, 18(9), 1159-1171.
Scopus280 WoS215 Europe PMC1412016 Harrison, S. J., Mainwaring, P., Price, T., Millward, M. J., Padrik, P., Underhill, C. R., . . . Spencer, A. (2016). Phase i clinical trial of marizomib (NPI-0052) in patients with advanced malignancies including multiple myeloma: Study NPI-0052-102 final results. Clinical Cancer Research, 22(18), 4559-4566.
Scopus65 WoS49 Europe PMC372016 Tomita, Y., Hsieh, A., Yuan, Y., Townsend, A., & Price, T. (2016). Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma. Cochrane Database of Systematic Reviews, 2016(2).
Scopus112016 Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2016). Colorectal cancer treatment and survival over three decades at four major public hospitals in South Australia: trends by age and in the elderly. European Journal of Cancer Care, 25(5), 753-763.
Scopus4 WoS4 Europe PMC42016 Patel, D., Townsend, A. R., Karapetis, C., Beeke, C., Padbury, R., Roy, A., . . . Price, T. J. (2016). Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry. Annals of Surgical Oncology, 23(11), 3616-3622.
Scopus16 WoS15 Europe PMC72016 Gormly, K. L., Coscia, C., Wells, T., Tebbutt, N., Harvey, J. A., Wilson, K., . . . Price, T. (2016). MRI rectal cancer in Australia and New Zealand: an audit from the PETACC-6 trial. Journal of Medical Imaging and Radiation Oncology, 60(5), 607-615.
Scopus6 WoS4 Europe PMC32016 Van Cutsem, E., Cervantes, A., Adam, R., Sobrero, A., Van Krieken, J. H., Aderka, D., . . . Arnold, D. (2016). ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Annals of Oncology, 27(8), 1386-1422.
Scopus2614 WoS2191 Europe PMC15292016 Tie, J., Wang, Y., Tomasetti, C., Li, L., Springer, S., Kinde, I., . . . Gibbs, P. (2016). Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Science Translational Medicine, 8(346), 1-10.
Scopus1056 WoS871 Europe PMC6572016 Patel, D., Chan, D., Cehic, G., Pavlakis, N., & Price, T. (2016). Systemic therapies for advanced gastroenteropancreatic neuroendocrine tumors. Expert Review of Endocrinology and Metabolism, 11(4), 311-327.
Scopus3 Europe PMC12016 Price, T., Thavaneswaran, S., Burge, M., Segelov, E., Haller, D., Punt, C., . . . Shapiro, J. (2016). Update on optimal treatment for metastatic colorectal cancer from the ACTG/AGITG expert meeting: ECCO 2015. Expert Review of Anticancer Therapy, 16(5), 557-571.
Scopus6 WoS5 Europe PMC62016 Schofield, P., Stockler, M., Zannino, D., Tebbutt, N., Price, T., Simes, R., . . . Jefford, M. (2016). Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer. Support Care Cancer, 24(1), 401-408.
Scopus28 WoS22 Europe PMC192016 Perera, T., Townsend, A., Price, T., Moldovan, M., & Roberts-Thomson, R. (2016). VENOUS THROMBOEMBOLISM: WHAT DO OUR PATIENTS KNOW?. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 12, 66-67. 2016 Segelov, E., Waring, P., Desai, J., Wilson, K., Gebski, V., Thavaneswaran, S., . . . Shapiro, J. (2016). ICECREAM: Randomised phase II study of cetuximab alone or in combination with irinotecan in patients with metastatic colorectal cancer with either KRAS, NRAS, BRAF and PI3KCA wild type, or G13D mutated tumours. BMC Cancer, 16(1), 8 pages.
Scopus14 WoS12 Europe PMC122016 Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Robledo, K., Gebski, V., . . . Shapiro, J. (2016). Response to cetuximab with or without irinotecan in patients with refractory metastatic colorectal cancer harboring the KRAS G13D mutation: Australasian gastro-intestinal trials group ICECREAM study. Journal of Clinical Oncology, 34(19), 2258-2264.
Scopus50 WoS45 Europe PMC342016 Bernhardt, S. M., Dasari, P., Walsh, D., Townsend, A. R., Price, T. J., & Ingman, W. V. (2016). Hormonal modulation of breast cancer gene expression: implications for intrinsic subtyping in premenopausal women. Frontiers in Oncology, 6(NOV), 241-1-241-16.
Scopus26 WoS22 Europe PMC152016 Townsend, A., Chong, L., Karapetis, C., & Price, T. (2016). Selective internal radiation therapy for liver metastases from colorectal cancer. Cancer Treatment Reviews, 50, 148-154.
Scopus22 WoS18 Europe PMC92016 Price, T., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., . . . Peeters, M. (2016). Final results and outcomes by prior bevacizumab exposure, skin toxicity, and hypomagnesaemia from ASPECCT: randomized phase 3 non-inferiority study of panitumumab versus cetuximab in chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer. European Journal of Cancer, 68, 51-59.
Scopus56 WoS48 Europe PMC322016 Tapia Rico, G., Townsend, A. R., Klevansky, M., & Price, T. J. (2016). Liver metastases resection for gastric and esophageal tumors: is there enough evidence to go down this path?. Expert Review of Anticancer Therapy, 16(12), 1219-1225.
Scopus6 WoS5 Europe PMC32016 Graham, C. N., Maglinte, G. A., Schwartzberg, L. S., Price, T. J., Knox, H. N., Hechmati, G., . . . Fakih, M. G. (2016). Economic Analysis of Panitumumab Compared with Cetuximab in Patients with Wild-type KRAS Metastatic Colorectal Cancer That Progressed after Standard Chemotherapy. Clinical Therapeutics, 38(6), 1376-1391.
Scopus10 WoS10 Europe PMC62016 Price, T., Karapetis, C., Piantadosi, C., Rico, G. T., Padbury, R., Maddern, G., . . . Townsend, A. (2016). Brain metastasis in advanced colorectal cancer: Results from the South Australian metastatic colorectal cancer (SAmCRC) registry. ANNALS OF ONCOLOGY, 27(suppl_6), 1 page.
2016 Ayoola, A., Vantandoust, S., Roy, A., Price, T. J., Kitchener, M., Roder, D., . . . Karapetis, C. (2016). Selective internal radiation therapy (SIRT) in metastatic colorectal cancer (mCRC): Safety, efficacy and survival outcomes from the South Australian registry. Annals of Oncology, 27, vi162.
2016 Tebbutt, N., Price, T., Ferraro, D., Wong, N., Veillard, A., Hall, M., . . . Gebski, V. (2016). Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. British Journal of Cancer, 114(5), 505-509.
Scopus44 WoS41 Europe PMC302016 Chandrasegaram, M., Chen, J., Price, T., Zalcberg, J., Sjoquist, K., & Merrett, N. (2016). Advances in molecular pathology and treatment of periampullary cancers. Pancreas, 45(1), 32-39.
Scopus24 WoS20 Europe PMC122016 Vatandoust, S., Price, T., Ullah, S., Roy, A., Beeke, C., Young, J., . . . Karapetis, C. (2016). Metastatic colorectal cancer in young adults: a study from the South Australian Population-Based Registry. Clinical Colorectal Cancer, 15(1), 32-36.
Scopus39 WoS36 Europe PMC202016 Wilson, E., Thompson, S., Bull, J., Jones, B., Price, T., Devitt, P., . . . Bright, T. (2016). Improving care for patients with oesophageal and gastric cancer: impact of a statewide multidisciplinary team. ANZ Journal of Surgery, 86(4), 270-273.
Scopus11 WoS10 Europe PMC62016 Young, J. P., Price, T. J., Moore, J., & Ruszkiewicz, A. R. (2016). Human intestinal spirochetosis and its relationship to sessile serrated adenomas in an Australian population. Pathology Research and Practice, 212(8), 751-753.
Scopus3 WoS3 Europe PMC42016 Dorward, H., Du, A., Bruhn, M., Wrin, J., Pei, J., Evdokiou, A., . . . Hardingham, J. (2016). Pharmacological blockade of aquaporin-1 water channel by AqB013 restricts migration and invasiveness of colon cancer cells and prevents endothelial tube formation in vitro. Journal of Experimental & Clinical Cancer Research, 35(1), 36-1-36-9.
Scopus65 WoS57 Europe PMC482016 Liu, G., Tu, D., Lewis, M., Cheng, D., Sullivan, L., Chen, Z., . . . Dobrovic, A. (2016). Fc-γ receptor polymorphisms, cetuximab therapy, and survival in the NCIC CTG CO.17 trial of colorectal cancer. Clinical Cancer Research, 22(10), 2435-2444.
Scopus35 WoS29 Europe PMC222016 Tomita, Y., Karapetis, C. S., Ullah, S., Townsend, A. R., Roder, D., Beeke, C., . . . Price, T. J. (2016). Survival improvements associated with access to biological agents: Results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry. Acta Oncologica, 55(4), 480-485.
Scopus11 WoS10 Europe PMC72016 Thavaneswaran, S., & Price, T. (2016). Optimal therapy for resectable rectal cancer. Expert Review of Anticancer Therapy, 16(3), 285-302.
2016 Tomita, Y., Karapetis, C., Roder, D., Beeke, C., Hocking, C., Roy, A., . . . Price, T. (2016). Comparable survival outcome of metastatic colorectal cancer in Indigenous and non-Indigenous patients: Retrospective analysis of the South Australian metastatic colorectal cancer registry. Australian Journal of Rural Health, 24(2), 85-91.
Scopus2 Europe PMC12016 Price, T. J., Beeke, C., Townsend, A. R., Lo, L., Amitesh, R., Padbury, R., . . . Karapetis, C. (2016). BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?. Molecular Diagnosis and Therapy, 20(1), 75-82.
Scopus8 WoS7 Europe PMC42015 Vatandoust, S., Price, T. J., & Karapetis, C. S. (2015). Colorectal cancer: Metastases to a single organ. World Journal of Gastroenterology, 21(41), 11767-11776.
Scopus233 WoS195 Europe PMC1512015 Lo, L., Patel, D., Townsend, A., & Price, T. (2015). Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer. Expert Opinion on Drug Metabolism & Toxicology, 11(12), 1907-1924.
Scopus12 WoS10 Europe PMC82015 Patel, G., Ullah, S., Beeke, C., Hakendorf, P., Padbury, R., Price, T., & Karapetis, C. (2015). Association of BMI with overall survival in patients with mCRC who received chemotherapy versus EGFR and VEGF-targeted therapies. Cancer Medicine, 4(10), 1461-1471.
Scopus19 WoS14 Europe PMC162015 Lo, L., Townsend, A. R., Patterson, W. K., Price, T. J., Yeend, S., Patel, D., . . . Pittman, K. B. (2015). NEOADJUVANT PACLITAXEL AND EPIRUBICIN FOR STAGE III BREAST CANCER: LONG TERM OUTCOMES OF PHASE II NAB TRIAL, ACTEC STUDY UPDATE. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 11, 57. 2015 Peeters, M., Oliner, K., Price, T., Cervantes, A., Sobrero, A., Ducreux, M., . . . Patterson, S. (2015). Analysis of KRAS/NRAS mutations in a phase III study of panitumumab with FOLFIRI compared with FOLFIRI zlone as second-line treatment for metastatic colorectal cancer. Clinical Cancer Research, 21(24), 5469-5479.
Scopus158 WoS136 Europe PMC1062015 Schmoll, H., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., . . . Haller, D. (2015). Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant Therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. Journal of Clinical Oncology, 33(32), 3733-3740.
Scopus218 WoS166 Europe PMC1302015 Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2015). Metastatic colorectal cancer treatment and survival: the experience of major public hospitals in South Australia over three decades. Asian Pacific Journal of Cancer Prevention, 16(14), 5923-5931.
Scopus12 Europe PMC22015 Chan, D., Pavlakis, N., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., & Segelov, E. (2015). Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature. PLoS One, 10(8), e0135599-1-e0135599-17.
Scopus24 WoS23 Europe PMC172015 Hardingham, J., Grover, P., Winter, M., Hewett, P., Price, T., & Thierry, B. (2015). Detection and clinical significance of circulating tumor cells in colorectal cancer - 20 years of progress. Molecular Medicine, 21(Suppl 1), S25-S31.
Scopus123 WoS101 Europe PMC792015 Price, T. J., Beeke, C., Ullah, S., Padbury, R., Maddern, G., Roder, D., . . . Karapetis, C. (2015). Does the Primary Site of Colorectal Cancer Impact Outcomes for Patients With Metastatic Disease?. Cancer, 121(6), 830-835.
Scopus140 WoS117 Europe PMC872015 Price, T. J., Tebbutt, N., & Townsend, A. R. (2015). Less surgery, improved survival from stage IV colorectal cancer?. JAMA Surgery, 150(8), 818.
2015 Weickhardt, A., Williams, D., Lee, C., Chionh, F., Simes, J., Murone, C., . . . Tebbutt, N. (2015). Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer. British Journal of Cancer, 113(1), 37-45.
Scopus54 WoS42 Europe PMC312015 Price, T., Bruhn, M., Lee, C., Hardingham, J., Townsend, A., Mann, K., . . . Tebbutt, N. (2015). Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer. British Journal of Cancer, 112(6), 963-970.
Scopus32 WoS30 Europe PMC172015 Roder, D., Karapetis, C., Wattchow, D., Moore, J., Singhal, N., Joshi, R., . . . Price, T. (2015). Colorectal cancer treatment and survival : the experience of major public hospitals in South Australia over three decades. Asian Pacific Journal of Cancer Prevention, 16(6), 2431-2440.
Scopus27 Europe PMC172015 Young, J., Win, A., Rosty, C., Flight, I., Roder, D., Young, G., . . . Price, T. (2015). Rising incidence of early-onset colorectal cancer in Australia over two decades: Report and review. Journal of Gastroenterology and Hepatology, 30(1), 6-13.
Scopus117 WoS95 Europe PMC652015 Roohullah, A., Wong, H., Sjoquist, K., Gibbs, P., Field, K., Tran, B., . . . Chantrill, L. (2015). Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World Journal of Gastroenterology, 21(17), 5352-5358.
Scopus5 WoS4 Europe PMC42015 Price, T. J. (2015). Second-line therapy for metastatic colorectal cancer. The Lancet Oncology, 16(5), 476-477.
2015 Chan, D. L., Pavlakis, N., Shapiro, J., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Segelov, E. (2015). Erratum: Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-Analysis of the literature (PLoS ONE (2015) 10:8 (e0135599) DOI: 10.1371/journal. pone.0135599). PLoS ONE, 10(9), e0138916.
Scopus42015 Van Cutsem, E., Bang, Y. J., Feng-yi, F., Xu, J. M., Lee, K. W., Jiao, S. C., . . . Rüschoff, J. (2015). HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer. Gastric Cancer, 18(3), 476-484.
Scopus432 WoS331 Europe PMC2882014 Karapetis, C. S., Jonker, D., Daneshmand, M., Hanson, J. E., O'Callaghan, C. J., Marginean, C., . . . Lorimer, I. A. J. (2014). PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer-results from NCIC CTG/AGITG CO.17. Clinical Cancer Research, 20(3), 744-753.
Scopus141 WoS129 Europe PMC1002014 Gibbs, P., Gebski, V., Van Buskirk, M., Thurston, K., Cade, D. N., Van Hazel, G. A., . . . Tatsch, K. (2014). Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: The SIRFLOX study. BMC Cancer, 14(1), 10 pages.
Scopus54 WoS44 Europe PMC312014 Newhall, K., Price, T., Peeters, M., Kim, T. W., Li, J., Cascinu, S., . . . Sidhu, R. (2014). Frequency of S492R Mutations in the Epidermal Growth Factor Receptor: Analysis of Plasma Dna from Metastatic Colorectal Cancer Patients Treated with Panitumumab or Cetuximab Monotherapy. Annals of Oncology, 25, ii109.
Scopus132014 Schmoll, H. J., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R., Daisne, J. F., . . . Van Cutsem, E. (2014). Preoperative Chemoradiotherapy and Postoperative Chemotherapy with Capecitabine and Oxaliplatin Vs. Capecitabine Alone in Locally Advanced Rectal Cancer: Disease Free Survival at Interim Analysis. Annals of Oncology, 25, ii111.
Scopus12014 Kumar, S. S., Price, T. J., Townsend, A. R., Hocking, C., & Hardingham, J. E. (2014). Predictive biomarkers of response to anti-EGF receptor monoclonal antibody therapies. COLORECTAL CANCER, 3(2), 223-232.
WoS12014 Bruhn, M., Townsend, A., Khoon Lee, C., Shivasami, A., Price, T., Wrin, J., . . . Hardingham, J. (2014). Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer. International Journal of Cancer, 135(3), 731-741.
Scopus31 WoS25 Europe PMC222014 Sree Kumar, S., Price, T., Mohyieldin, O., Borg, M., Townsend, A., & Hardingham, J. (2014). KRAS G13D mutation and sensitivity to cetuximab or panitumumab in a colorectal cancer cell line model. Gastrointestinal Cancer Research, 7(1), 23-26.
Scopus53 Europe PMC392014 Hocking, C., Hardingham, J. E., Broadbridge, V., Wrin, J., Townsend, A. R., Tebbutt, N., . . . Price, T. J. (2014). Can we accurately report PTEN status in advanced colorectal cancer?. BMC Cancer, 14(1), 128-1-128-7.
Scopus13 WoS11 Europe PMC62014 Segelov, E., Chan, D., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., & Pavlakis, N. (2014). The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. British Journal of Cancer, 111(6), 1122-1131.
Scopus29 WoS27 Europe PMC192014 Price, T., Peeters, M., Kim, T., Li, J., Cascinu, S., Ruff, P., . . . Sidhu, R. (2014). Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. The Lancet Oncology, 15(6), 569-579.
Scopus391 WoS328 Europe PMC2262014 Jonker, D., Karapetis, C., Harbison, C., O'Callaghan, C., Tu, D., Simes, R., . . . Khambata-Ford, S. (2014). Epiregulin gene expression as a biomarker of benefit from cetuximab in the treatment of advanced colorectal cancer. British Journal of Cancer, 110(3), 648-655.
Scopus66 WoS55 Europe PMC482014 Carter, H., Zannino, D., John Simes, R., Schofield, D., Howard, K., Zalcberg, J., . . . Tebbutt, N. (2014). The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study. European Journal of Cancer, 50(3), 535-543.
Scopus12 WoS15 Europe PMC122014 Sommeijer, D., Karapetis, C., Zalcberg, J., Tu, D., Jonker, D., Simes, J., . . . O'Callaghan, C. (2014). The relationship between rash, tumour KRAS mutation status and clinical and quality of life outcomes in patients with advanced colorectal cancer treated with cetuximab in the NCIC CTG/AGITG CO.17. Acta Oncologica, 53(7), 877-884.
Scopus9 WoS8 Europe PMC72014 Kumar, R., Price, T., Beeke, C., Jain, K., Patel, G., Padbury, R., . . . Karapetis, C. (2014). Colorectal cancer survival: an analysis of patients with metastatic disease synchronous and metachronous with the primary tumor. Clinical Colorectal Cancer, 13(2), 87-93.
Scopus54 WoS49 Europe PMC322014 Ransom, D., Wilson, K., Fournier, M., Simes, R., Gebski, V., Yip, D., . . . Price, T. (2014). Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines. Annals of Oncology, 25(1), 117-121.
Scopus56 WoS43 Europe PMC372014 Peeters, M., Price, T., Cervantes, A., Sobrero, A., Ducreux, M., Hotko, Y., . . . Sidhu, R. (2014). Final results from a randomized phase 3 study of FOLFIRI ± panitumumab for second-line treatment of metastatic colorectal cancer. Annals of Oncology, 25(1), 107-116.
Scopus178 WoS167 Europe PMC1092014 Vatandoust, S., Joshi, R., Pitman, K., Esterman, A., Broadbridge, V., Adams, J., . . . Price, T. (2014). A descriptive study of persistent oxaliplatin-induced peripheral neuropathy in patients with colorectal cancer. Supportive Care in Cancer, 22(2), 513-518.
Scopus29 WoS24 Europe PMC172014 Patel, G., Jain, K., Kumar, R., Strickland, A., Pellegrini, L., Slavotinek, J., . . . Karapetis, C. (2014). Comparison of peripherally inserted central venous catheters (PICC) versus subcutaneously implanted port-chamber catheters by complication and cost for patients receiving chemotherapy for non-haematological malignancies. Supportive Care in Cancer, 22(1), 121-128.
Scopus116 WoS82 Europe PMC582014 Wan, Y., Winter, M., Delalat, B., Hardingham, J., Grover, P., Wrin, J., . . . Thierry, B. (2014). Nanostructured polystyrene well plates allow unbiased high-throughput characterization of circulating tumor cells. ACS Applied Materials and Interfaces, 6(23), 20828-20836.
Scopus30 WoS30 Europe PMC152014 Price, T. J., Townsend, A. R., & Peeters, M. (2014). FOLFIRI with cetuximab or bevacizumab: FIRE-3. The Lancet Oncology, 15(13), e582-e583.
Scopus2 WoS2 Europe PMC22014 Price, T. J., Segelov, E., Burge, M., Haller, D. G., Tebbutt, N. C., Karapetis, C. S., . . . Shapiro, J. D. (2014). Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013. Expert Review of Anticancer Therapy, 14(12), 1477-1493.
Scopus11 WoS10 Europe PMC62014 Price, T. J., Peeters, M., Ruff, P., Murugappan, S., & Sidhu, R. (2014). Authors' reply. Lancet Oncology, 15(8), e303.
Scopus2 WoS2 Europe PMC12014 Hocking, C., & Price, T. (2014). Panitumumab in the management of patients with KRAS wild-type metastatic colorectal cancer. Therapeutic Advances in Gastroenterology, 7(1), 20-37.
Scopus26 WoS19 Europe PMC132014 Bhardwaj, N., Li, M., Price, T., & Maddern, G. J. (2014). Spontaneous regression of a biopsy confirmed hepatocellular carcinoma. BMJ Case Reports, 2014, bcr2014204897-1-bcr2014204897-3.
Scopus9 Europe PMC52014 Hocking, C., Broadbridge, V., Karapetis, C., Beeke, C., Padbury, R., Maddern, G., . . . Price, T. (2014). Equivalence of outcomes for rural and metropolitan patients with metastatic colorectal cancer in South Australia. Medical Journal of Australia, 201(8), 462-466.
Scopus9 WoS10 Europe PMC42014 Kumarasinghe, M. P., Brown, I., Raftopoulos, S., Bourke, M. J., Charlton, A., De Boer, W. B., . . . Lauwers, G. Y. (2014). Standardised reporting protocol for endoscopic resection for Barrett oesophagus associated neoplasia: Expert consensus recommendations. Pathology, 46(6), 473-480.
Scopus18 WoS14 Europe PMC62014 Grover, P., Cummins, A., Price, T., Roberts-Thomson, I., & Hardingham, J. (2014). Circulating tumour cells: the evolving concept and the inadequacy of their enrichment by EpCAM-based methodology for basic and clinical cancer research. Annals of Oncology, 25(8), 1506-1516.
Scopus181 WoS154 Europe PMC1192013 Padman, S., Padbury, R., Beeke, C., Karapetis, C., Bishnoi, S., Townsend, A., . . . Price, T. (2013). Liver only metastatic disease in patients with metastatic colorectal cancer: impact of surgery and chemotherapy. Acta Oncologica, 52(8), 1699-1706.
Scopus18 WoS14 Europe PMC122013 Broadbridge, V., Karapetis, C., Beeke, C., Woodman, R., Padbury, R., Maddern, G., . . . Price, T. (2013). Do metastatic colorectal cancer patients who present with late relapse after curative surgery have a better survival?. British Journal of Cancer, 109(5), 1338-1343.
Scopus25 WoS25 Europe PMC222013 Hocking, C., Townsend, A., & Price, T. (2013). Panitumumab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 13(7), 781-793.
Scopus4 WoS3 Europe PMC12013 Siu, L., Shapiro, J., Jonker, D., Karapetis, C., Zalcberg, J., Simes, J., . . . O'Callaghan, C. (2013). Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: The NCIC clinical trials group and AGITG co.. Journal of Clinical Oncology, 31(19), 2477-2484.
Scopus110 WoS94 Europe PMC772013 Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., . . . Tebbutt, N. (2013). Prognostic impact and the relevance of PTEN copy number alterations in patients with advanced colorectal cancer (CRC) receiving bevacizumab. Cancer Medicine, 2(3), 277-285.
WoS26 Europe PMC212013 Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., . . . Tabernero, J. (2013). Overview of biomarkers in metastatic colorectal cancer: tumour, blood and patient-related factors. Critical Reviews in Oncology Hematology, 85(2), 121-135.
Scopus18 WoS16 Europe PMC132013 Kumar, R., Jain, K., Beeke, C., Price, T., Townsend, A., Padbury, R., . . . Karapetis, C. (2013). A population-based study of metastatic colorectal cancer in individuals aged ≥ 80 years: findings from the South Australian Clinical Registry for Metastatic Colorectal Cancer. Cancer, 119(4), 722-728.
Scopus40 WoS34 Europe PMC212013 Townsend, A., Bishnoi, S., Broadbridge, V., Beeke, C., Karapetis, C., Jain, K., . . . Price, T. (2013). Rechallenge with oxaliplatin and fluoropyrimidine for metastatic colorectal carcinoma after prior therapy. American Journal of Clinical Oncology-Cancer Clinical Trials, 36(1), 49-52.
Scopus28 WoS22 Europe PMC192013 Shen, L., Shan, Y., Hu, H., Price, T., Sirohi, B., Yeh, K., . . . Chen, L. (2013). Management of gastric cancer in Asia: resource-stratified guidelines. Lancet Oncology, 14(12), e535-e547.
Scopus413 WoS261 Europe PMC2992013 Rosen, L., Lipton, L., Price, T., Belman, N., Boccia, R., Hurwitz, H., . . . Tebbutt, N. (2013). The effect of different dosing regimens of motesanib on the gallbladder: a randomized phase 1b study in patients with advanced solid tumors. BMC Cancer, 13(242), 1-11.
Scopus7 WoS9 Europe PMC62013 Price, T., Segelov, E., Burge, M., Haller, D., Ackland, S., Tebbutt, N., . . . Shapiro, J. (2013). Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 13(5), 597-611.
Scopus31 WoS29 Europe PMC222013 Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., . . . Jonker, D. (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960.
Scopus36 WoS37 Europe PMC242013 Willson, K., Nott, L., Broadbridge, V., & Price, T. (2013). Hepatic encephalopathy associated with cancer or anticancer therapy. Gastrointestinal Cancer Research, 6(1), 11-16.
Scopus22 Europe PMC202013 Tran, G., Hack, S. P., Kerr, A., Stokes, L., Gibbs, P., Price, T., & Todd, C. (2013). Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with XELOX or modified FOLFOX-6 regimens: Implications for health-care utilization in Australia. Asia-Pacific Journal of Clinical Oncology, 9(3), 239-248.
Scopus7 WoS6 Europe PMC22013 Leung, J. T., Kichendasse, G., Nott, L., & Price, T. (2013). Adjuvant therapy for resected pancreatic adencarcinoma (Protocol). Cochrane Database of Systematic Reviews, 2013(7).
2012 Padman, S. J., & Price, T. J. (2012). Age and treatment choices in advanced colorectal cancer. COLORECTAL CANCER, 1(4), 343-353.
2012 Karapetis, C. S., & Price, T. J. (2012). Resistance to EGF receptor-targeted monoclonal antibodies in the management of advanced colorectal cancer. COLORECTAL CANCER, 1(2), 137-148.
WoS12012 Price, T. (2012). ESMO consensus guidelines for management of patients with colon and rectal cancer: a personalized approach to clinical decision making. Annals of Oncology, 23(10), 2479-2516.
Scopus1221 WoS1087 Europe PMC8342012 Khattak, M., Martin, H., Beeke, C., Price, T., Carruthers, S., Kim, S., . . . Karapetis, C. (2012). Survival differences in patients with metastatic colorectal cancer and with single site metastatic disease at initial presentation: results from South Australian clinical registry for advanced colorectal cancer. Clinical Colorectal Cancer, 11(4), 247-254.
Scopus67 WoS52 Europe PMC442012 Grover, P., Cummins, A., Price, T., Roberts-Thomson, I., & Hardingham, J. (2012). A simple, cost-effective and flexible method for processing of snap-frozen tissue to prepare large amounts of intact RNA using laser microdissection. Biochimie, 94(12), 2491-2497.
Scopus10 WoS10 Europe PMC92012 Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Custem, E., . . . Tebbutt, N. (2012). Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 6(2), 199-209.
Scopus69 WoS63 Europe PMC532012 Weickhardt, A., Price, T., Chong, G., Gebski, V., Pavlakis, N., Johns, T., . . . Tebbutt, N. (2012). Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: Preclinical evaluation and results of the Phase II DUX Study in chemotherapy-refractory, advanced colorectal cancer. Journal of Clinical Oncology, 30(13), 1505-1512.
Scopus90 WoS81 Europe PMC622012 Vatandoust, S., Joshi, R., & Price, T. (2012). Guillain-Barré syndrome in colorectal cancer. Asia Pacific Journal of Clinical Oncology, 8(2), 205-208.
Scopus4 WoS3 Europe PMC32012 Broadbridge, V., Karapetis, C., & Price, T. (2012). Cetuximab in metastatic colorectal cancer. Expert Review of Anticancer Therapy, 12(5), 555-565.
Scopus31 WoS25 Europe PMC242012 Khattak, M., Townsend, A., Beeke, C., Karapetis, C., Luke, C., Padbury, R., . . . Price, T. (2012). Impact of age on choice of chemotherapy and outcome in advanced colorectal cancer. European Journal of Cancer, 48(9), 1293-1298.
Scopus25 WoS26 Europe PMC182012 Peeters, M., & Price, T. (2012). Biologic therapies in the metastatic colorectal cancer treatment continuum - applying current evidence to clinical practice. Cancer Treatment Reviews, 38(5), 397-406.
Scopus69 WoS67 Europe PMC552012 Millward, M., Price, T., Townsend, A., Sweeney, C., Spencer, A., Sukumaran, S., . . . Spear, M. (2012). Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. Investigational New Drugs, 30(6), 2303-2317.
Scopus127 WoS111 Europe PMC822012 Price, T., Zannino, D., Wilson, K., Simes, R., Cassidy, J., van Hazel, G., . . . Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536.
Scopus112 WoS99 Europe PMC722012 Arentz, G., Chataway, T., Condina, M., Price, T., Hoffmann, P., & Hardingham, J. (2012). Increased phospho-keratin 8 isoforms in colorectal tumors associated with EGFR pathway activation and reduced apoptosis. ISRN Molecular Biology, 2012, 1-8.
Europe PMC22012 Price, T., Townsend, A., Beeke, C., Bishnoi, S., Padbury, R., Maddern, G., & Karapetis, C. (2012). "Watchful waiting" for metastatic colorectal cancer, antediluvian or an option to be considered again?. Asia Pacific Journal of Clinical Oncology, 8(1), 10-13.
Scopus10 WoS8 Europe PMC62012 Tran, G., Hack, S., Kerr, A., Stokes, L., Gibbs, P., Price, T., & Todd, C. (2012). PHARMACOECONOMIC ANALYSIS OF DIRECT MEDICAL COSTS ASSOCIATED WITH THE TREATMENT OF ADVANCED ESOPHAGO-GASTRIC CANCER THERAPY WITH XELODA OR 5-FLUOROURACIL (5-FU) REGIMENS: IMPLICATIONS FOR HEALTH CARE UTILISATION IN AUSTRALIA. VALUE IN HEALTH, 15(7), A426.
2012 Moualed, D., Qayyum, A., Price, T., Sharma, A., & Mahendran, S. (2012). Bilateral synchronous tonsillar carcinoma: a case series and review of the literature. European Archives of Oto-Rhino-Laryngology, 269(1), 255-259.
WoS10 Europe PMC72012 Ransom, D., Wilson, K., Simes, J., Yip, D., Tebbutt, N., Karapetis, C., . . . Price, T. (2012). FINAL RESULTS OF AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP (AGITG) ARCTIC STUDY - AN INTERNATIONAL AUDIT OF RALTITREXED FOR PATIENTS WITH CARDIAC TOXICITY (CT) INDUCED BY FLUOROPYRIMIDINES (FP). ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 8, 314. 2011 Bishnoi, S., & Price, T. J. (2011). Reviewing the role of cytotoxics in oesophagogastric cancer in the refractory relapsed and advanced settings. Cancer Forum, 35(3), 145-150.
Scopus1 WoS12011 Vickers, M. M., Karapetis, C. S., Tu, D., O'Callaghan, C. J., Price, T. J., Tebbutt, N. C., . . . Jonker, D. J. (2011). The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
WoS22011 Elimova, E., O'Callaghan, C. J., Tu, D., Karapetis, C. S., Price, T. J., Zhu, L., . . . Jonker, D. J. (2011). Cetuximab (CET)-related hypersensitivity reactions (HSRs): An analysis of timing, demographics, and outcomes from the AGITG/NCIC CTG CO.17 trial. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
WoS12011 O'Callaghan, C. J., Tu, D., Karapetis, C. S., Au, H., Moore, M. J., Tebbutt, N. C., . . . Jonker, D. J. (2011). The relationship between the development of rash and clinical and quality of life outcomes by Kras mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17.. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 2 pages.
2011 O'Callaghan, C. J., Tu, D., Karapetis, C. S., Au, H., Moore, M. J., Tebbutt, N. C., . . . Jonker, D. J. (2011). The relationship between the development of rash and clinical and health-related quality of life outcomes by <i>KRAS</i> mutation status in patients with colorectal cancer treated with cetuximab in NCIC CTG CO.17. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
WoS12011 Price, T. J., Zannino, D., Wilson, K., Simes, J., Van Hazel, G. A., Robinson, B. A., . . . Tebbutt, N. C. (2011). Geriatric subgroup of AGITG MAX trial: International randomized phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page.
WoS12011 Van Hazel, G. A., Tu, D., Tebbutt, N. C., Jonker, D. J., Price, T. J., O'Callaghan, C., . . . Karapetis, C. S. (2011). Early change in tumor size from waterfall plot analysis and RECIST response as predictor of overall survival (OS) in advanced, chemotherapy-refractory colorectal cancer (ACRC): NCIC CTG/AGITG CO.17 study. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
WoS12011 Tebbutt, N. C., Lipton, L. R., Price, T. J., Belman, N. D., Boccia, R. V., Hurwitz, H., . . . Rosen, L. S. (2011). The effect of motesanib treatment on the gallbladder: A randomized phase Ib study in patients (pts) with advanced solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
WoS12011 Jain, K., Beeke, C., Price, T., Young, G., Roder, D., Padbury, R., . . . Karapetis, C. (2011). A population-based study of metastatic colorectal cancer (mCRC) in people age 80 and older: Findings from the South Australian Clinical Registry (SACR) for mCRC.. J Clin Oncol, 29(4_suppl), 514. 2011 Bishnoi, S., Pittman, K., Yeend, S., Brown, M., Koczwara, B., Kotasek, D., . . . Price, T. (2011). Gemcitabine and carboplatin in carcinoma of unknown primary site (CUP) in elderly patients: Analysis of a phase 2 Adelaide Cancer Trials and Education Collaborative (ACTEC) study. Journal of Geriatric Oncology, 2(4), 233-238.
Scopus1 WoS12011 Bishnoi, S., Pittman, K., Colbeck, M., Townsend, A., Hardingham, J., Sukumaran, S., . . . Price, T. (2011). Small cell lung cancer: Patterns of care and their influence on survival - 25 years experience of a single Australian oncology unit. Asia Pacific Journal of Clinical Oncology, 7(3), 252-257.
Scopus7 WoS7 Europe PMC22011 Kotasek, D., Tebbutt, N., Desai, J., Welch, S., Siu, L., McCoy, S., . . . Price, T. (2011). Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study. BMC Cancer, 11(1), 313-1-313-13.
Scopus9 WoS8 Europe PMC62011 Tebbutt, N., Murphy, F., Zannino, D., Wilson, K., Cummins, M., Abdi, E., . . . Price, T. (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838.
Scopus42 WoS35 Europe PMC302011 Price, T., Hardingham, J., Lee, C., Weickhardt, A., Townsend, A., Wrin, J., . . . Tebbutt, N. (2011). Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX Trial of capecitabine alone or in combination with Bevacizumab and Mitomycin in advanced colorectal cancer. Journal of Clinical Oncology, 29(19), 2675-2682.
Scopus187 WoS182 Europe PMC1342011 Neo, E., Beeke, C., Price, T., Maddern, G., Karapetis, C., Luke, C., . . . Padbury, R. (2011). South Australian clinical registry for metastatic colorectal cancer. Australian and New Zealand Journal of Surgery, 81(5), 352-357.
Scopus48 WoS43 Europe PMC332011 Haller, D., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., . . . Schmoll, H. (2011). Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. Journal of Clinical Oncology, 29(11), 1465-1471.
Scopus668 WoS562 Europe PMC3862011 Arentz, G., Chataway, T., Price, T., Izwan, Z., Hardi, G., Cummins, A., & Hardingham, J. (2011). Desmin expression in colorectal cancer stroma correlates with advanced stage disease and marks angiogenic microvessels. Clinical Proteomics, 8(1), 16:1-16:13.
Scopus37 Europe PMC232011 Townsend, A. R., Broadbridge, V., Beeke, C., Karapetis, C. S., Bishnoi, S., Jain, K., . . . Price, T. J. (2011). Rechallenge with oxaliplatin and fluoropyrimidine (FOX) after prior therapy in metastatic colorectal carcinoma (mCRC). JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
2011 Karapetis, C. S., Townsend, A., Beeke, C., Bishnoi, S., Kunal, J., Luke, C., . . . Price, T. J. (2011). Impact of watching prior to commencement of chemotherapy for metastatic colorectal cancer (mCRC): Findings from the South Australian Clinical Registry (SACR) for mCRC. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
2011 Jain, K., Price, T. J., Beeke, C., Padbury, R., Young, G. P., Roder, D., . . . Karapetis, C. S. (2011). An analysis of the effect of stage at diagnosis of bowel cancer on survival: Findings from the South Australian Clinical Registry (SACR) for metastatic colorectal cancer (mCRC).. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
2011 Jain, K., Beeke, C., Price, T. J., Young, G. P., Roder, D., Padbury, R., . . . Karapetis, C. S. (2011). A population-based study of metastatic colorectal cancer (mCRC) in people age 80 and older: Findings from the South Australian Clinical Registry (SACR) for mCRC. JOURNAL OF CLINICAL ONCOLOGY, 29(4), 1 page.
2011 Townsend, A. R., Pirc, L., Hardingham, J., Karapetis, C. S., Tebbutt, N. C., Singhal, N., & Price, T. J. (2011). A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).. JOURNAL OF CLINICAL ONCOLOGY, 29(15), 1 page.
2011 Luke, C., Sargent, N., Pittman, K., Price, T., & Roder, D. (2011). Epidemiology of cancers of the kidney in an Australian population. Asian Pacific Journal of Cancer Prevention, 12(11), 2893-2899.
Scopus13 WoS12 Europe PMC82010 Broadbridge, V., Townsend, A., Pittman, K., Kimber, R., Patterson, W., Sukumaran, S., & Price, T. J. (2010). Reversing Hyperammonemia in Neuroendocrine Tumors. Journal of Clinical Gastroenterology, 44(8), e186-e189.
Scopus7 WoS5 Europe PMC52010 Sukumaran, S., Pittman, K., Patterson, W., Dickson, J., Yeend, S., Townsend, A., . . . Price, T. (2010). A phase I study to determine the safety, tolerability and maximum tolerated dose of green-lipped mussel (Perna canaliculus) lipid extract, in patients with advanced prostate and breast cancer. Annals of Oncology, 21(5), 1089-1093.
Scopus10 WoS8 Europe PMC62010 Price, T. J., Townsend, A. R., & Khattak, A. (2010). Capecitabine in combination with oxaliplatin or irinotecan in elderly patients with advanced colorectal cancer: Results of a randomised phase II study. Annals of Oncology, 21(10), 2121.
Europe PMC12010 Price, T. J., Sobrero, A. F., Wilson, G., Van Cutsem, E., Aleknaviciene, B., Zaniboni, A., . . . Peeters, M. (2010). Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). JOURNAL OF CLINICAL ONCOLOGY, 28(15), 2 pages. 2010 Townsend, A., Price, T., Yeend, S., Pittman, K., Patterson, K., & Luke, C. (2010). Metastatic carcinoid tumor: changing patterns of care over two decades. Journal of Clinical Gastroenterology, 44(3), 195-199.
Scopus21 WoS18 Europe PMC122010 Peeters, M., Price, T., Cervantes, A., Sobrero, A., Ducreux, M., Hotko, Y., . . . Gansert, J. (2010). Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. Journal of Clinical Oncology, 28(31), 4706-4713.
Scopus881 WoS772 Europe PMC5742010 Luke, C., Price, T., Townsend, A., Karapetis, C., Kotasek, D., Singhal, N., . . . Roder, D. (2010). Epidemiology of neuroendocrine cancers in an Australian population. Cancer Causes & Control, 21(6), 931-938.
Scopus36 WoS31 Europe PMC172010 Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., . . . Price, T. (2010). Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian gastrointestinal trials group randomized phase III MAX study. Journal of Clinical Oncology, 28(19), 3191-3198.
Scopus366 WoS330 Europe PMC2502010 Price, T., Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis, N., Cunningham, D., . . . Shapiro, J. (2010). Current opinion on optimal treatment choices in first-line therapy for advanced or metastatic colorectal cancer: Report from the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 9(1), 8-14.
Scopus9 WoS9 Europe PMC52010 Khasraw, M., Townsend, A., Price, T., Hart, J., Bell, D., & Pavlakis, N. (2010). Objective radiological disease control with Sandostatin monotherapy in metastatic neuroendocrine tumours. Internal Medicine Journal, 40(6), 453-458.
Scopus5 WoS4 Europe PMC42010 Luke, C., Price, T., & Roder, D. (2010). Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population. Asian Pacific Journal of Cancer Prevention, 11(6), 1479-1485.
Scopus21 WoS16 Europe PMC112010 Haller, D. G., Cassidy, J., Tabernero, J., Maroun, J. A., De Braud, F. G., Price, T. J., . . . Schmoll, H. (2010). Efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin versus bolus 5-FU/LV for state III colon cancer (NO16968): Impact of age on disease-free survival (DFS). JOURNAL OF CLINICAL ONCOLOGY, 28(15), 2 pages.
WoS42010 Schofield, P., Stockler, M., Zannino, D., Wong, N., Ransom, D., Moylan, E., . . . Jefford, M. (2010). Hope, optimism, and survival in a randomized trial of first-line chemotherapy for patients with metastatic colorectal cancer. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
2010 Stockler, M., Zannino, D., Wilson, K., Gebski, V., Abdi, E. A., Strickland, A., . . . Tebbutt, N. C. (2010). Patient-rated outcomes (PRO) in a randomized trial of first-line chemotherapy with capecitabine (C), bevacizumab (B), and mitomycin-C (M) for metastatic colorectal cancer: The AGITG MAX trial. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
2010 Weickhardt, A. J., Price, T. J., Pavlakis, N., Skrinos, E., Dobrovic, A., Salemi, R., . . . Tebbutt, N. C. (2010). DUX study A phase 11 study of evaluating dual targeting of the EGFR using the combination of cetuximab and erlotinib in patients with chemotherapy refractory metastatic colorectal cancer.. JOURNAL OF CLINICAL ONCOLOGY, 28(15), 1 page.
2010 Chua, Y. J., Michael, M., Zalcberg, J. R., Hicks, R. J., Goldstein, D., Liauw, W., & Price, T. (2010). Antitumor effect of somatostatin analogs in neuroendocrine tumors. Journal of Clinical Oncology, 28(3), E41-E42.
Scopus8 WoS6 Europe PMC22009 Peeters, M., Price, T., & Van Laethem, J. L. (2009). Erratum: Anti epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: Where are we today? (The Oncologist (2009) 14 (29-39)). Oncologist, 14(3), 307.
Scopus22009 Townsend, A., Price, T., & Karapetis, C. (2009). Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database of Systematic Reviews, 2009(4), 16 pages.
Scopus27 WoS19 Europe PMC92009 Herbertson, R. A., Karapetis, C., Price, T., Tebbutt, N., & Pavlakis, N. (2009). Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, (4).
Scopus82009 Michael, M., Price, T., Ngan, S. Y., Ganju, V., Strickland, A. H., Muller, A., . . . Leong, T. (2009). A phase I trial of Capecitabine+Gemcitabine with radical radiation for locally advanced pancreatic cancer. British Journal of Cancer, 100(1), 37-43.
Scopus5 WoS4 Europe PMC32009 Sukumaran, S., Pavlakis, N., Pittman, K., Patterson, K., & Price, T. (2009). Capecitabine and irinotecan (XELIRI) in first-line treatment of metastatic colorectal cancer (mCRC): A systematic review of controlled clinical trials.. J Clin Oncol, 27(15_suppl), e15100. 2009 Tebbutt, N. C., Gebski, V., Wilson, K., Cummins, M., Chua, Y., Robinson, B., . . . Price, T. (2009). International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial.. J Clin Oncol, 27(15_suppl), 4023. 2009 Luke, C., Price, T., Karapetis, C., Singhal, N., & Roder, D. (2009). Pancreatic cancer epidemiology and survival in an Australian population. Asian Pacific Journal of Cancer Prevention, 10(3), 369-374.
Scopus15 WoS16 Europe PMC52009 Peeters, M., Price, T., & Van Laethem, J. (2009). Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?. The Oncologist, 14(1), 29-39.
Scopus67 WoS63 Europe PMC522009 Mushtaq, U., Price, T., Laddipeerla, N., Townsend, A., & Broadbridge, V. (2009). Contrast induced hyperthyroidism due to iodine excess.. BMJ case reports, 2009(nov03 1), bcr06.2009.1982.
Europe PMC12008 Kichenadasse, G., Townsend, A. R., Pittman, K. B., Patterson, K., Stephens, J. H., Borg, M., . . . Price, T. J. (2008). Rectal cancer: Pattern of care in the elderly. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
2008 Nott, L., Price, T. J., Pittman, K., Patterson, K., Young, R., & Fletcher, J. (2008). Hyperammonaemic encephalopathy associated with rituximab-containing chemotherapy.. Internal Medicine Journal, 38(10), 800-803. 2008 Townsend, A. R., Yeend, S., Luke, C., Pittman, K. B., Patterson, K., & Price, T. J. (2008). Metastatic carcinoid tumour (MCT): 20 years experience at the Queen Elizabeth Hospital. Does management by a medical oncology unit (MOU) improve outcome?. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
2008 Kotasek, D., Tebbutt, N. C., Welch, S., Wagner, V., McCoy, S., Sun, Y., & Price, T. J. (2008). Safety and pharmacokinetics (PK) of motesanib diphosphate in combination with gemcitabine (G) and erlotinib (E) for the treatment of patients (pts) with solid tumors. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
WoS42008 Townsend, A., Price, T., Patterson, K., & Pittman, K. (2008). Fluorouracil-induced Hepatic Artery Spasm Preventing Yttrium-90 Microsphere Administration. Clinical Nuclear Medicine, 33(8), 528-530.
Scopus2 WoS2 Europe PMC22008 Price, T., Lipton, L., McGreivy, J., McCoy, S., Sun, Y., & Rosenthal, M. (2008). Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. British Journal of Cancer, 99(9), 1387-1394.
Scopus16 WoS16 Europe PMC112008 Lewis, K., Robinson, W., Millward, M., Powell, A., Price, T., Thomson, D., . . . Gonzalez, R. (2008). A phase II study of the heparanase inhibitor PI-88 in patients with advanced melanoma. Investigational New Drugs, 26(1), 89-94.
Scopus69 WoS68 Europe PMC492008 Nott, L., Price, T., Patterson, K., Young, R., & Fletcher, J. (2008). Hyperammonaemic encephalopathy associated with rituximab-containing chemotherapy. Internal Medicine Journal, 38(10), 800-803.
Scopus11 WoS6 Europe PMC62008 Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., . . . Zalcberg, J. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine, 359(17), 1757-1765.
Scopus3273 WoS2901 Europe PMC21732008 Price, T., Pittman, K., Patterson, W., Colbeck, M., Rieger, N., Hewett, P., . . . Roder, D. (2008). Management and survival trends in advanced colorectal cancer. Clinical Oncology, 20(8), 626-630.
Scopus8 WoS10 Europe PMC72008 Luke, C., Koczwara, B., Karapetis, C., Pittman, K., Price, T., Kotasek, D., . . . Roder, D. (2008). Exploring the epidemiological characteristics of cancers of unknown primary site in an Australian population: implications for research and clinical care. Australian and New Zealand Journal of Public Health, 32(4), 383-389.
Scopus30 WoS31 Europe PMC182008 Price, T. J., & Townsend, A. (2008). Yttrium 90 microsphere selective internal radiation treatment of hepatic colorectal metastases. Archives of Surgery, 143(3), 313-314.
Scopus6 WoS6 Europe PMC62008 Price, T. J., Gebski, V., van Hazel, G. A., Robinson, B. A., Broad, A., Ganju, V., . . . Tebbutt, N. C. (2008). International multi-centre randomised Phase II/III study of Capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) as first-line treatment for metastatic colorectal cancer (mCRC): Final safety analysis of the AGITG MAX trial. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page. 2008 Price, T. J., & Nott, L. (2008). Unusual hair changes with prolonged erlotinib exposure. Internal Medicine Journal, 38(10), 807.
Scopus1 WoS1 Europe PMC12008 Stockler, M. R., Grimison, P. S., Price, T. J., van Hazel, G. A., Robinson, B. A., Broad, A., . . . Tebbutt, N. C. (2008). Comparing utilities for advanced colorectal cancer valued from societal and cancer patients' perspectives using baseline data from the MAX study. JOURNAL OF CLINICAL ONCOLOGY, 26(15), 1 page.
2008 Townsend, A., Price, T., & Karapetis, C. (2008). Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database of Systematic Reviews, (2).
Scopus22008 Herbertson, R. A., Karapetis, C., Pavlakis, N., Price, T., & Tebbutt, N. (2008). Epidermal growth factor receptor (EGF-R) inhibitors for metastatic colorectal cancer. Cochrane Database of Systematic Reviews, (2).
Scopus652007 Schmoll, H., Cartwright, T., Tabernero, J., Nowacki, M., Figer, A., Maroun, J., . . . Haller, D. (2007). Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: A planned safety analysis in 1 864 patients. Journal of Clinical Oncology, 25(1), 102-109.
Scopus275 WoS226 Europe PMC1652007 Nott, L., Yeend, S., Pirc, L., Pittman, K., Patterson, K., & Price, T. (2007). Successfully improving access and accrual to oncology clinical trials. Cancer, 109(8), 1451-1453.
Scopus3 WoS3 Europe PMC32007 Luke, C., Gill, P., Birrell, S., Humeniuk, V., Borg, M., Karapetis, C., . . . Roder, D. (2007). Treatment and survival from breast cancer: The experience of patients at South Australian teaching hospitals between 1977 and 2003. Journal of Evaluation in Clinical Practice, 13(2), 212-220.
Scopus7 WoS7 Europe PMC52007 Kichenadasse, G., Zakaria, J., Rodda, D., Hewett, P., Rieger, N., Stephens, J., . . . Price, T. (2007). Squamous cell carcinoma of the anal canal at the Queen Elizabeth Hospital: A local experience. Asia Pacific Journal of Clinical Oncology, 3(4), 214-218.
Scopus3 WoS32007 Jonker, D., O'Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., . . . Moore, M. (2007). Cetuximab for the treatment of colorectal cancer. New England Journal of Medicine, 357(20), 2040-2048.
Scopus1798 WoS1583 Europe PMC11442007 Nott, L., Price, T., Pittman, K., Patterson, K., & Fletcher, J. (2007). Hyperammonemia encephalopathy: An important cause of neurological deterioration following chemotherapy. Leukemia & Lymphoma, 48(9), 1702-1711.
Scopus89 WoS77 Europe PMC502006 Pittman, K., Olver, I., Koczwara, B., Kotasek, D., Patterson, W., Keefe, D., . . . Price, T. (2006). Gemcitabine and carboplatin in carcinoma of unknown primary site: a phase 2 Adelaide Cancer Trials and Education Collaborative study. British Journal of Cancer, 95(10), 1309-1313.
Scopus32 WoS29 Europe PMC222005 Luke, C., Koczwara, B., Moore, J., Olver, I., Penniment, M., Pittman, K., . . . Roder, D. (2005). Treatment and survival from colorectal cancer: The experience of patients at South Australian teaching hospitals between 1980 and 2002. Clinical Oncology, 17(5), 372-381.
Scopus14 WoS12 Europe PMC72005 Chong, G., Dickson, J. L. B., Cunningham, D., Norman, A. R., Rao, S., Hill, M. E., . . . Tebbutt, N. (2005). Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan. British Journal of Cancer, 93(5), 510-514.
Scopus60 WoS56 Europe PMC372005 Schmoll, H., Tabernero, J., Nowacki, M., Maroun, J., Price, T., Lim, R., . . . Haller, D. (2005). Initial safety findings from XELOXA: a randomised phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. EJC SUPPLEMENTS, 3(2), 174. 2005 Leong, T., Michael, M., Ganju, V., Price, T., Strickland, A., Jefford, M., . . . Zalcberg, J. (2005). Phase I trial of capecitabine and gemcitabine with concurrent radical radiotherapy in locally advanced pancreatic cancer: interim results. EJC SUPPLEMENTS, 3(2), 222. 2004 Price, T. J., Ross, P. J., Hickish, T., Tait, D., Norman, A. R., Ford, H. E. R., . . . Cunningham, D. (2004). Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clinical Colorectal Cancer, 3(4), 235-242.
Scopus32 Europe PMC182004 Bardy, P., Sage, E., Norman, J., Chunilal, S., Dart, G., Pittman, K., . . . Roder, D. (2004). Reasons for lower survival from non-hodgkin's lymphoma among older patients. Asian Pacific Journal of Cancer Prevention, 5(3), 301-307. 2004 Rao, S., Cunningham, D., Price, T., Hill, M., Ross, P., Tebbutt, N., . . . Shellito, P. (2004). Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer. British Journal of Cancer, 91(5), 839-843.
Scopus34 WoS32 Europe PMC202003 Mackay, H. J., Hill, M., Twelves, C., Glasspool, R., Price, T., Campbell, S., . . . Cunningham, D. (2003). A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer. Annals of Oncology, 14(8), 1264-1269.
Scopus21 WoS22 Europe PMC182002 Price, T., Karapetis, C., Chevalier, V., Curé, H., Chollet, P., & Lévi, F. (2002). Chronomodulated chemotherapy in advanced colorectal carcinoma [7] (multiple letters). Journal of Clinical Oncology, 20(18), 3937-3939.
Scopus12002 Price, T., Hill, M., Norman, A., Sumpter, K., & Cunningham, D. (2002). The Royal Marsden experience of the use of carboplatin in oesophageal carcinoma. Gastrointestinal Oncology, 4(1), 23-26.
Scopus32002 Ross, P., Nicolson, M., Cunningham, D., Valle, J., Seymour, M., Harper, P., . . . Norman, A. (2002). Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) with epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer. Journal of Clinical Oncology, 20(8), 1996-2004.
Scopus485 WoS394 Europe PMC2862000 Price, T., & Hill, M. (2000). UFT/leucovorin plus irinotecan in advanced or metastatic colorectal cancer. Oncology, 14(10 SUPPL. 9), 28-31.
Scopus10 WoS7 Europe PMC22000 Hill, M., Mackay, H., Cunningham, D., Glasspool, R., Price, T., Campbell, S., . . . Twelves, C. (2000). Phase I/II study of oral uracil/tegafur (UFT®), leucovorin and irinotecan in patients with advanced colorectal cancer.. ANNALS OF ONCOLOGY, 11, 45.
WoS62000 Price, T., Walton, M., Cunningham, D., & Workman, P. (2000). Activity of paullones in colon cell lines does not correlate to cell cycle protein expression.. ANNALS OF ONCOLOGY, 11, 13.
WoS12000 Zuha, R., Price, T., Powles, R., & Treleaven, J. (2000). Paradoxical emboli after central venous catheter removal. Annals of Oncology, 11(7), 885-886.
Scopus20 WoS16 Europe PMC142000 Ford, H. E. R., Cunningham, D., Ross, P. J., Rao, S., Aherne, G. W., Benepal, T. S., . . . Gruia, G. (2000). Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma. British Journal of Cancer, 83(2), 146-152.
Scopus24 WoS19 Europe PMC102000 Price, T., Walton, M. I., Titley, J., Cunningham, D., & Workman, P. (2000). Studies on the mechanism of action of the cyclin dependent kinase inhibitors 9-nitro and 10-bromopaullone in human colon tumour cell lines.. CLINICAL CANCER RESEARCH, 6, 4530S. 2000 Massacesi, C., Norman, A., Price, T., Hill, M., Ross, P., & Cunningham, D. (2000). A clinical nomogram for predicting long-term survival in advanced colorectal cancer. European Journal of Cancer, 36(16), 2044-2052.
Scopus45 WoS40 Europe PMC331999 Castagnola, E., Viscoli, C., Olver, I. N., Price, T. J., & Patterson, W. K. (1999). Rifampicin as treatment for pruritus in malignant cholestasis: An example of an improper indication for anti-infective drugs (multiple letters). Supportive Care in Cancer, 7(3), 160.
Scopus2 Europe PMC21998 Price, T. J., Patterson, W. K., & Olver, I. N. (1998). Rifampicin as treatment for pruritus in malignant cholestasis. Supportive Care in Cancer, 6(6), 533-535.
Scopus19 WoS18 Europe PMC8- Mikaeel, R. R., Price, T. J., Smith, E., Drew, P. A., Uylaki, W., Horsnell, M., & Young, J. P. (n.d.). Colorectal Cancer in Australian Young Adults. Mathews Journal of Cancer Science, 4(1).
-
Book Chapters
Year Citation 2016 Lo, L., Young, J., Price, T., & Townsend, A. (2016). BRAF Mutation in Colorectal Cancer. In L. Rodrigo (Ed.), Colorectal Cancer-From pathogenesis to treatment (pp. 89-117). Online: INTECH. 2014 Savas, P., & Price, T. (2014). Medical oncology. In M. Wichmann, & G. Maddern (Eds.), Palliative Surgery (Vol. 9783642537097, pp. 71-82). Germany: Springer.
DOI Scopus12012 Hardingham., Wrin, J., Shivasami, A., Tebbutt, N., & Price, T. (2012). BRAF V600E Mutation Detection Using High Resolution Probe Melting Analysis. In P. Hernandez-Rodriguez, & A. Gomez (Eds.), Polymerase Chain Reaction (pp. 143-156). Online: InTech. -
Conference Papers
Year Citation 2023 Vasconcelos, J. P. S., Chen, N., Tu, D., Brule, S. Y., Goodwin, R. A., Jonker, D. J., . . . Loree, J. M. (2023). Predictive and prognostic features of metastatic colorectal cancer arising from the transverse colon: A pooled analysis of the CCTG/AGITG CO.17 and CO.20 randomized trials.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 41 (pp. 124). CA, San Francisco: LIPPINCOTT WILLIAMS & WILKINS.
WoS12023 Day, D., Starus, A., Gebski, V., Simes, J., Hayes, T., Padinharakam, S., . . . Segelov, E. (2023). Minimal residual disease (MRD) detection using a tumour naive circulating tumour DNA (ctDNA) assay in patients (pts) with resected colorectal cancer (CRC) in the phase III ASCOLT trial. In ANNALS OF ONCOLOGY Vol. 34 (pp. S426-S427). SPAIN, Madrid: ELSEVIER.
DOI2022 Jungels, C., Kotecki, N., Calvo, E., Garralda, E., Price, T., Zahn, X., . . . Legrande, J. (2022). Study of PRS-344/S095012 a PD-L1/4-1BB bispecific antibody-Anticalin®-fusion in patients with solid tumors.. In CANCER RESEARCH Vol. 82 (pp. 1 page). LA, New Orleans: AMER ASSOC CANCER RESEARCH. 2022 Price, T., Grewal, J., Abed, A., Moore, M., Yeh, Y. -M., Gadgeel, S., . . . Millward, M. (2022). A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRAS<SUP>G12C</SUP> inhibitor, in patients with advanced or metastatic solid tumor harboring KRAS<SUP>G12C</SUP> mutation.. In CANCER RESEARCH Vol. 82 (pp. 2 pages). LA, New Orleans: AMER ASSOC CANCER RESEARCH.
WoS22022 Prenen, H., Fakih, M., Falchook, G., Strickler, J., Hindoyan, A., Anderson, A., . . . Price, T. (2022). Evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated colorectal cancer: Exploratory plasma biomarker analysis of CodeBreaK 100. In ANNALS OF ONCOLOGY Vol. 33 (pp. S373). Barcelona, SPAIN: ELSEVIER.
DOI WoS32022 Wyrwicz, L., Taieb, J., Price, T., Bachet, J., Karthaus, M., Vidot, L., . . . Heinemann, V. (2022). Reinforcing clinical outcomes with patient-reported QoL outcomes in patients with mCRC receiving FTD/TPI: Pooled analysis of PRECONNECT and TALLISUR studies. In ANNALS OF ONCOLOGY Vol. 33 (pp. S364). Barcelona, SPAIN: ELSEVIER.
DOI2022 Price, T. J. (2022). International trial activity of AGITG. In ANNALS OF ONCOLOGY Vol. 33 (pp. S406). Kyoto, JAPAN: ELSEVIER.
DOI2022 Siu, D., Gormly, K., Espinoza, D., Hague, W., Jeffery, M., Price, T., . . . Jameson, M. (2022). Progress and challenges for AGITG spar - A randomised phase II trial of preoperative chemoradiation with simvastatin for rectal cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 48). WILEY. 2022 Bob, T. L., Velcheti, V., Price, T. J., Hong, D. S., Fakih, M., Kim, D. -W., . . . Skoulidis, F. (2022). Largest evaluation of acquired resistance to sotorasib in KRAS p.G12C-mutated non-small cell lung cancer (NSCLC) and colorectal cancer (CRC): Plasma biomarker analysis of CodeBreaK100.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 40 (pp. 1 page). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS. 2022 Hsu, K., Karapetis, C., Bright, T., Tomita, Y., Singhal, N., Gowda, R., . . . Roy, A. (2022). Feasibility study of adjuvant chemotherapy in patients with oesophageal adenocarcinoma following neoadjuvant treatment: Results of the ACES trial. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 18 (pp. 38-39). WILEY. 2021 Li, B., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., Dy, G., . . . Wolf, J. (2021). Registrational Phase 2 Trial of Sotorasib in <i>KRAS</i> p.G12C Mutant NSCLC: First Disclosure of the Codebreak 100 Primary Analysis. In JOURNAL OF THORACIC ONCOLOGY Vol. 16 (pp. S61). ELSEVIER SCIENCE INC.
WoS202021 Gormly, K., Espinoza, D., Hague, W., Jeffrey, M., Price, T., Karapetis, C., . . . Ackland, S. (2021). SPAR: Randomised phase II study of chemoradiation with or without simvastatin as preoperative treatment for rectal cancer (an AGITG trial). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 36). WILEY. 2021 Desai, J., Kopetz, S., Murphy, D. A., Pu, J., Ciardiello, F., Grothey, A., . . . Tabernero, J. (2021). Molecular correlates of clinical benefit in previously treated patients (pts) with <i>BRAF</i> V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 89). WILEY. 2021 Cummins, M., Leyden, S., Pavlakis, N., Chan, D., Michael, M., Hicks, R., . . . Stell, A. (2021). Optimal PLAnning of treatment and research of neuroendocrine tumours (NETs) in Australia: The PLANET registry and patient-reported outcomes via PLANET App. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 169-170). WILEY. 2021 Desai, J., Kopetz, S., Aderka, D., Grothey, A., Van Cutsem, E., Yaeger, R., . . . Tabernero, J. (2021). Overall survival (OS) with encorafenib (enco) plus cetuximab (cetux) in BEACON CRC: Effect of prior therapy for <i>BRAF</i> V600E-mutant metastatic colorectal cancer (mCRC). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 17 (pp. 119-120). WILEY. 2021 Taieb, J., Price, T., Wyrwicz, L., Vidot, L., Raimond-Thibaut, A., Chrostek, H., . . . Falcone, A. (2021). Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: Final results according to duration of treatment from the phase IIIb, international, open-label, early-access PRECONNECT study. In ANNALS OF ONCOLOGY Vol. 32 (pp. S210). ELECTR NETWORK: ELSEVIER.
DOI WoS22021 Skoulidis, F., Schuler, M., Wolf, J., Barlesi, F., Price, T., Dy, G., . . . Velcheti, V. (2021). Genomic Profiles and Potential Determinants of Response and Resistance in <i>KRAS</i> p.G12C-mutated NSCLC Treated With Sotorasib. In JOURNAL OF THORACIC ONCOLOGY Vol. 16 (pp. S929-S930). ELSEVIER SCIENCE INC. 2021 Schuler, M., Li, B. T., Skoulidis, F., Falchook, G., Sacher, A., Velcheti, V., . . . Wolf, J. (2021). Registrational phase 2 trial of sotorasib in KRAS p. G12C mutant NSCLC: first disclosure of the CodeBreaK 100 primary analysis. In PNEUMOLOGIE Vol. 75 (pp. S38). GEORG THIEME VERLAG KG.
DOI2020 Chiu, C. -F., Yeh, Y. -M., Yeh, K. -H., Desai, J., Price, T. J., Tebbutt, N., . . . Kopetz, S. (2020). Management of adverse events associated with encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (BEACON CRC Study). In ANNALS OF ONCOLOGY Vol. 31 (pp. S1276). ELECTR NETWORK: ELSEVIER.
DOI WoS12020 Price, T., Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H. S., . . . Tabernero, J. (2020). Encorafenib plus cetuximab with or without binimetinib for BRAF V600E metastatic colorectal cancer: Updated survival results from a randomized, three-arm, phase III study versus choice of either irinotecan or FOLFIRI plus cetuximab (BEACON CRC). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 128). WILEY. 2020 Price, T., Chawla, S., Falchook, G., Prenen, H., Lugowska, I., Subbiah, V., . . . Sadraei, N. (2020). EARLY RESULTS FROM A PHASE 1 STUDY TO EVALUATE SAFETY, PHARMACOKINETICS, AND EFFICACY OF AMG 404, A PROGRAMMED DEATH-1 (PD-1) ANTIBODY, IN PATIENTS WITH ADVANCED SOLID TUMORS. In JOURNAL FOR IMMUNOTHERAPY OF CANCER Vol. 8 (pp. A245). BMJ PUBLISHING GROUP.
DOI2020 Yong, C., Holden, C., Buckley, E., Poprawski, D., Turnbull, D., Ratcliffe, J., . . . Price, T. (2020). Age of uncertainty: The management of older patients diagnosed with colorectal cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 132). WILEY. 2020 Buckley, E., Holden, C., Poprawski, D., Singal, N., Turnbull, D., Roder, D., . . . Price, T. (2020). Variation in colorectal cancer MDT, treatment and survival outcomes: A population-based linked data study in South Australia (SA). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 16 (pp. 90). WILEY. 2020 Strickler, J., Fakih, M., Price, T., Desai, J., Durm, G., Krauss, J., . . . Hong, D. (2020). AMG 510, a novel small molecule inhibitor of KRAS G12C, for patients with advanced gastrointestinal cancers: Results from the CodeBreak 100 phase 1 trial. In ANNALS OF ONCOLOGY Vol. 31 (pp. S226). ELECTR NETWORK: ELSEVIER.
DOI WoS12020 Loupakis, F., Peeters, M., Geissler, M., Modest, D., Valladares-Ayerbes, M., Price, T., . . . Taieb, J. (2020). Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies. In ANNALS OF ONCOLOGY Vol. 31 (pp. S114-S115). ELECTR NETWORK: ELSEVIER.
DOI2020 Fakih, M., Desai, J., Kuboki, Y., Strickler, J. H., Price, T. J., Durm, G. A., . . . Hong, D. S. (2020). CodeBreak 100: Activity of AMG 510, a novel small molecule inhibitor of KRAS<SUP>G12C</SUP>, in patients with advanced colorectal cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 38 (pp. 2 pages). ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS152020 Young, J. P., Horsnell, M. E., Uylaki, W., Mikaeel, R. R., Townsend, A., Poplawski, N., & Price, T. J. (2020). RELATIONSHIP BETWEEN GERMLINE MUTATION, PHENOTYPE AND FAMILY HISTORY IN YOUNG ONSET COLORECTAL CANCER. In GASTROENTEROLOGY Vol. 158 (pp. S1023). Austin, TX: W B SAUNDERS CO-ELSEVIER INC. 2019 Sartore-Bianchi, A., Peeters, M., Geissler, M., Taieb, J., Garcia-Alfonso, P., Price, T., . . . Koehne, C. -H. (2019). Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Kohne prognostic category: Retrospective analysis of the panitumumab (Pmab) PRIME study. In ANNALS OF ONCOLOGY Vol. 30 (pp. 216). Barcelona, SPAIN: OXFORD UNIV PRESS. 2019 Loree, J. M., Dowers, A., Tu, D., O'Callaghan, C. J., Edelstein, D., Quinn, H., . . . Kopetz, S. (2019). Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 37 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12019 Young, J. P., Symonds, E. L., Jesudason, D., Poplawski, N., Ruszkiewicz, A., Uylaki, W., . . . Price, T. J. (2019). INCREASED PREVALENCE OF TYPE 2 DIABETES IN YOUNG ONSET COLORECTAL CANCER. In GASTROENTEROLOGY Vol. 156 (pp. S676-S677). San Diego, CA: W B SAUNDERS CO-ELSEVIER INC.
DOI2019 Mikaeel, R., Symonds, E., Kimber, J., Uylaki, W., Horsnell, M., Rico, G., . . . Price, T. (2019). Personal history of type 2 diabetes is a potential risk marker for colorectal cancer in young people. In JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY Vol. 34 (pp. 42). WILEY. 2019 Desai, J., Kopetz, S., Grothey, A., Van Cutsem, E., Yaeger, R., Wasan, H., . . . Tabernero, J. (2019). BEACON CRC: A randomized, 3-Arm, phase 3 study of Encorafenib (ENCO) and Cetuximab (CETUX) with or without Binimetinib (BINI) versus choice of either Irinotecan or FOLFIRI plus Cetuximab in BRAF V600E-mutant metastatic colorectal cancer. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 15 (pp. 99). WILEY. 2019 Govindan, R., Fakih, M. G., Price, T. J., Falchook, G. S., Desai, J., Kuo, J. C., . . . Hong, D. S. (2019). Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours. In ANNALS OF ONCOLOGY Vol. 30 (pp. 163-+). Barcelona, SPAIN: OXFORD UNIV PRESS.
WoS222019 Govindan, R., Fakih, M., Price, T., Falchook, G., Desai, J., Kuo, J., . . . Hong, D. (2019). Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRAS<SUP>G12C</SUP> Inhibitor, in Patients with Non-Small Cell Lung Cancer. In JOURNAL OF THORACIC ONCOLOGY Vol. 14 (pp. S1125-S1126). ELSEVIER SCIENCE INC.
WoS22019 Govindan, R., Fakih, M., Price, T., Falchook, G., Desai, J., Kuo, J., . . . Hong, D. (2019). Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRAS<SUP>G12C</SUP> Inhibitor, Evaluated in NSCLC. In JOURNAL OF THORACIC ONCOLOGY Vol. 14 (pp. S208). ELSEVIER SCIENCE INC.
DOI WoS222018 Boedigheimer, M., Ang, A. L., Kim, T. W., Thomas, A., Gibbs, P., Ruff, P., . . . Price, T. (2018). Circulating tumor (ct)DNA mutations in <i>EGFR</i> pathway genes and clinical outcomes for patients with metastatic colorectal cancer (mCRC) treated with panitumumab from the ASPECCT study. In MOLECULAR CANCER THERAPEUTICS Vol. 17 (pp. 4 pages). AMER ASSOC CANCER RESEARCH.
DOI2018 Price, T. J., Shen, L., Ma, B., Esser, R., Chen, W. -F., Gibbs, P., . . . Cheng, A. -L. (2018). Impact of primary tumor side on outcomes of every-2-weeks (q2w) cetuximab plus first-line FOLFOX or FOLFIRI in patients with RAS wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY.
DOI2018 Taniguchi, H., Yamanaka, T., Sakai, D., Yamazaki, K., Muro, K., Peeters, M., & Price, T. J. (2018). Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer. In Annals of oncology : official journal of the European Society for Medical Oncology Vol. 29 (pp. viii151). Munich, GERMANY: OXFORD UNIV PRESS.
DOI2018 Price, T. J., Cehic, G., Kirkwood, I., Maddern, G., Wachter, E. A., Sarson, D., . . . Neuhaus, S. J. (2018). A phase I study of oncolytic immunotherapy of metastatic neuroendocrine tumours using intralesional rose bengal disodium. In Annals of oncology : official journal of the European Society for Medical Oncology Vol. 29 (pp. viii478). Munich, GERMANY: OXFORD UNIV PRESS.
DOI2018 Falcone, A., Taieb, J., Price, T. J., Seitz, J. F., Wyrwicz, L., Becquart, M., . . . Van Cutsem, E. (2018). Quality of life at baseline in the international open-label early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb). In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS22018 Price, T. J., Taieb, J., Falcone, A., Seitz, J. F., Wyrwicz, L., Becquart, M., . . . Van Cutsem, E. (2018). Baseline characteristics in the international, open-label, early-access program of trifluridine/tipiracil in previously treated metastatic colorectal cancer (phase IIIb).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI2018 Taniguchi, H., Yamanaka, T., Sakai, D., Yamazaki, K., Muro, K., Peeters, M., & Price, T. J. (2018). Panitumumab versus cetuximab in patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer who received prior bevacizumab therapy: A combined analysis of individual patient data from ASPECCT and WJOG6510G.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI2018 Price, T. J., Falcone, A., Chantrill, L., Horvath, L., Chua, Y. J., Burge, M., . . . Van Cutsem, E. (2018). Baseline Patient Characteristics in the International, Open-Label, Preconnect Study of Trifluridine/Tipiracil in Previously Treated Metastatic Colorectal Cancer (PHASE-IIIB). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 14 (pp. 71-72). WILEY. 2018 Shepshelovich, D., Townsend, A. R., Espin-Garcia, O., Latifovic, L., O'Callaghan, C. J., Jonker, D. J., . . . Liu, G. (2018). The Association of <i>FCGR2A</i> and <i>FCGR3A</i> polymorphisms with outcomes in cetuximab treated metastatic colorectal cancer patients: CCTG and AGITG CO.20 trial analysis.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS12018 Klevansky, M., Vatandoust, S., Dykes, L., Padbury, R., Price, T. J., Roder, D., . . . Karapetis, C. (2018). The impact of primary tumour resection and sidedness in patients with synchronous metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI2018 Townsend, A. R., Asher, R., Price, T. J., Lee, C. K., Dorward, H., Gebski, V., . . . Hardingham, J. (2018). Single nucleotide polymorphisms (SNPs) in COL4A2, PPP1R17, and ARHGAPP44 and prognostic value in metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI2018 Clarke, S. J., Burge, M. E., Feeney, K., Jones, K., Gibbs, P., Molloy, M. P., . . . Tebbutt, N. C. (2018). The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI2018 Price, T. J., Karapetis, C. S., Joanne, Y., Roy, A., Padbury, R., Maddern, G., . . . Townsend, A. R. (2018). Outcomes for metastatic colorectal cancer (mCRC) based on microsatellite instability.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS12018 Price, T. J., Shen, L., Ma, B., Esser, R., Chen, W. -F., Gibbs, P., . . . Cheng, A. -L. (2018). Impact of primary tumor side (TS) on outcomes of once-every-2-weeks (q2w) cetuximab plus first-line (1L) FOLFOX or FOLFIRI in patients with <i>RAS</i> wild-type (wt) metastatic colorectal cancer (mCRC) in the phase 2 APEC trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 36 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS12017 Price, T. J., Hardingham, J., Karapetis, C., Smith, E., Padbury, R., Roy, A., . . . Townsend, A. (2017). Bevacizumab first line and impact on subsequent anti-EGFR activity. In ANNALS OF ONCOLOGY Vol. 28 (pp. 1 page). Madrid, SPAIN: OXFORD UNIV PRESS.
WoS12017 Price, T. J., Karapetis, C. S., Piantadosi, C., Padbury, R., Roy, A. C., Maddern, G., . . . Townsend, A. R. (2017). Nonagenarian patients with metastatic colorectal cancer: Results from the South Australian metastatic colorectal cancer registry.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI2017 Roy, A. C., Karapetis, C. S., Piantadosi, C., Townsend, A. R., Padbury, R., Carruthers, S., . . . Price, T. J. (2017). Patterns of care for synchronous rectal cancer with liver-only metastasis: Results from the South Australian registry of metastatic colorectal cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12017 Price, T. J., Karapetis, C. S., Roy, A. C., Padbury, R., Maddern, G., Roder, D., . . . Townsend, A. R. (2017). Bevacizumab and its impact on survival for patients receiving subsequent anti-EGFR therapy: Results from the South Australian metastatic colorectal cancer registry.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI2017 Townsend, A. R., Hardingham, J., Tebbutt, N. C., Karapetis, C. S., Singhal, N., Joshi, R., . . . Price, T. J. (2017). A phase Ib/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT): Biomarker substudy.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12017 Price, T. J., Peeters, M., Boedigheimer, M., Kim, T. W., Gibbs, P., Thomas, A. L., . . . Bach, B. A. (2017). Clinical outcomes and emergent circulating tumor (ct)DNA RAS mutations and allele fraction for patients with metastatic colorectal cancer (mCRC) treated with panitumumab from the ASPECCT study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 6 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12017 Boedigheimer, M., Ang, A., Price, T. J., Peeters, M., Kim, T. W., Gibbs, P., . . . Bach, B. A. (2017). Profiling circulating tumor (ct)DNA mutations after panitumumab treatment in patients with refractory metastatic colorectal cancer (mCRC) from the phase III ASPECCT study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS32017 Prasanna, T., Craft, P. S., Chua, Y. J., Karapetis, C. S., Gibbs, P., Wong, R., . . . Yip, D. (2017). The outcome of patients (pts) with metastatic colorectal cancer (mCRC) based on site of metastases (mets) and the impact of molecular markers and site of primary cancer on metastatic pattern.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS72017 Li, M., Rico, G. T., Chan, D. L., Oatley, M., Roach, P., Bailey, D., . . . Pavlakis, N. (2017). Case Series: Prevention and Management of Carcinoid Crises in High-Risk Neuroendocrine Patients Undergoing Peptide Receptor Radioligand Therapy (PRRT). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 13 (pp. 127). WILEY. 2017 Michael, M., Liauw, W., McLachlan, S. -A., Link, E., Matera, A., Thompson, M., . . . Burge, M. E. (2017). The utility of genomics and functional imaging to predict irinotecan pharmacokinetics and pharmacodynannics: The PREDICT IR study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 35 (pp. 5 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12016 Price, T. J., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., . . . Peeters, M. (2016). Outcomes by hypomagnesemia in the randomized phase III ASPECCT trial in patients with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI2016 Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., . . . Price, T. J. (2016). Efficacy of panitumumab vs cetuximab in patients with wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer treated with prior bevacizumab: Results from ASPECCT.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI2016 Sud, S., O'Callaghan, C. J., Karapetis, C. S., Jonker, C., Price, T. J., Tebbutt, N. C., . . . Goodwin, R. A. (2016). Hypertension and beta-blocker use as prognostic and predictive factors in metastatic colorectal cancer: A retrospective analysis of NCIC CTG CO.17. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 2 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI2016 Kim, T. W., Price, T., Peeters, M., Thomas, A., Gibbs, P., Hool, K., . . . Bach, B. (2016). Evaluation of emergent circulating tumor (ct) DNA RAS mutations in patients with metastatic colorectal cancer (mCRC) treated with panitumumab (pmab) monotherapy from the ASPECCT study. In EUROPEAN JOURNAL OF CANCER Vol. 69 (pp. S13-S14). Munich, GERMANY: ELSEVIER SCI LTD.
DOI WoS22016 Cheng, A. -L., Cornelio, G., Shen, L., Price, T., Yang, T. -S., Chung, I. -J., . . . Lim, R. (2016). Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study. In ANNALS OF ONCOLOGY Vol. 27 (pp. 123-124). Barcelona, SPAIN: OXFORD UNIV PRESS.
WoS12016 Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., . . . Price, T. J. (2016). Efficacy of panitumumab (pmab) vs. cetuximab (cmab) in patients (pts) with wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC) treated with prior bevacizumab (bev): Results from ASPECCT.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2016 Sud, S., O'Callaghan, C. J., Jonker, C., Karapetis, C. S., Price, T. J., Tebbutt, N. C., . . . Goodwin, R. A. (2016). Hypertension as a predictor of outcome and treatment response to cetuximab: A retrospective analysis of NCIC CTG CO.17.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: LIPPINCOTT WILLIAMS & WILKINS.
DOI2016 Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. V., . . . Price, T. J. (2016). Outcomes by hypomagnesemia (hypomag) in the randomized phase III ASPECCT trial of patients (pts) with chemofractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 34 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2015 Segelov, E., Thavaneswaran, S., Waring, P., Desai, J., Mann, K., Elez, E., . . . Shapiro, J. (2015). The AGITG ICECREAM Study: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation - analysis of outcomes in patients with refractory metastatic colorectal cancer harbouring the KRAS G13D mutation. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S726). Vienna, AUSTRIA: ELSEVIER SCI LTD.
DOI WoS12015 Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., . . . Murugappan, S. (2015). Randomized phase III study of panitumumab (pmab) vs. cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC): Outcomes by hypomagnesemia (hypomag) in ASPECCT.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12015 Price, T. J., Newhall, K., Peeters, M., Kim, T. W., Li, J., Cascinu, S., . . . Murugappan, S. (2015). Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2015 Spencer, A., Harrison, S., Burrows, F., Mainwaring, P., Price, T., Millward, M. J., . . . Trikha, M. (2015). Marizomib Overcomes Compensatory Hyperactivation of Trypsin-like and Caspase-like Subunits to Provide Pan-Proteasome Subunit Inhibition in Patients with Multiple Myeloma and Solid Tumors. In BLOOD Vol. 126 (pp. 3 pages). Orlando, FL: AMER SOC HEMATOLOGY.
WoS12015 Peeters, M., Price, T. J., Kim, T. W., Li, J., Cascinu, S., Ruff, P., . . . Murugappan, S. (2015). Randomized phase 3 study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC): outcomes by hypomagnesemia (hypomag) in ASPECCT. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI2015 Price, T. J., Newhall, K., Peeters, M., Kim, T. W., Li, J., Cascinu, S., . . . Murugappan, S. (2015). Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs cetuximab (cmab) in pts with chemorefractory wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS22015 Price, T. J., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., . . . Murugappan, S. (2015). Final results from ASPECCT: Randomized phase 3 non-inferiority study of panitumumab (pmab) vs cetuximab (cmab) in chemorefractory wild-type (WT) <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12015 Price, T., Townsend, A., Beeke, C., Roder, D., Padbury, R., Maddern, G., . . . Karapetis, C. (2015). BRAF testing in the community setting; are we testing enough given the importance of BRAF mutation and the clinical implications?. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S388). Vienna, AUSTRIA: ELSEVIER SCI LTD.
DOI2015 Price, T., Pavlakis, N., Karapetis, C., Michael, M., Singhal, N., Goldstein, D., . . . Chua, Y. J. (2015). The Clinical Oncology Society of Australia (COSA) SIGNETURe Neuroendocrine Tumor (NET) Registry of Australia: First Report of Patient Characteristics and Patterns of Care. In NEUROENDOCRINOLOGY Vol. 102 (pp. 98). Barcelona, SPAIN: KARGER. 2015 Klevansky, M., Mislang, A. R. A., Kwatra, V., Griffiths, C. L., Hsieh, A. H. -C., Takhar, H., . . . Roy, A. (2015). FOLFIRINOX for advanced pancreato-biliary adenocarcinoma, a multi-centre retrospective analysis: The South Australian Experience. In ANNALS OF ONCOLOGY Vol. 26 (pp. 66). Singapore, SINGAPORE: OXFORD UNIV PRESS.
WoS12015 Mooi, J., Chong, G., Brown, S., Wong, R., Price, T. J., Skrinos, E., & Tebbutt, N. C. (2015). Dual targeting of vascular endothelial growth factor-A (VEGF-A) and angiopoietins (Ang) without chemotherapy in metastatic colorectal cancer (mCRC): Results of the VENGEANCE study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS22015 Sobrero, A. F., Price, T. J., Cervantes, A., Ducreux, M., Andre, T., Lordick, F., . . . Peeters, M. (2015). Quality of life (QoL) during second-line treatment with FOLFIRI plus /- panitumumab (pmab) in patients (pts) with RAS wild-type (WT) metastatic colorectal carcinoma (mCRC). In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S369-S370). Vienna, AUSTRIA: ELSEVIER SCI LTD.
DOI2015 Patel, D., Lawrie, J., Cehic, G., Kitchener, M., Unger, S., Singhal, N., . . . Price, T. (2015). Outcome of peptide receptor radionuclide therapy with 177-Lu-octreotate in advanced neuroendocrine tumours (NET): South Australian sub study of the SIGNETURe Registry. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S413). Vienna, AUSTRIA: ELSEVIER SCI LTD.
DOI WoS12015 Cheng, A. -L., Cornelio, G. H., Shen, L., Price, T. J., Yang, T. -S., Chung, I. J., . . . Lim, R. S. C. (2015). Final analysis of the phase 2 APEC study: Overall survival (OS) data and biomarker subanalyses for first-line FOLFOX or FOLFIRI with cetuximab (cet) once every 2 weeks in patients (pts) with KRAS or RAS (KRAS and NRAS, exons 2-4) wild-type (wt) metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 33 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2015 Price, T., Kim, T. W., Li, J., Cascinu, S., Ruff, P., Suresh, A. S., . . . Peeters, M. (2015). Efficacy outcomes by severity of skin toxicity from ASPECCT: Randomized phase 3 study of panitumumab (pmab) versus cetuximab (cmab) in chemorefractory wild-type (WT) KRAS exon 2 metastatic colorectal cancer (mCRC). In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S366). Vienna, AUSTRIA: ELSEVIER SCI LTD.
DOI2015 Cheng, A. L., Cornelio, G. H., Shen, L., Price, T. J., Yang, T. S., Chung, I. J., . . . Lim, R. S. C. (2015). Association between early tumour shrinkage and outcomes in RAS-wild type patients with metastatic colorectal cancer receiving first-line FOLFOX or FOLFIRI plus cetuximab once every 2 weeks in the APEC study. In EUROPEAN JOURNAL OF CANCER Vol. 51 (pp. S367). Vienna, AUSTRIA: ELSEVIER SCI LTD.
DOI2015 Leyden, J., Khaswraw, M., Michael, M., Clarke, S., Pavlakis, N., & Price, T. J. (2015). NET CARE IN AUSTRALIA; THE PATIENT'S PERSPECTIVE OF THEIR NEUROENDOCRINE TUMOURS (NET) AND IMPACT OF DIAGNOSIS. In Asia-Pacific Journal of Clinical Oncology Vol. 11 (pp. 177). WILEY-BLACKWELL. 2014 Schmoll, H. -J., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R. D., Daisne, J. -F., . . . Van Cutsem, E. (2014). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis. In EUROPEAN JOURNAL OF CANCER Vol. 50 (pp. S6). ELSEVIER SCI LTD.
DOI WoS42014 Price, T., Peeters, M., Oliner, K., Cervantes, A., Sobrero, A., Ducreux, M., . . . Patterson, S. (2014). UPDATED ANALYSIS OF KRAS/NRAS AND BRAF MUTATIONS IN STUDY 20050181 OF PANITUMUMAB plus FOLFIRI FOR 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (mCRC). In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 10 (pp. 49-50). ASIA-PACIFIC: WILEY-BLACKWELL. 2014 Price, T. J., Beeke, C., Padbury, R., Roder, D., Townsend, A., Maddern, G., . . . Karapetis, C. S. (2014). DOES EXACT PRIMARY SITE IMPACT ON OUTCOME FOR METASTATIC COLORECTAL CANCER (MCRC)?. In ANNALS OF ONCOLOGY Vol. 25 (pp. 1 page). Madrid, SPAIN: OXFORD UNIV PRESS. 2014 Tomita, Y., Karapetis, C. S., Beeke, C., Padbury, R., Maddern, G., Roder, D., . . . Price, T. J. (2014). Survival outcomes for patients with metastatic colorectal cancer (mCRC) based on primary site, right (R) colon versus left (L) colon versus rectal (Rec) primary: Results from the South Australian Registry of mCRC.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS62014 Vatandoust, S., Price, T. J., Padbury, R., Roder, D., Beeke, C., Roy, A., . . . Karapetls, C. S. (2014). Patterns of care and outcomes for young patients (age < 40) with metastatic colorectal cancer (mCRC): Findings from a population-based registry. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS32014 Price, T. J., Bruhn, M., Lee, C., Hardingham, J., Townsend, A. R., Mann, K., . . . Tebbutt, N. C. (2014). Correlation of <i>PI3KCA</i>and extended <i>RAS</i> gene mutation status with outcomes from the phase III AGITG MAX involving capecitabine (C) alone or in combination with bevacizumab (B) with or without mitomycin C (M) in advanced colorectal cancer (CRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI2014 Charakidis, M., Price, T. J., Beeke, C., Padbury, R., Roder, D., Townsend, A. R., . . . Karapetis, C. S. (2014). Survival improvements associated with access to biologic agents: Results from the South Australian (SA) Metastatic Colorectal (mCRC) Registry. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI2014 Roohullah, A., Sjoquist, K. M., Gebski, V., Ng, W., Chua, W., Price, T. J., . . . Chantrill, L. A. (2014). The efficacy and safety outcomes of bevacizumab and systemic therapy in metastatic colorectal cancer patients with peritoneal disease in the AGITG MAX clinical trial and in nontrial patients in two cancer centers.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2014 Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., . . . Patterson, S. D. (2014). Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI WoS22014 Yeung, Y. H., Chionh, F. J. M., Price, T. J., Scott, A. M., Hoanh, T., Fang, G., . . . Tebbutt, N. C. (2014). Phase II study of everolimus monotherapy as first-line treatment in advanced biliary tract cancer: RADichol.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS62014 Schmoll, H. -J., Haustermans, K., Price, T. J., Nordlinger, B., Hofheinz, R., Daisne, J. -F., . . . Van Cutsem, E. (2014). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Disease-free survival results at interim analysis.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS752014 Peeters, M., Oliner, K., Price, T., Cervantes, A., Sobrero, A., Ducreux, M., . . . Patterson, S. (2014). KRAS/NRAS AND BRAF MUTATIONS IN THE 20050181 STUDY OF PANITUMUMAB plus FOLFIRI FOR THE 2ND-LINE TREATMENT OF METASTATIC COLORECTAL CANCER: UPDATED ANALYSIS. In ANNALS OF ONCOLOGY Vol. 25 (pp. 5). Barcelona, SPAIN: OXFORD UNIV PRESS.
DOI WoS22014 Peeters, M., Oliner, K. S., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., . . . Patterson, S. D. (2014). Updated analysis of <i>KRAS</i>/<i>NRAS</i> and <i>BRAF</i> mutations in study 20050181 of panitumumab (pmab) plus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 2 pages). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS252014 Chionh, F. J. M., Gebski, V., Chueh, A. C., Al-Obaidi, S. J., Welckhardt, A. J., Lee, C., . . . Tebbutt, N. C. (2014). Single nucleotide polymorphisms (SNPs) in vascular endothelial growth factor (<i>VEGF</i>) family genes as predictive or prognostic biomarkers in patients (pts) with metastatic colorectal cancer (mCRC): Analysis of the phase III MAX Inter study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI2014 Karapetis, C. S., Padman, S. J. -A., Beeke, C., Padbury, R., Kitchener, M., Kirkwood, I., . . . Price, T. J. (2014). The management of colorectal cancer (CRC) liver metastases with yttrium-90 microspheres (Y90): The south Australian (SA) experience.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2014 Chan, K. K., Tu, D., O'Callaghan, C. J., Au, H. -J., Leighl, N. B., Brundage, M. D., . . . Mittmann, N. (2014). A mapping algorithm of health preferences from EORTC QLQ C30 to health utility index mark 3 (HUI3) in advanced colorectal cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2014 Chan, D., Pavlakis, N., Price, T. J., Karapetis, C. S., Tebbutt, N. C., Shapiro, J. D., & Segelov, E. (2014). Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
DOI WoS42014 Chan, D., Segelov, E., Shapiro, J. D., Price, T. J., Karapetis, C. S., Tebbutt, N. C., & Pavlakis, N. (2014). Meta-analysis of outcomes of VEGF and EGFR targeted biologic therapy in relapsed metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 32 (pp. 1 page). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2013 Segelov, E., Wilson, K., Gebski, V., Waring, P. M., Tabernero, J., Wasan, H., . . . Shapiro, J. D. (2013). ICE CREAM: Irinotecan cetuximab evaluation and the cetuximab response evaluation among patients with G13D mutation. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Patel, G. S., Ullah, S., Beeke, C., Hakendorf, P., Padbury, R., Price, T. J., & Karapetis, C. S. (2013). Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT). In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Price, T. J., Broadbridge, V., Beeke, C., Padbury, R., Maddern, G., Roder, D., & Karapetis, C. S. (2013). Outcomes of rural patients with metastatic colorectal cancer treated in a centralized system compared with their metropolitan counterparts. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Kumar, S. S., Price, T., & Hardingham, J. (2013). Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S493). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. 2013 Kumar, S. S., Price, T., Mohyieldin, O., Borg, M., Townsend, A., & Hardingham, J. (2013). KRAS G13D mutations associated with sensitivity to cetuximab or panitumumab treatment in colorectal cancer cell lines. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S494). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. 2013 Cheng, A. -L., Cornelio, G. H., Shen, L., Price, T. J., Yang, T. -S., Chung, I. -J., . . . Lim, R. S. C. (2013). Efficacy and safety of every-2-weeks cetuximab combined with FOLFOX or FOLFIRI as first-line therapy in patients with <i>KRAS</i> wild-type metastatic colorectal cancer (mCRC): An Asia-Pacific nonrandomized phase II study (APEC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Tebbutt, N. C., Price, T. J., Sjoquist, K. M., Veillard, A. -S., Hall, M., Ferraro, D. A., . . . Gebski, V. (2013). Final results of AGITG ATTAX3 study: Randomized phase II study of weekly docetaxel (T), cisplatin, and fluoropyrimidine (F) with or without panitumumab (P) in advanced esophagogastric (OG) cancer. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS32013 Pavlakis, N., Goldstein, D., Sjoquist, K. M., Martin, A., Tsobanis, E., Yip, S., . . . O'Callaghan, C. J. (2013). INTEGRATE: A randomized phase II double-blind placebo-controlled study of regorafenib in refractory advanced esophagogastric cancer (AOGC)-A study by the Australasian Gastrointestinal Trials Group (AGITG). In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS12013 Kumar, R., Beeke, C., Ullah, S., Price, T. J., Padbury, R., Roder, D., & Karapetis, C. S. (2013). Survival outcomes for patient with equivocal 18FDG-PET CT scan for extrahepatic disease prior to liver resection for metastatic colorectal cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS. 2013 Hocking, C., Karapetis, C., Beeke, C., Priest, K., Roder, D., Padbury, R., . . . Price, T. J. (2013). INDIGENOUS PATIENTS AND METASTATIC COLORECTAL CANCER: RESULTS FROM THE SOUTH AUSTRALIAN (SA) METASTATIC COLORECTAL CANCER (MCRC) REGISTRY. In ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY Vol. 9 (pp. 132). WILEY-BLACKWELL. 2013 Schmoll, H. -J., Haustermans, K., Price, T. J., Nordlinger, B., Hofheinz, R., Daisne, J. -F., . . . Van Cutsem, E. (2013). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: First results of the PETACC-6 randomized phase III trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 31 (pp. 1 page). Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS242013 Schmoll, H. J., Haustermans, K., Price, T., Nordlinger, B., Hofheinz, R. D., Daisne, J. F., . . . Van Cutsem, E. (2013). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: Response to the local treatment after chemoradiation and surgery as secondary endpoint. In EUROPEAN JOURNAL OF CANCER Vol. 49 (pp. S482). Amsterdam, NETHERLANDS: ELSEVIER SCI LTD.
WoS42013 Schmoll, H. -J., Price, T., Haustermanns, K., Nordlinger, B., Hofheinz, R. -D., Daisne, J. -F., . . . van Cutsem, E. (2013). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: Response to the local treatment after chemoradiation and surgery as secondary endpoint. In ONKOLOGIE Vol. 36 (pp. 103). KARGER.
WoS12012 Hahn, H. U., Keenan, A., Price, T., Borg, M., Thomas, H., Tucker, G., & Bardy, P. (2012). HEALTH OUTCOMES IN HODGKIN'S LYMPHOMA SURVIVORS: INCIDENCE OF LATE COMPLICATIONS WITH A FOCUS ON CARDIOVASCULAR DISEASE AND IMPACT OF SCREENING AND INTERVENTION. In HAEMATOLOGICA Vol. 97 (pp. 87). FERRATA STORTI FOUNDATION. 2012 Sobrero, A. F., Peeters, M., Price, T. J., Hotko, Y., Cervantes-Ruiperez, A., Ducreux, M., . . . Sidhu, R. (2012). Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY.
DOI WoS42012 Price, T. J., Beeke, C., Woodman, R., Karapetis, C. S., Kim, S., Maddern, G., . . . Padbury, R. (2012). Do patients with metastatic colorectal cancer (mCRC) with late relapse after curative surgery have a better survival?. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 2 pages). San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2012 Schmoll, H. -J., Tabernero, J., Maroun, J. A., De Braud, F. G., Price, T. J., Van Cutsem, E., . . . Haller, D. G. (2012). Capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Survival follow-up of study NO16968 (XELOXA).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 2 pages). AMER SOC CLINICAL ONCOLOGY.
DOI WoS92012 Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Wilson, K., . . . Tebbutt, N. (2012). PTEN AND ADVANCED COLORECTAL CANCER (CRC): ANALYSIS FROM THE PHASE III AGITG MAX TRIAL OF CAPECITABINE ALONE OR IN COMBINATION WITH BEVACIZUMAB ± MITOMYCIN C. In ANNALS OF ONCOLOGY Vol. 23 (pp. 182). Vienna, AUSTRIA: OXFORD UNIV PRESS. 2012 Broadbridge, V. T., Hardingham, J., Pittman, K., Townsend, A., Colbeck, M., Hooper, B., & Price, T. (2012). ARE PATIENTS WITH RESECTABLE RECTAL CANCER BETTER OFF IN THE ERA OF MULTIDISCIPLINARY CARE?. In ANNALS OF ONCOLOGY Vol. 23 (pp. 208). Vienna, AUSTRIA: OXFORD UNIV PRESS. 2012 Siu, L. L., Shapiro, J. D., Jonker, D. J., Karapetis, C. S., Zalcberg, J. R., Simes, J., . . . O'Callaghan, C. J. (2012). Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, <i>K</i>-<i>RAS</i> wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. 2012 Schmoll, H. -J., Tabernero, J., Alfred Maroun, J., De Braud, F. G., Jay Price, T., Van Cutsem, E., . . . Haller, D. G. (2012). The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA). In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS32012 Sobrero, A. F., Peeters, M., Price, T. J., Hotko, Y., Cervantes-Ruiperez, A., Ducreux, M., . . . Sidhu, R. (2012). Final results of study 20050181: A randomized phase III study of FOLFIRI with our without panitumumab (pmab) for the second -line treatment (tx) of metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
WoS12012 Price, T., Wilson, K., Simes, R. J., Yip, D., Karapetis, C. S., Tebbutt, N. C., . . . Ransom, D. (2012). FINAL RESULTS OF AUSTRALASIAN GASTRO-INTESTINAL TRIALS GROUP (AGITG) ARCTIC STUDY: AN INTERNATIONAL AUDIT OF RALTITREXED FOR PATIENTS WITH CARDIAC TOXICITY INDUCED BY FLUOROPYRIMIDINES (FP). In ANNALS OF ONCOLOGY Vol. 23 (pp. 178). Vienna, AUSTRIA: OXFORD UNIV PRESS.
WoS12012 Van Cutsem, E., Hamamoto, Y., Lee, J., Ohtsu, A., Qin, S., Price, T., . . . Doi, T. (2012). PROGNOSTIC FACTORS OF OVERALL SURVIVAL (OS) IN PREVIOUSLY TREATED ADVANCED GASTRIC CANCER (AGC): ANALYSIS OF THE PHASE 3 GRANITE-1 TRIAL. In ANNALS OF ONCOLOGY Vol. 23 (pp. 9). Barcelona, SPAIN: OXFORD UNIV PRESS.
WoS12012 Schmoll, H., Tabernero, J., Maroun, J. A., De Braud, F., Price, T., Van Cutsem, E., . . . Haller, D. (2012). TP, TS AND DPD AS POTENTIAL PREDICTORS OF OUTCOME FOLLOWING CAPECITABINE PLUS OXALIPLATIN (XELOX) VS. BOLUS 5-FLUOROURACIL/LEUCOVORIN (5-FU/LV) AS ADJUVANT THERAPY FOR STAGE III COLON CANCER: UPDATED BIOMARKER FINDINGS FROM STUDY NO16968 (XELOXA). In ANNALS OF ONCOLOGY Vol. 23 (pp. 187). Vienna, AUSTRIA: OXFORD UNIV PRESS. 2012 Douillard, J. -Y., Peeters, M., Rong, A., Siena, S., Braun, S., Sidhu, R., & Price, T. (2012). EFFECT OF POST-PROTOCOL ANTI-EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) MONOCLONAL ANTIBODY (MAB) THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH WILD-TYPE (WT) KRAS METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH PANITUMUMAB (PMAB) PLUS CHEMOTHERAPY. In ANNALS OF ONCOLOGY Vol. 23 (pp. 194-195). Vienna, AUSTRIA: OXFORD UNIV PRESS. 2012 Douillard, J. -Y., Peeters, M., Rong, A., Siena, S., Braun, S., Sidhu, R., & Price, T. (2012). EFFECT OF POST-PROTOCOL ANTI-EGFR MAB THERAPY ON SURVIVAL OUTCOMES IN PATIENTS WITH WILD-TYPE KRAS MCRC TREATED WITH PANITUMUMAB PLUS CHEMOTHERAPY. In ANNALS OF ONCOLOGY Vol. 23 (pp. 10-11). Barcelona, SPAIN: OXFORD UNIV PRESS. 2012 Ransom, D., Wilson, K., Bishnoi, S. K., Simes, J., Yip, D., Karapetis, C. S., . . . Price, T. J. (2012). Results of Australasian Gastrointestinal Trials Group (AGITG) Arctic study: An international audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines (FP).. In JOURNAL OF CLINICAL ONCOLOGY Vol. 30 (pp. 1 page). Chicago, IL: AMER SOC CLINICAL ONCOLOGY. 2011 Bishnoi, S., Price, T., Beeke, C., Karapetis, C., Townsend, A., Maddern, G., & Padbury, R. (2011). Liver Only Metastatic Disease in Patients With Metastatic Colorectal Cancer (mCRC), Impact of Surgery and Chemotherapy. In EUROPEAN JOURNAL OF CANCER Vol. 47 (pp. S403). Stockholm, SWEDEN: ELSEVIER SCI LTD.
DOI2011 Shapiro, J. D., Siu, L. L., Zalcberg, J. R., Moore, M. J., Ringash, J., Mittmann, N., . . . Jonker, D. J. (2011). A phase III study of cetuximab (CET) plus either brivanib alaninate (BRIV) versus placebo in patients with chemotherapy-refractory KRAS wild-type (WT) advanced colorectal cancer (aCRC): The NCIC CTG/AGITG CO.20 trial.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 29 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
DOI WoS42011 Price, T. J., Zannino, D., Wilson, K., Simes, J., Van Hazel, G. A., Robinson, B. A., . . . Tebbutt, N. C. (2011). Outcome and dose intensity (DI) in the elderly subgroup of the AGITG MAX phase III trial of capecitabine (C), bevacizumab (B), and mitomycin C (M) in first-line metastatic colorectal cancer (CRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 29 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
DOI2011 Peeters, M., Price, T. J., Strickland, A. H., Ciuleanu, T. E., Scheithauer, W., O'Reilly, S., . . . Krishnan, K. (2011). Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181. In JOURNAL OF CLINICAL ONCOLOGY Vol. 29 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
DOI2011 Weickhardt, A. J., Williams, D., Lee, C., Simes, J., Murone, C., Wilson, K., . . . Tebbutt, N. C. (2011). Vascular endothelial growth factors (VEGF) and VEGF receptor expression as predictive biomarkers for benefit with bevacizumab in metastatic colorectal cancer (mCRC): Analysis of the phase III MAX study.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 29 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY.
WoS252011 Price, T., Peeters, M., Strickland, A., Ciuleanu, T. E., Scheithauer, W., O'Reilly, S., . . . Kartik, K. (2011). Efficacy of Panitumumab Plus FOLFIRI Versus FOLFIRI Alone in Patients With Wild-Type (WT) KRas Metastatic Colorectal Cancer (mCRC) Treated With Prior Oxaliplatin or Bevacizumab Regimens: Results From 20050181. In EUROPEAN JOURNAL OF CANCER Vol. 47 (pp. S431-S432). Stockholm, SWEDEN: ELSEVIER SCI LTD.
DOI WoS12011 Peeters, M., Price, T., Strickland, A., Ciuleanu, T. -E., Scheithauer, W., O'Reilly, S., . . . Krishnan, K. (2011). EVALUATION OF PANITUMUMAB (PMAB) PLUS FOLFIRI VERSUS FOLFIRI ALONE AS SECOND-LINE THERAPY IN PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (MCRC) RECEIVING PRIOR BEVACIZUMAB (BEV) IN STUDY 20050181. In ANNALS OF ONCOLOGY Vol. 22 (pp. v103-v104). Barcelona, SPAIN: OXFORD UNIV PRESS. 2010 Peeters, M., Price, T., Hotko, Y., Cervantes, A., Ducreux, M., Andre, T., . . . Gansert, J. (2010). RANDOMIZED PHASE 3 STUDY OF PANITUMUMAB (PMAB) WITH FOLFIRI COMPARED TO FOLFIRI ALONE AS SECOND-LINE TREATMENT (TX) FOR METASTATIC COLORECTAL CANCER (MCRC): SECONDARY ENDPOINT RESULTS. In ANNALS OF ONCOLOGY Vol. 21 (pp. 15). Barcelona, SPAIN: OXFORD UNIV PRESS.
WoS22010 Andre, T., Peeters, M., Price, T., Hotko, Y., Cervantes, A., Ducreux, M., . . . Gansert, J. (2010). PANITUMUMAB WITH FOLFIRI VS FOLFIRI ALONE: A RANDOMISED PHASE 3 STUDY FOR THE SECOND LINE TREATMENT OF PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC). In ANNALS OF ONCOLOGY Vol. 21 (pp. I13). Nice, FRANCE: OXFORD UNIV PRESS.
WoS12010 Lordick, F., Peeters, M., Price, T., Hotko, Y., Cervantes, A., Ducreux, M., . . . Gansert, J. (2010). Panitumumab with FOLFIRI versus FOLFIRI alone: results from a randomised phase III study of second-line treatment of patients with metastatic colorectal cancer (mCRC). In ONKOLOGIE Vol. 33 (pp. 3). KARGER. 2010 Price, T. J., Hardingham, J., Lee, C., Weickhardt, A., Townsend, A., Wrin, J. W., . . . Tebbutt, N. (2010). IMPACT OF KRAS AND BRAF GENE MUTATION STATUS ON OUTCOMES FROM THE PHASE III AGITG MAX TRIAL OF CAPECITABINE (C) ALONE OR IN COMBINATION WITH BEVACIZUMAB (B) ± MITOMYCIN C (M) IN ADVANCED COLORECTAL CANCER (CRC). In ANNALS OF ONCOLOGY Vol. 21 (pp. 198). Milan, ITALY: OXFORD UNIV PRESS. 2010 Jain, K., Strickland, A. H., Slavotinek, J., Eaton, M., McLeay, W., Price, T. J., . . . Karapetis, C. S. (2010). A RANDOMISED TRIAL COMPARING PERIPHERALLY INSERTED CENTRAL VENOUS CATHETERS (PICC) VS SUBCUTANEOUSLY IMPLANTED PORT-CHAMBER CATHETERS (PORT) FOR DELIVERY OF CHEMOTHERAPY TO PATIENTS WITH NON-HAEMATOLOGICAL MALIGNANCIES. In ANNALS OF ONCOLOGY Vol. 21 (pp. 383-384). Milan, ITALY: OXFORD UNIV PRESS. 2010 Townsend, A., Price, T. J., Beeke, C., Karapetis, C., Luke, C., Roder, D., . . . Padbury, R. (2010). PRELIMINARY RESULTS FROM THE SOUTH AUSTRALIAN (SA) CLINICAL REGISTRY FOR ADVANCED COLORECTAL CANCER (CRC) ASSESSING THE IMPACT OF AGE AND CHOICE OF CHEMOTHERAPY ON OUTCOME. In ANNALS OF ONCOLOGY Vol. 21 (pp. 203-204). Milan, ITALY: OXFORD UNIV PRESS.
WoS12010 Haller, D., Cassidy, J., Tabernero, J., Maroun, J. A., De Braud, F., Price, T. J., . . . Schmoll, H. (2010). RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): IMPACT OF AGE ON DISEASE-FREE SURVIVAL (DFS) OR OVERALL SURVIVAL (OS). In ANNALS OF ONCOLOGY Vol. 21 (pp. 207). Milan, ITALY: OXFORD UNIV PRESS.
WoS22010 Haller, D., Cassidy, J., Tabernero, J., Maroun, J., De Braud, F., Price, T., . . . Schmoll, H. (2010). EFFICACY FINDINGS FROM A RANDOMISED PHASE III TRIAL OF CAPECITABINE plus OXALIPLATIN VS. BOLUS 5-FU/LV FOR STAGE III COLON CANCER (NO16968): NO IMPACT OF AGE ON DISEASE-FREE SURVIVAL. In ANNALS OF ONCOLOGY Vol. 21 (pp. 12). Barcelona, SPAIN: OXFORD UNIV PRESS. 2009 Spencer, A., Millward, M., Mainwaring, P., Harrison, S., Catley, L., Townsend, A., . . . Price, T. (2009). Phase 1 Clinical Trial of the Novel Structure Proteasome Inhibitor NPI-0052. In BLOOD Vol. 114 (pp. 1053-1054). New Orleans, LA: AMER SOC HEMATOLOGY.
WoS12009 Hailer, D., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., . . . Schmoll, H. (2009). First efficacy findings from a randomized phase III trial of capecitabine plus oxaliplatin vs. bolus 5-FU/LV for stage III colon cancer (NO16968/XELOXA study). In EJC SUPPLEMENTS Vol. 7 (pp. 4). Berlin, GERMANY: PERGAMON-ELSEVIER SCIENCE LTD. 2009 Tebbutt, N. C., Gebski, V., Wilson, K., Cummins, M., Chua, Y., Robinson, B., . . . Price, T. (2009). International randomized phase III study of capecitabine (Cap), bevacizumab (Bev), and mitomycin C (MMC) in first-line metastatic colorectal cancer (mCRC): Final results of the AGITG MAX trial. In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 2 pages). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS22009 Tebbutt, N., Gebski, V., Wilson, K., Cummins, M., Robinson, B., Broad, A., . . . Price, T. (2009). International randomised phase III study of capecitabine (Cap), bevacizumab (Bev) and mitomycin C (MMC) in first line treatment of metastatic colorectal cancer (mCRC): final results of the AGITG MAX trial. In EJC SUPPLEMENTS Vol. 7 (pp. 321). Berlin, GERMANY: PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS22009 Sukumaran, S., Pavlakis, N., Pittman, K. B., Patterson, K., & Price, T. J. (2009). Capecitabine and irinotecan (XELIRI) in first-line treatment of metastatic colorectal cancer (mCRC): A systematic review of controlled clinical trials. In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 1 page). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS12009 Peeters, M., Price, T., Hotko, Y., Cervantes, A., Ducreux, M., Andre, T., . . . Gansert, J. (2009). Randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). In EJC SUPPLEMENTS Vol. 7 (pp. 10). Berlin, GERMANY: PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS92009 Townsend, A. R., Millward, M., Price, T., Mainwaring, P., Spencer, A., Longenecker, A., . . . Padrik, P. (2009). Clinical trial of NPI-0052 in advanced malignancies including lymphoma and leukemia (advanced malignancies arm). In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 2 pages). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS112009 Price, T. J., Peeters, M., Douillard, J., Mitchell, E., Cohn, A., Strickland, A. H., . . . Siena, S. (2009). Safety summary of panitumumab (pmab) in combination with chemotherapy (ctx) from four clinical trials in patients (pts) with metastatic colorectal cancer (mCRC). In JOURNAL OF CLINICAL ONCOLOGY Vol. 27 (pp. 2 pages). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS142009 Millward, M., Spear, M. A., Townsend, A., Sweeney, C., Sukumaran, S., Longenecker, A., . . . Price, T. (2009). Clinical trial combining proteasome (NPI-0052) and HDAC (vorinostat) inhibition in melanoma, pancreatic, and lung cancer. In MOLECULAR CANCER THERAPEUTICS Vol. 8 (pp. 3 pages). AMER ASSOC CANCER RESEARCH.
DOI2009 Price, T., Millward, M., Mainwaring, P., Harrison, S., Galley, L., Townsend, A., . . . Spencer, A. (2009). A two-arm phase 1 clinical trial with NPI-0052, a novel proteasome inhibitor. In MOLECULAR CANCER THERAPEUTICS Vol. 8 (pp. 3 pages). AMER ASSOC CANCER RESEARCH.
DOI WoS12008 Peeters, M., Wilson, G., Ducreux, M., Cervantes, A., Andre, T., Hotko, Y., . . . Price, T. J. (2008). Phase III study (20050181) of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Pooled safety results. In JOURNAL OF CLINICAL ONCOLOGY Vol. 26 (pp. 1 page). AMER SOC CLINICAL ONCOLOGY. 2008 Kichenadasse, G., Townsend, A., & Price, T. (2008). Rectal cancers in the elderly - Lessons learned. In Cancer Forum Vol. 32 (pp. 20-22). AUSTRALIAN CANCER SOC INC.
Scopus12008 Kotasek, D., Tebbutt, N., Welch, S., Hei, Y., McCoy, S., Sun, Y., . . . Price, T. (2008). SAFETY AND PHARMACOKINETICS (PK) OF MOTESANIB DIPHOSPHATE IN COMBINATION WITH GEMCITABINE AND ERLOTINIB FOR THE TREATMENT OF SOLID TUMORS. In ANNALS OF ONCOLOGY Vol. 19 (pp. 159-160). Stockholm, SWEDEN: OXFORD UNIV PRESS.
WoS12008 Price, T. J., Gebski, V., van Hazel, G., Robinson, B., Broad, A., Ganju, V., . . . Tebbutt, N. (2008). SAFETY ANALYSIS OF AN INTERNATIONAL MULTI-CENTRE RANDOMISED PHASE II/III STUDY OF CAPECITABINE (CAP), BEVACIZUMAB (BEV) AND MITOMYCIN C (MMC) IN METASTATIC COLORECTAL CANCER (MCRC): AGITG MAX TRIAL. In ANNALS OF ONCOLOGY Vol. 19 (pp. 127). Stockholm, SWEDEN: OXFORD UNIV PRESS. 2008 Townsend, A., Price, T. J., Yeend, S., Pittman, K., Patterson, K., & Luke, C. (2008). METASTATIC CARCINOID TUMOR (MCT): SURVIVAL IMPROVED WITH OCTREOTIDE LAR (OLAR). In ANNALS OF ONCOLOGY Vol. 19 (pp. 248). Stockholm, SWEDEN: OXFORD UNIV PRESS. 2008 Padrik, P., Price, T. J., Spear, M. A., Townsend, A., Longenecker, A., Palladino, M. A., . . . Millward, M. (2008). PHASE 1 STUDY OF THE NOVEL PROTEASOME INHIBITOR NPI-0052 IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING LEUKEMIAS. In ANNALS OF ONCOLOGY Vol. 19 (pp. 162). Stockholm, SWEDEN: OXFORD UNIV PRESS.
WoS22008 Townsend, A., Padrik, P., Mainwaring, P., Price, T., Catley, L., Longenecker, A., . . . Millward, M. (2008). Phase I clinical trial of the 2nd generation proteasome inhibitor NPI-0052 in patients with advanced malignancies with a CLL RP2D. In EJC SUPPLEMENTS Vol. 6 (pp. 74). Geneva, SWITZERLAND: PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS12007 Michael, M., Price, T., Leong, T., Ganju, V., Strickland, A., Jefford, M., . . . Zalcberg, J. (2007). Phase I trial of capecitabine and gemcitabine with concurrent radical radiotherapy in locally advanced pancreatic cancer: final results. In EJC SUPPLEMENTS Vol. 5 (pp. 272). Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS12007 Price, T. J., Morelli, L., Howarth, G. S., Webster, J., Zacharakis, B., Brooker, C., . . . Butler, R. N. (2007). Residual damage to the small intestine induced by chemotherapy can be detected and monitored using the non-invasive <SUP>13</SUP>C Sucrose Breath Test (SBT). In EJC SUPPLEMENTS Vol. 5 (pp. 152). Barcelona, SPAIN: PERGAMON-ELSEVIER SCIENCE LTD.
DOI2006 Schmoll, H., Tabernero, J., Nowacki, M., Maroun, J., Price, T., Lim, R., . . . Haller, D. (2006). Capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer: Final safety findings from a randomized phase III trial. In ANNALS OF ONCOLOGY Vol. 17 (pp. 25-26). Barcelona, SPAIN: OXFORD UNIV PRESS. 2006 Schmoll, H. J., Tabernero, J., Nowacki, M., Maroun, J., Price, T., Lim, R., . . . Haller, D. (2006). Final safety findings from a randomized phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 24 (pp. 163S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY.
WoS42006 Michael, M., Leong, T., Price, T. J., Ganju, V., Strickland, A., Jefford, M., . . . Zalcberg, J. R. (2006). Phase I trial of capecitabine (CAP) and gemcitabine (GEM) with concurrent radical radiotherapy in locally advanced pancreatic cancer (PAC): Initial results. In ANNALS OF ONCOLOGY Vol. 17 (pp. 311). Istanbul, TURKEY: OXFORD UNIV PRESS.
DOI2006 Price, T. J., Roder, D., Pittman, K., Patterson, K., Rieger, N., Hewett, P., . . . Luke, C. (2006). Survival trends for advanced colorectal cancer (CRC): Are improvements only for patients in clinical trials?. In JOURNAL OF CLINICAL ONCOLOGY Vol. 24 (pp. 331S). Atlanta, GA: AMER SOC CLINICAL ONCOLOGY. 2006 Leong, T., Michael, M., Price, T., Ganju, V., Strickland, A., Jefford, M., . . . Zalcberg, J. (2006). Phase I trial of capecitabine and gemcitabine with radiotherapy in locally advanced pancreatic cancer. In ANNALS OF ONCOLOGY Vol. 17 (pp. 34). Barcelona, SPAIN: OXFORD UNIV PRESS. 2005 Price, T. J., Zakaria, J., Rodda, D., Hewett, P., Rieger, N., Stephens, J., . . . Borg, M. (2005). Squamous cell carcinoma of the anal canal at the Queen Elizabeth Hospital: A local experience.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 559S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. 2005 Thomson, D. B., Gonzalez, R., Millward, M., Price, T., Haydon, A., Robinson, W., . . . Creese, B. (2005). A phase II trial of PI-88, a novel antiangiogenic and antimetastatic heparanase inhibitor, in patients with advanced melanoma.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 724S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY. 2005 Schmoll, H. J., Tabernero, J., Nowacki, M., Maroun, J., Figer, A., Price, T., . . . Braud, F. (2005). Early safety findings from a phase III trial of capecitabine plus oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 251S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS72005 Pittman, K. B., Olver, I. N., Karapetis, C. S., Kotasek, D., Price, T. J., Patterson, W. K., . . . Greer, D. (2005). Mulicenter phase II study of gemcitabine and carboplatin combination therapy for patients with metastatic carcinoma of unknown primary site: final results.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 23 (pp. 764S). Orlando, FL: AMER SOC CLINICAL ONCOLOGY.
WoS12004 Price, T. J., Pittman, K., Patterson, K., Colbeck, M., Sim, S., Roder, D., . . . Luke, C. (2004). Survival and treatment trends for advanced colorectal cancer (CRC) treated in a University Hospital, 1992-2001.. In JOURNAL OF CLINICAL ONCOLOGY Vol. 22 (pp. 295S). New Orleans, LA: AMER SOC CLINICAL ONCOLOGY. 2003 Rao, S., Cunningham, D., Ross, P. J., Price, T., Watkins, D., Norman, A. R., . . . Hill, M. E. (2003). A phase II trial of capecitabine and mitomycin C (MMC) in 1<SUP>st</SUP> line treatment of metastatic colorectal cancer (MCRC).. In BRITISH JOURNAL OF CANCER Vol. 88 (pp. S58). BOURNEMOUTH, ENGLAND: NATURE PUBLISHING GROUP. 2003 Rao, S., Cunningham, D., Ross, P. J., Price, T., Ward, C., Norman, A. R., & Hill, M. E. (2003). Capecitabineand mitomycin C (MMC) is an active regimen for patients with metastatic colorectal carcinoma (MCRC) resistant to 5FU and irinotecan. In BRITISH JOURNAL OF CANCER Vol. 88 (pp. S56). BOURNEMOUTH, ENGLAND: NATURE PUBLISHING GROUP. 1999 Ross, P., Cunningham, D., Scarffe, H., Nicolson, M., Seymour, M., Harper, P., . . . Norman, A. (1999). Results of a randomised trial comparing ECF with MCF in advanced oesophago-gastric cancer. In EUROPEAN JOURNAL OF CANCER Vol. 35 (pp. S137). PERGAMON-ELSEVIER SCIENCE LTD.
DOI WoS3 -
Conference Items
Year Citation 2022 Krishnan, T., Piantadosi, C., Karapetis, C., Townsend, A., Roy, A., Geerinckx, B., . . . Price, T. (2022). First-line anti-EGFR or anti-VEGF therapy in metastatic colorectal cancer (mCRC) by tumour sidedness: Results from the South Australian mCRC registry. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY. 2021 Adams, J., Vanlint, A., & Price, T. (2021). COVID-19 prompts rapid and safe transition of chemotherapy into homes. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY.
DOI2020 Price, T. J., Piantadosi, C., Townsend, A. R., Padbury, R., Roy, A. C., Moore, J., . . . Karapetis, C. S. (2020). Prognostic differences of RAS mutations: Results from South Australian (SA) metastatic colorectal (mCRC) registry.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. ELECTR NETWORK: LIPPINCOTT WILLIAMS & WILKINS.
WoS22020 Nakhjavani, M., Smith, E., Price, T., Townsend, A., & Hardingham, J. (2020). PS11-38. Ginsenoside Rg3 enantiomers in a defined ratio as a novel treatment for metastatic triple-negative breast cancer. Poster session presented at the meeting of San Antonio Breast Cancer Symposium. San Antonio, TX U.S.A.. 2019 Smith, E., Tomita, Y., Palethorpe, H., Howell, S., Nakhjavani, M., Townsend, A., . . . Hardingham, J. (2019). Reduced aquaporin-1 transcript expression in colorectal carcinoma is associated with promoter hypermethylation and improved overall survival. Poster session presented at the meeting of 31st Lorne Cancer Conference. Lorne, VIC, Australia. 2019 Tie, J., Cohen, J., Wang, Y., Li, L., Lee, M., Wong, R., . . . Gibbs, P. (2019). A pooled analysis of multicenter cohort studies of post-surgery circulating tumor DNA (ctDNA) in early stage colorectal cancer (CRC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS22019 Prasanna, T., Wong, R., Price, T. J., Shapiro, J. D., Tie, J., Wong, H. -L., . . . Yip, D. (2019). Metastasectomy and BRAF mutation: An analysis of survival outcome in metastatic colorectal cancer.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12019 Taieb, J., Price, T. J., Ciardiello, F., Peeters, M., Wyrwicz, L., Bachet, J. -B., . . . Falcone, A. (2019). Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12018 Taieb, J., Geissler, M., Rivera, F., Karthaus, M., Wilson, R., Loupakis, F., . . . Peeters, M. (2018). Early tumour shrinkage (ETS) and its impact on tumour-related symptoms in patients with previously untreated RAS wild-type metastatic colorectal cancer (mCRC): A retrospective analysis of three panitumumab studies. Poster session presented at the meeting of Annals of oncology : official journal of the European Society for Medical Oncology. Barcelona, SPAIN: OXFORD UNIV PRESS.
DOI Scopus12018 Leung, J. T., Roy, A., Price, T., & Singhal, N. (2018). Phase 1 trial of nab-paclitaxel administered concurrently with radiotherapy in patients with locally advanced inoperable pancreatic adenocarcinoma. Poster session presented at the meeting of ASCO 2014. United States: LIPPINCOTT WILLIAMS & WILKINS.
DOI Scopus12018 Palethorpe, H. M., Tomita, Y., Smith, E., Townsend, A. R., Price, T. J., Yool, A. J., & Hardingham, J. E. (2018). Bacopaside II reduces endothelial cell migration and angiogenesis in vitro. Poster session presented at the meeting of 30th Lorne Cancer Conference. Lorne. 2018 Smith, E., Palethorpe, H. M., Tomita, Y., Townsend, A. R., Price, T. J., Yool, A. J., & Hardingham, J. E. (2018). Anti-tumour effects of Bacopaside II on colorectal cancer cells in vitro. Poster session presented at the meeting of 30th Lorne Cancer Conference. Lorne, VIC. 2018 Bernhardt, S., Townsend, A., Price, T., & Ingman, W. (2018). Hormonal modulation of breast cancer gene expression and implications for diagnosis and treatment of premenopausal women. Poster session presented at the meeting of CLINICAL ENDOCRINOLOGY. Perth, AUSTRALIA: WILEY. 2018 Abbas, N., Barnes, M., Price, T., Karapetis, C., Bright, T., Bull, J., . . . Roy, A. (2018). Patterns of care and clinical outcomes for gastric and gastro-oesophageal cancers in South Australian population: Initial results of a state-wide audit. Poster session presented at the meeting of Annals of oncology : official journal of the European Society for Medical Oncology. Barcelona, SPAIN: OXFORD UNIV PRESS.
DOI2017 Mooi, J., Wirapati, P., Asher, R., Lee, C., Savas, P., Price, T. J., . . . Tebbutt, N. (2017). Consensus molecular subtypes (cms) as predictors of benefit from bevacizumab in first line treatment of metastatic colorectal cancer: Retrospective analysis of the MAX clinical trial. Poster session presented at the meeting of ANNALS OF ONCOLOGY. Madrid, SPAIN: OXFORD UNIV PRESS. 2017 Michael, M., Liauw, W., McLachlan, S. -A., Link, E., Matera, A., Thompson, M., . . . Burge, M. E. (2017). Hepatic functional imaging and genomics to predict irinotecan pharmacokinetics and pharmacodynamics: The PREDICT IR study. Poster session presented at the meeting of Abstracts of the 42nd European Society for Medical Oncology Congress (ESMO 2017), as published in Annals of Oncology. Madrid, SPAIN: Elsevier.
DOI2016 Roy, A., Price, T., Townsend, A., Piantadosi, C., Padbury, R., Moore, J., . . . Karapetis, C. (2016). TREATMENT AND OUTCOMES OF METASTATIC COLORECTAL CANCER PATIENTS IN PUBLIC AND PRIVATE HOSPITALS: RESULTS FROM THE SOUTH AUSTRALIAN METASTATIC COLORECTAL CANCER REGISTRY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2016 Wong, S., Lidums, I., Parry, S., Win, A. K., Vatandoust, S., Patel, D., . . . Young, J. P. (2016). Characteristics of Advanced Neoplasia of the Large Bowel in Young Adults: Results From a Hospital Colonoscopy Service Database. Poster session presented at the meeting of GASTROINTESTINAL ENDOSCOPY. MOSBY-ELSEVIER.
DOI2016 Townsend, A., Tebbutt, N., Karapetis, C., Cooper, P., Singhal, N., Yeend, S., . . . Price, T. J. (2016). A phase IB/II study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT). Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS.
DOI Scopus1 WoS12016 Price, T. J., Douillard, J. Y., Guan, X., Bohac, C., & Peeters, M. (2016). Associations between dermatologic toxicity severity, patient characteristics, and efficacy among patients treated with panitumumab (Pmab) and chemotherapy. Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS.
DOI2016 Diakos, C. I., Tu, D., Gebski, V., Yip, S., Wilson, K., Karapetis, C. S., . . . Clarke, S. (2016). Is the derived neutrophil to lymphocyte ratio (dNLR) an independent prognostic marker in patients with metastatic colorectal cancer (mCRC)? Analysis of the CO.17 and CO.20 studies. Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS.
DOI Scopus2 WoS32016 Schmoll, H. J., Stein, A., Hofheinz, R. D., Price, T. J., Nordlinger, B., Daisne, J. F., . . . Haustermans, K. (2016). Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: final analyses. Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS.
DOI Scopus10 WoS32016 Diakos, C. I., Wilson, K., Asher, R., Gebski, V., Yip, S., van Hazel, G., . . . Clarke, S. (2016). Is baseline neutrophil to lymphocyte ratio (NLR) an independent prognostic biomarker for progression free survival (PFS) and overall survival (OS) in metastatic colorectal cancer (mCRC)? Analysis of the AGITG MAX study. Poster session presented at the meeting of Annals of Oncology. Copenhagen, DENMARK: OXFORD UNIV PRESS.
DOI Scopus5 WoS42015 Patel, D., Broadbridge, V., Hardingham, J., Colbeck, M., Pittman, K., Townsend, A., . . . Price, T. (2015). OUTCOME FOR EARLY STAGE RECTAL CANCER NOT IMPROVED OVER TIME FOR THOSE AGED ≥75 YEARS: ANALYSIS OF SINGLE CENTRE CANCER REGISTRY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2015 Tomita, Y., Karapetis, C. S., Ullah, S., Townsend, A. R., Padbury, R., & Price, T. J. (2015). Survival improvement associated with access to biological agents: Updated results from the South Australian (SA) metastatic colorectal cancer (mCRC) registry.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI2015 Vatandoust, S., Roy, A. C., Price, T. J., Ullah, S., Beeke, C., Townsend, A. R., . . . Karapetis, C. S. (2015). Survival impact of primary tumor resection in patients (pts) with unresectable metastatic colorectal cancer (mCRC): Findings from the South Australian Metastatic Colorectal Cancer Registry (SAMCRC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12015 Price, T. J., Tomita, Y., Beeke, C., Padbury, R., Townsend, A. R., Maddern, G., . . . Karapetis, C. S. (2015). Survival for patients with resectable lung metastatic colorectal cancer (mCRC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI WoS52015 Chan, D. L., Leyden, J., Michael, M., Price, T. J., Clarke, S., Pavlakis, N., & Khasraw, M. (2015). SYMPTOM BURDEN OF AUSTRALIA AND NEW ZEALAND (ANZ) PATIENTS WITH NEUROENDOCRINE TUMOURS (NET). Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. 2015 Chan, D. L., Leyden, J., Price, T. J., Michael, M., Clarke, S., Diakos, C., . . . Pavlakis, N. (2015). EXPERIENCE OF AUSTRALIA AND NEW ZEALAND (ANZ) PATIENTS WITH NEUROENDOCRINE TUMOURS (NET) TREATED AT A NET SPECIALIST CENTRE: RESULTS OF A NATIONAL SURVEY AND THE ROYAL NORTH SHORE EXPERIENCE. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. 2015 Leyden, J., Pavlakis, N., Chan, D., Michael, M., Clarke, S., Khasraw, M., & Price, T. (2015). NEUROENDOCRINE TUMOR (NET) OCEANIA PATIENT EXPERIENCE: RESULTS FROM THE FIRST GLOBAL NET PATIENT SURVEY - A COLLABORATION BETWEEN THE INTERNATIONAL NEUROENDOCRINE CANCER ALLIANCE (INCA) AND NOVARTIS. Poster session presented at the meeting of Asia-Pacific Journal of Clinical Oncology. WILEY-BLACKWELL. 2014 Charakidis, M., Hocking, C., Pittman, K., Townsend, A., Hsieh, A. H. C., & Price, T. (2014). IMMUNOHISTOCHEMISTRY DIRECTED THERAPY IN CARCINOMA OF UNKNOWN PRIMARY. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2014 Price, T. J., Beeke, C., Padbury, R., Maddern, G., Roder, D., Moore, J., . . . Karapetis, C. S. (2014). Right (R) or left (L) primary site of colorectal cancer and outcomes for metastatic colorectal cancer (mCRC): Results from the south Australian registry of mCRC.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI WoS12014 Price, T. J., Townsend, A. R., Bruhn, M., Lee, C., Wrin, J., Shivasami, A., . . . Hardingham, J. (2014). Assessment of IL-6, IL-8, bFGF, PDGF-BB, and VEGF-A as prognostic and predictive biomarkers for anti-VEGF in metastatic colorectal cancer (mCRC).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. San Francisco, CA: AMER SOC CLINICAL ONCOLOGY.
DOI2014 Baylock, B., Dhillon, H. M., Goddard, E. M., Turner, J., Rice, H., Kabourakis, M., . . . Vardy, J. L. (2014). THE COLON HEALTH AND LIFE-LONG EXERCISE CHANGE (CHALLENGE) TRIAL: PARTICIPANT ADHERENCE TO FITNESS ASSESSMENTS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
WoS12014 Vatandoust, S., Karapetis, C. S., Padman, S. J., Beeke, C., Padbury, R., Kitchener, M., . . . Price, T. J. (2014). THE MANAGEMENT OF COLORECTAL CANCER (CRC) LIVER METASTASES WITH YTTRIUM-90 MICROSPHERES (Y90), THE SOUTH AUSTRALIAN (SA) EXPERIENCE. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2014 Chan, D., Pavlakis, N., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., & Segelov, E. (2014). IMPACT OF CHEMOTHERAPY PARTNER ON EFFICACY OF TARGETED AGENTS IN METASTATIC COLORECTAL CANCER (MCRC): SYSTEMATIC REVIEW AND META-ANALYSIS. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL.
WoS12013 Chan, D., Segelov, E., Shapiro, J., Price, T. J., Karapetis, C. S., Tebbutt, N., & Pavlakis, N. (2013). META-ANALYSIS OF PROGRESSION-FREE SURVIVAL IMPACT OF BIOLOGICAL THERAPY IN RELAPSED METASTATIC COLORECTAL CANCER. Poster session presented at the meeting of ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY. WILEY-BLACKWELL. 2013 Peeters, M., Douillard, J. Y., Siena, S., Price, T., Tabernero, J., Sidhu, R., . . . Rong, A. (2013). Impact of post-protocol anti-epidermal growth factor receptor therapy on survival in wild-type KRAS/NRAS metastatic colorectal cancer: Data from the PRIME study. Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.
WoS12013 Price, T., Peeters, M., Kim, T. W., Li, J., Cascinu, S., Ruff, P., . . . Sidhu, R. (2013). ASPECCT: A randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.
WoS22013 Peeters, M., Douillard, J. Y., Siena, S., Price, T., Tabernero, J., Sidhu, R., . . . Davison, C. (2013). Impact of post-progression anti-vascular endothelial growth factor-containing therapy on survival in patients with metastatic colorectal cancer: Data from the PRIME study. Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. ELSEVIER SCI LTD.
WoS22013 Price, T., Hocking, C., Broadbridge, V., Wrin, J., Townsend, A. R., Tebbutt, N., . . . Hardingham, J. (2013). Can we accurately report PTEN status in advanced colorectal cancer?. Poster session presented at the meeting of European Cancer Congress 2013 Abstract Book, as published in European Journal of Cancer. Amsterdam, Netherlands: Elsevier.
DOI2013 Price, T. J., Pirc, L., Cooper, P., Tebbutt, N., Karapetis, C., Singhai, N., & Townsend, A. R. (2013). A phase 1B study of second-line therapy with panitumumab, irinotecan and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT). Poster session presented at the meeting of EUROPEAN JOURNAL OF CANCER. Amsterdam, NETHERLANDS: ELSEVIER SCI LTD. 2013 Vatandoust, S., Joshi, R., Pittman, K., Esterman, A., Broadbridge, V., Adams, J., . . . Price, T. (2013). A descriptive study of persistent oxaliplatin induced peripheral neuropathy in patients with colorectal cancer. Poster session presented at the meeting of Abstracts of the Medical Oncology Group of Australia Incorporated Annual Scientific Meeting, Blood, Biomarkers and Beyond, 31 July - 2 August 2013, as published in Asia-Pacific Journal of Clinical Oncology. Melbourne, Victoria: Wiley-Blackwell.
DOI2013 Townsend, A. R., Pirc, L., Cooper, P., Tebbutt, N. C., Karapetis, C. S., Singhal, N., & Price, T. J. (2013). A phase Ib study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer (mCRC) with KRAS wild type (WT).. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: LIPPINCOTT WILLIAMS & WILKINS.
WoS22012 Schmoll, H. -J., Tabernero, J., Maroun, J., De Braud, F., Price, T., Van Cutsem, E., . . . Haller, D. (2012). The role of TP, TS, and DPD as potential predictors of outcome following capecitabine plus oxaliplatin (XELOX) versus bolus 5-fluorouracil/leucovorin (5-FU/LV) as adjuvant therapy for stage III colon cancer: Biomarker findings from study NO16968 (XELOXA). Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. 2012 Siu, L., Shapiro, J., Jonker, D., Karapetis, C., Zalcberg, J., Simes, J., . . . O'Callaghan, C. (2012). Final analysis of the phase III randomized trial of cetuximab (CET) plus either brivanib alaninate (BRIV) or placebo in patients (pts) with chemotherapy refractory, K-RAS wild-type (WT), metastatic colorectal carcinoma (mCRC): The NCIC Clinical Trials Group and AGITG CO.20 trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. 2012 Vatandoust, S., Joshi, R., Broadbridge, V., Pittman, K. B., Adams, J., Singhal, N., . . . Price, T. J. (2012). Persistent oxaliplatin (OX) induced peripheral neuropathy in patients (pts) with colorectal cancer: A descriptive study.. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. 2012 Price, T. J., Hardingham, J., Lee, C., Wrin, J., Townsend, A. R., Wilson, K., . . . Tebbutt, N. C. (2012). Analysis of PTEN in patients with advanced colorectal cancer (CRC) receiving capecitabine alone or in combination with bevacizumab with or without mitomycin C in the phase III AGITG MAX trial. Poster session presented at the meeting of JOURNAL OF CLINICAL ONCOLOGY. Chicago, IL: AMER SOC CLINICAL ONCOLOGY. 2010 Pittman, K. B., Colbeck, M., Price, T. J., Sukumaran, S., Hooper, B., Tuck, M., . . . Hardingham, J. (2010). PATTERNS OF CARE AND INFLUENCE ON SURVIVAL IN SMALL CELL LUNG CANCER: A SINGLE AUSTRALIAN ONCOLOGY UNIT EXPERIENCE. Poster session presented at the meeting of JOURNAL OF THORACIC ONCOLOGY. LIPPINCOTT WILLIAMS & WILKINS. -
Preprint
Year Citation 2024 Li, R., Liu, S., Yeo, K., Edwards, S., Li, M. Y., Santos, R., . . . Smith, E. (2024). Circulating SFRP5 levels are elevated in colorectal cancer and correlate with overall survival in stage II-III disease.
DOI
| Date | Project Title | Investigators | Funding Body | Amount |
|---|---|---|---|---|
| 2015-17 | SCOT Study – Short Course Oncology Therapy – a study of adjuvant chemotherapy in colorectal cancer | A Haydon, J Zalcberg, E Walpole, D Yip, TJ Price et al. | Cancer Australia | 150,000 |
| 2014-2017 | Individualised Risk Assessment and Therapeutic Intervention for Colorectal Cancer in the South Australian Population | G Maddern, J Young, TJ Price et al. | SAHMRI BEAT Cancer Hospital Research grant | 1,500,000 |
| Innovative Cancer Imaging and Therapeutics Facility | C Mulligan, T Hughes, A Zannettino, S Grothos, D White, D Keefe, T Monro, D Roder, W Tilley, TJ Price, P MacKenzie | Australian Cancer Research Founda | 1,800,000 | |
| 2013 | PETACC-6: Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer | TJ Price | Cancer Australia + Cancer Council NSW | 123,331 + 19,624 |
| 2012 | Impact of the activated EGFR-AKT-mTOR signalling pathway on prognosis and tumour resistance to anti-angiogenic targeted therapy for metastatic colorectal cancer | A Townsend, JE Hardingham, TJ Price, N Tebbutt | Cancer Council of South Australia | 92,678 |
| 2009 - 2011 | SCOT Study – Short Course Oncology Therapy – a study of adjuvant chemotherapy in colorectal cancer | A Haydon, J Zalcberg, E Walpole, D Yip, TJ Price, M Jefford, K Howard | Cancer Australia | 599,000 |
| 2009 | A new prognostic multi-marker assay for early stage bowel cancer | J Hardingham, P Hewett, T Price, T Chataway | Cancer Council SA | 89,750 |
| 2009 - 2011 | PETACC 6 trial, neoadjuvant chemotherapy for T3/T4 rectal carcinoma | TJ Price, J Harvey, N Tebbutt, J Zalcberg, J Simes, G Hururby | Cancer Australia | 477,800 |
I am involved in the cancer curriculum initially overseeing the curriculum for 4th year Medical Students and involvement in 5th year Medical Student lecturing. As the cancer curriculum evolved over time my involvement with Medical Student Teaching has primarily been clinical based on the Oncology placements. This includes direct patient teaching together with tutorial style teaching at the time of clinics and during ward rounds.
I am actively involved in the Physician Training Program having been involved in the pre-written exam tutorial program and I have been part of the National Examining Panel (NEP) for the College of Physicians for over ten years and continue to be part of the panel. This of course involves ongoing involvement in the long case program within the Queen Elizabeth Hospital, and previously also at the Lyell McEwin Health Service. I am also involved in the Medical Oncology Advanced Training Tutorial Program lecturing on gastrointestinal cancer and in particular colorectal cancer.
As part of my University of Adelaide teaching duties I have established the TQEH campus Nurse Practitioner Candidate (NPC) clinical course, facilitating clinical placements as well as direct supervision of the NPC. This training program consists of direct clinical skill training, supervision of patient clinic practice as well as tutorial program. I have also had involvement in teaching of the Rural NPC via as part of my clinical attachment both with direct patient skill training and additional instruction in telemedicine skill training. In addition to NPC teaching, I also have Flinders University Medical student placements in Mount Gambier.
-
Current Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2022 Co-Supervisor Over-expression of SFRP5 in hepatocytes: a novel treatment strategy for colorectal cancer liver metastases Doctor of Philosophy Doctorate Full Time Mr Runhao Li -
Past Higher Degree by Research Supervision (University of Adelaide)
Date Role Research Topic Program Degree Type Student Load Student Name 2018 - 2022 Principal Supervisor Towards an Understanding of the Growing Incidence of Colorectal Cancer and Appendiceal Neoplasms in Young Adults Doctor of Philosophy Doctorate Full Time Mr Reger Romi Mikaeel 2016 - 2020 Co-Supervisor The effect of menstrual cycling on genomic predictive biomarkers in premenopausal breast cancer Doctor of Philosophy Doctorate Full Time Miss Sarah Margaret Bernhardt 2015 - 2021 Co-Supervisor Evaluation of Anti-Cancer Effect of Synthetic and Plant-based Inhibitors of Aquaporin 1 in Colon Cancer Doctor of Philosophy Doctorate Part Time Miss Yoko Tomita 2011 - 2015 Co-Supervisor Biomarkers of resistance to anti-EGFR in wild type KRAS/BRAF colorectal cancer cell lines Doctor of Philosophy Doctorate Full Time Miss Shalini Sree Kumar
-
Board Memberships
Date Role Board name Institution name Country 2015 - ongoing Member Executive committee Clinical Oncology Society of Australia (COSA) Australia 2015 - ongoing Chair Colorectal Guidelines Management Committee NHMRC/Cancer Council Austra Australia 2014 - ongoing Board Member Gastrointestinal Cancer Institute New Zealand - New Zealand 2014 - ongoing Chair Australasian Gastrointestinal Trials Group - Australia -
Memberships
Date Role Membership Country 2002 - ongoing Member European Society of Medical Oncology Sweden 2000 - ongoing Member American Society of Clinical Oncology United States
Connect With Me
External Profiles
